WO2024220746A2 - Agents d'arni ciblant la synthase d'acides gras et procédés associés - Google Patents

Agents d'arni ciblant la synthase d'acides gras et procédés associés Download PDF

Info

Publication number
WO2024220746A2
WO2024220746A2 PCT/US2024/025323 US2024025323W WO2024220746A2 WO 2024220746 A2 WO2024220746 A2 WO 2024220746A2 US 2024025323 W US2024025323 W US 2024025323W WO 2024220746 A2 WO2024220746 A2 WO 2024220746A2
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotides
sense strand
set forth
nucleotide sequence
fasn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/025323
Other languages
English (en)
Other versions
WO2024220746A3 (fr
Inventor
Scott Joseph HAYTON
Janno HARJES
Kathrin HULTSCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flagship Pioneering Innovations VII Inc
Original Assignee
Flagship Pioneering Innovations VII Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations VII Inc filed Critical Flagship Pioneering Innovations VII Inc
Publication of WO2024220746A2 publication Critical patent/WO2024220746A2/fr
Publication of WO2024220746A3 publication Critical patent/WO2024220746A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Definitions

  • RNAI AGENTS TARGETING FATTY ACID SYNTHASE AND RELATED METHODS RELATED APPLICATIONS [0001] This application claims priority to U.S. Serial No.: 63/497,568, filed April 21, 2023, the entire contents of each of which is incorporated herein by reference. 1.
  • FIELD RNAi agents (e.g., double stranded RNA (dsRNA) agents comprising a sense strand and an antisense strand) targeting fatty acid synthase (FASN).
  • dsRNA double stranded RNA
  • FASN fatty acid synthase
  • pharmaceutical compositions comprising the same; and methods of utilizing the same, including, e.g., methods of treating FASN associated diseases (e.g., liver diseases). 2.
  • Fatty acids serve a multitude of functions within a cell, including, e.g., as components of cell membranes, substrates in energy metabolism, and as secondary messengers in cell signaling pathways. Structurally, fatty acids comprise a carboxylic acid with a saturated or unsaturated aliphatic chain. Fatty acids can generally be grouped into two categories: essential fatty acids (those an organism cannot synthesize de novo) and non-essential fatty acids (those an organism can synthesize de novo). A critical enzyme in de novo fatty acid synthesis is fatty acid synthase (FASN).
  • FASN fatty acid synthase
  • RNAi agents e.g., RNAi agents, dsRNA agents
  • methods of inhibiting or decreasing FASN expression e.g., mRNA expression
  • methods of treating FASN associated diseases e.g., nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD)
  • liver diseases e.g., nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD)
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from any sense strand set forth in Table 2 or Table 3 or set forth in any one of SEQ ID NOS: 4-231 or 688-915.
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the corresponding sense strand set forth in Table 2 or Table 3 or the corresponding sense strand set forth in one of SEQ ID NOS: 4-231 or 688-915.
  • the sense strand comprises at least one modified nucleotide and/or the antisense strand comprises at least one modified nucleotide.
  • At least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides of the sense strand and/or antisense strand are modified.
  • substantially all (or all) of the nucleotides in the sense strand and/or antisense strand are modified.
  • at least one of the modified nucleotides comprises a modified sugar (e.g., ribose moiety).
  • at least one of the modified nucleotides comprises a modified nucleobase.
  • the sense strand comprises at least one modified internucleoside linkage and/or the antisense strand comprises at least one modified internucleoside linkage.
  • each of the antisense strand and the sense strand are not more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15 nucleotides in length.
  • the antisense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19- 3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19- 22, 19-23, 19-24, or 19-25 nucleotides; and/or the sense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19-3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19-22, 19-23, 19-24, or 19-25 nucleotides.
  • antisense strand comprises from about 19-23 nucleotides; and/or the sense strand comprises [0009] In some embodiments, the sense strand and/or the antisense strand comprises a 3′ and/or 5′ overhang of 1, 2, or 3 nucleotides. In some embodiments, the antisense strand comprises a 3′ overhang of 1, 2, or 3 nucleotides (e.g., 2 nucleotides).
  • the sense strand comprises at least one modified nucleotide and/or the antisense strand comprises at least one modified nucleotide. In some embodiments, at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides of the sense strand and/or antisense strand are modified. In some embodiments, substantially all (or all) of the nucleotides in the sense strand and/or antisense strand are modified. In some embodiments, at least one of the modified nucleotides comprises a modified sugar (e.g., ribose moiety).
  • a modified sugar e.g., ribose moiety
  • At least one of the modified nucleotides comprises a modified nucleobase.
  • the sense strand comprises at least one modified internucleoside linkage and/or the antisense strand comprises at least one modified internucleoside linkage.
  • each of the antisense strand and the sense strand are not more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15 nucleotides in length.
  • antisense strand comprises from about 19-23 nucleotides; and/or the sense strand comprises from about 19-23 nucleotides. In some embodiments, antisense strand comprises or consists of about 23 nucleotides; and/or the sense strand comprises or consists of about 21 nucleotides. [0015] In some embodiments, the sense strand and/or the antisense strand comprises a 3′ and/or 5′ overhang of 1, 2, or 3 nucleotides. In some embodiments, the antisense strand comprises a 3′ overhang of 1, 2, or 3 nucleotides (e.g., 2 nucleotides).
  • the double stranded region is from about 19-30, 19-29, 19- 28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-20, 19-21, 23-30, 23-29, 23-28, 23-27, 23- 26, 23-25, 23-24, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotide pairs in length.
  • the double stranded region is from about 19-23 or 19- 21 nucleotide pairs in length. In some embodiments, the double stranded region is about 21 nucleotide pairs in length.
  • dsRNA agents for inhibiting expression of FASN e.g., hFASN
  • the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514- 558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048- 1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 15
  • the antisense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21, 22, or 23) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2 or set forth in any one of SEQ ID NOS: 232-459.
  • the antisense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21, 22, or 23) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3 or set forth in any one of SEQ ID NOS: 916-1143.
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2 or Table 3 or set forth in any one of SEQ ID NOS: 4-231 or 688-915.
  • 15 e.g., 16, 17, 18, 19, 20, 21
  • 3 e.g., 0, 1, 2, or 3
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2 or Table 3 or the corresponding sense strand set forth in one of SEQ ID NOS: 4-231 or 688-915.
  • 15 e.g., 16, 17, 18, 19, 20, 21
  • 3 e.g., 0, 1, 2, or 3
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2 or set forth in any one of SEQ ID NOS: 4-231.
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2 or the corresponding sense strand set forth in one of SEQ ID NOS: 4-231.
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3 or set forth in any one of SEQ ID NOS: 688-915.
  • At least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides of the sense strand and/or antisense strand are modified.
  • substantially all (or all) of the nucleotides in the sense strand and/or antisense strand are modified.
  • at least one of the modified nucleotides comprises a modified sugar (e.g., ribose moiety).
  • at least one of the modified nucleotides comprises a modified nucleobase.
  • the sense strand comprises at least one modified internucleoside linkage and/or the antisense strand comprises at least one modified internucleoside linkage.
  • each of the antisense strand and the sense strand are not more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15 nucleotides in length.
  • the antisense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19- 3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19- 22, 19-23, 19-24, or 19-25 nucleotides; and/or the sense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19-3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19-22, 19-23, 19-24, or 19-25 nucleotides.
  • antisense strand comprises from about 19-23 nucleotides; and/or the sense strand comprises from about 19-23 nucleotides. In some embodiments, antisense strand comprises or consists of about 23 nucleotides; and/or the sense strand comprises or consists of about 21 nucleotides. [0023] In some embodiments, the sense strand and/or the antisense strand comprises a 3′ and/or 5′ overhang of 1, 2, or 3 nucleotides. In some embodiments, the antisense strand comprises a 3′ overhang of 1, 2, or 3 nucleotides (e.g., 2 nucleotides).
  • the double stranded region is from about 19-30, 19-29, 19- 28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-20, 19-21, 23-30, 23-29, 23-28, 23-27, 23- 26, 23-25, 23-24, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotide pairs in length.
  • the double stranded region is from about 19-23 or 19- 21 nucleotide pairs in length. In some embodiments, the double stranded region is about 21 nucleotide pairs in length.
  • the sense strand and the antisense strand are part of a single nucleic acid molecule (e.g., wherein a hairpin loop is between the sense strand and the antisense strand of the single nucleic acid molecule.
  • the sense strand and the antisense strand are separate nucleic acid molecules (i.e., connected only through the double stranded region).
  • dsRNA agents for inhibiting expression of FASN e.g., hFASN
  • the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region
  • the antisense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21, 22, or 23) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2 or set forth in any one of SEQ ID NOS: 232-459.
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from any sense strand set forth in Table 2 or set forth in any one of SEQ ID NOS: 4-231.
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the corresponding sense strand set forth in Table 2 or the corresponding sense strand set forth in one of SEQ ID NOS: 4-231.
  • the sense strand comprises at least one modified nucleotide and/or the antisense strand comprises at least one modified nucleotide. In some embodiments, at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides of the sense strand and/or antisense strand are modified. In some embodiments, substantially all (or all) of the nucleotides in the sense strand and/or antisense strand are modified. In some embodiments, at least one of the modified nucleotides comprises a modified sugar (e.g., ribose moiety).
  • a modified sugar e.g., ribose moiety
  • At least one of the modified nucleotides comprises a modified nucleobase.
  • the sense strand comprises at least one modified internucleoside linkage and/or the antisense strand comprises at least one modified internucleoside linkage.
  • each of the antisense strand and the sense strand are not more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15 nucleotides in length.
  • the antisense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19- 3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19- 22, 19-23, 19-24, or 19-25 nucleotides; and/or the sense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19-3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19-22, 19-23, 19-24, or 19-25 nucleotides.
  • antisense strand comprises from about 19-23 nucleotides; and/or the sense strand comprises from about 19-23 nucleotides. In some embodiments, antisense strand comprises or consists of about 23 nucleotides; and/or the sense strand comprises or consists of about 21 nucleotides. [0030] In some embodiments, the sense strand and/or the antisense strand comprises a 3′ and/or 5′ overhang of 1, 2, or 3 nucleotides. In some embodiments, the antisense strand comprises a 3′ overhang of 1, 2, or 3 nucleotides (e.g., 2 nucleotides).
  • the double stranded region is from about 19-30, 19-29, 19- 28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-20, 19-21, 23-30, 23-29, 23-28, 23-27, 23- 26, 23-25, 23-24, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotide pairs in length.
  • the double stranded region is from about 19-23 or 19- 21 nucleotide pairs in length. In some embodiments, the double stranded region is about 21 nucleotide pairs in length.
  • the sense strand and the antisense strand are part of a single nucleic acid molecule (e.g., wherein a hairpin loop is between the sense strand and the antisense strand of the single nucleic acid molecule.
  • the sense strand and the antisense strand are separate nucleic acid molecules (i.e., connected only through the double stranded region).
  • dsRNA agents for inhibiting expression of FASN e.g., hFASN
  • the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region
  • the antisense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21, 22, or 23) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strands of any one of dsRNA agents 1-228 set forth in Table 2
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21, 22, or 23) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding dsRNA agent set forth in Table 2.
  • the sense strand comprises at least one modified nucleotide and/or the antisense strand comprises at least one modified nucleotide. In some embodiments, at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides of the sense strand and/or antisense strand are modified. In some embodiments, substantially all (or all) of the nucleotides in the sense strand and/or antisense strand are modified. In some embodiments, at least one of the modified nucleotides comprises a modified sugar (e.g., ribose moiety).
  • a modified sugar e.g., ribose moiety
  • At least one of the modified nucleotides comprises a modified nucleobase.
  • the sense strand comprises at least one modified internucleoside linkage and/or the antisense strand comprises at least one modified internucleoside linkage.
  • each of the antisense strand and the sense strand are not more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15 nucleotides in length.
  • the antisense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19- 3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19- 22, 19-23, 19-24, or 19-25 nucleotides; and/or the sense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19-3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19-22, 19-23, 19-24, or 19-25 nucleotides.
  • antisense strand comprises from about 19-23 nucleotides; and/or the sense strand comprises from about 19-23 nucleotides. In some embodiments, antisense strand comprises or consists of about 23 nucleotides; and/or the sense strand comprises or consists of about 21 nucleotides. [0036] In some embodiments, the sense strand and/or the antisense strand comprises a 3′ and/or 5′ overhang of 1, 2, or 3 nucleotides. In some embodiments, the antisense strand comprises a 3′ overhang of 1, 2, or 3 nucleotides (e.g., 2 nucleotides).
  • the double stranded region is from about 19-30, 19-29, 19- 28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-20, 19-21, 23-30, 23-29, 23-28, 23-27, 23- 26, 23-25, 23-24, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotide pairs in length.
  • the double stranded region is from about 19-23 or 19- 21 nucleotide pairs in length. In some embodiments, the double stranded region is about 21 nucleotide pairs in length.
  • the sense strand and the antisense strand are part of a single nucleic acid molecule (e.g., wherein a hairpin loop is between the sense strand and the antisense strand of the single nucleic acid molecule.
  • the sense strand and the antisense strand are separate nucleic acid molecules (i.e., connected only through the double stranded region).
  • the sense strand comprises at least one modified nucleotide and/or the antisense strand comprises at least one modified nucleotide.
  • At least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides of the sense strand and/or antisense strand are modified.
  • substantially all (or all) of the nucleotides in the sense strand and/or antisense strand are modified.
  • at least one of the modified nucleotides comprises a modified sugar (e.g., ribose moiety).
  • at least one of the modified nucleotides comprises a modified nucleobase.
  • the sense strand comprises at least one modified internucleoside linkage and/or the antisense strand comprises at least one modified internucleoside linkage.
  • each of the antisense strand and the sense strand are not more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15 nucleotides in length.
  • the antisense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19- 3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19- 22, 19-23, 19-24, or 19-25 nucleotides; and/or the sense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19-3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19-22, 19-23, 19-24, or 19-25 nucleotides.
  • antisense strand comprises from about 19-23 nucleotides; and/or the sense strand comprises from about 19-23 nucleotides. In some embodiments, antisense strand comprises or consists of about 23 nucleotides; and/or the sense strand comprises or consists of about 21 nucleotides. [0041] In some embodiments, the sense strand and/or the antisense strand comprises a 3′ and/or 5′ overhang of 1, 2, or 3 nucleotides. In some embodiments, the antisense strand comprises a 3′ overhang of 1, 2, or 3 nucleotides (e.g., 2 nucleotides).
  • the double stranded region is from about 19-30, 19-29, 19- 28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-20, 19-21, 23-30, 23-29, 23-28, 23-27, 23- 26, 23-25, 23-24, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotide pairs in length.
  • the double stranded region is from about 19-23 or 19- 21 nucleotide pairs in length. In some embodiments, the double stranded region is about 21 nucleotide pairs in length.
  • the sense strand and the antisense strand are part of a single nucleic acid molecule (e.g., wherein a hairpin loop is between the sense strand and the antisense strand of the single nucleic acid molecule.
  • the sense strand and the antisense strand are separate nucleic acid molecules (i.e., connected only through the double stranded region).
  • dsRNA agents for inhibiting expression of FASN e.g., hFASN
  • the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region
  • the antisense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21, 22, or 23) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3 or set forth in any one of SEQ ID NOS: 916-1143.
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from any sense strand set forth in Table 3 or set forth in any one of SEQ ID NOS: 688-915.
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the corresponding sense strand set forth in Table 3 or the corresponding sense strand set forth in one of SEQ ID NOS: 688-915.
  • the sense strand comprises at least one modified nucleotide and/or the antisense strand comprises at least one modified nucleotide. In some embodiments, at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides of the sense strand and/or antisense strand are modified. In some embodiments, substantially all (or all) of the nucleotides in the sense strand and/or antisense strand are modified. In some embodiments, at least one of the modified nucleotides comprises a modified sugar (e.g., ribose moiety).
  • a modified sugar e.g., ribose moiety
  • At least one of the modified nucleotides comprises a modified nucleobase.
  • the sense strand comprises at least one modified internucleoside linkage and/or the antisense strand comprises at least one modified internucleoside linkage.
  • each of the antisense strand and the sense strand are not more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15 nucleotides in length.
  • the antisense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19- 3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19- 22, 19-23, 19-24, or 19-25 nucleotides; and/or the sense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19-3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19-22, 19-23, 19-24, or 19-25 nucleotides.
  • antisense strand comprises from about 19-23 nucleotides; and/or the sense strand comprises from about 19-23 nucleotides. In some embodiments, antisense strand comprises or consists of about 23 nucleotides; and/or the sense strand comprises or consists of about 21 nucleotides. [0049] In some embodiments, the sense strand and/or the antisense strand comprises a 3′ and/or 5′ overhang of 1, 2, or 3 nucleotides. In some embodiments, the antisense strand comprises a 3′ overhang of 1, 2, or 3 nucleotides (e.g., 2 nucleotides).
  • the double stranded region is from about 19-30, 19-29, 19- 28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-20, 19-21, 23-30, 23-29, 23-28, 23-27, 23- 26, 23-25, 23-24, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotide pairs in length.
  • the double stranded region is from about 19-23 or 19- 21 nucleotide pairs in length. In some embodiments, the double stranded region is about 21 nucleotide pairs in length.
  • the sense strand and the antisense strand are part of a single nucleic acid molecule (e.g., wherein a hairpin loop is between the sense strand and the antisense strand of the single nucleic acid molecule.
  • the sense strand and the antisense strand are separate nucleic acid molecules (i.e., connected only through the double stranded region).
  • dsRNA agents for inhibiting expression of FASN e.g., hFASN
  • the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region
  • the antisense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21, 22, or 23) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strands of any one of dsRNA agents 1-228 set forth in Table 3
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21, 22, or 23) contiguous nucleotides of and differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding dsRNA agent set forth in Table 3.
  • the sense strand comprises at least one modified nucleotide and/or the antisense strand comprises at least one modified nucleotide. In some embodiments, at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides of the sense strand and/or antisense strand are modified. In some embodiments, substantially all (or all) of the nucleotides in the sense strand and/or antisense strand are modified. In some embodiments, at least one of the modified nucleotides comprises a modified sugar (e.g., ribose moiety).
  • a modified sugar e.g., ribose moiety
  • At least one of the modified nucleotides comprises a modified nucleobase.
  • the sense strand comprises at least one modified internucleoside linkage and/or the antisense strand comprises at least one modified internucleoside linkage.
  • each of the antisense strand and the sense strand are not more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15 nucleotides in length.
  • the antisense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19- 3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19- 22, 19-23, 19-24, or 19-25 nucleotides; and/or the sense strand comprises from about 15-30, 16-30, 17-30, 18-30, 19-3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19-22, 19-23, 19-24, or 19-25 nucleotides.
  • antisense strand comprises from about 19-23 nucleotides; and/or the sense strand comprises from about 19-23 nucleotides. In some embodiments, antisense strand comprises or consists of about 23 nucleotides; and/or the sense strand comprises or consists of about 21 nucleotides. [0055] In some embodiments, the sense strand and/or the antisense strand comprises a 3′ and/or 5′ overhang of 1, 2, or 3 nucleotides. In some embodiments, the antisense strand comprises a 3′ overhang of 1, 2, or 3 nucleotides (e.g., 2 nucleotides).
  • the double stranded region is from about 19-30, 19-29, 19- 28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-20, 19-21, 23-30, 23-29, 23-28, 23-27, 23- 26, 23-25, 23-24, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotide pairs in length.
  • the double stranded region is from about 19-23 or 19- 21 nucleotide pairs in length. In some embodiments, the double stranded region is about 21 nucleotide pairs in length.
  • the heterologous moiety is carbohydrate. In some embodiments, the heterologous moiety comprises one or more GalNac. [0060] In some embodiments, the heterologous moiety is a targeting moiety. In some embodiments, the targeting moiety specifically binds to a moiety expressed by hepatocytes (e.g., on the surface of the hepatocytes). In some embodiments, the targeting moiety comprises GalNac. In some embodiments, the targeting moiety comprises Formula II: [ ] , g g y g p y g specific binding to the asialoglycoprotein receptor (e.g., expressed on the surface of hepatocytes).
  • the heterologous moiety is attached to the dsRNA agent via a linker.
  • the linker is cleavable.
  • the heterologous moiety attached to the 3′ end of the sense and/or antisense strand and/or the 5′ end of the sense and/or antisense strand, and/or at an internal site of the sense and/or antisense strand.
  • vectors e.g., a viral vector, a non-viral vector
  • lipid-based delivery system is a lipid nanoparticle (LNP), liposome, lipoplex, nanoliposome, an exosome, or a micelle.
  • LNP lipid nanoparticle
  • cells comprising a dsRNA described herein, a conjugate described herein, a vector described herein, or a carrier described herein.
  • compositions comprising a dsRNA described herein, a conjugate described herein, a vector described herein, a carrier described herein, or a cell described herein, and a pharmaceutically acceptable excipient.
  • kits comprising a dsRNA described herein, a conjugate described herein, a vector described herein, a carrier described herein, a cell described herein, or a pharmaceutical composition described herein.
  • dsRNA described herein a conjugate described herein, a vector described herein, a carrier described herein, a cell described herein, or a pharmaceutical composition described herein, to thereby deliver the dsRNA, conjugate, vector, carrier, or pharmaceutical composition into the cell.
  • the cell is in vitro, ex vivo, or in vivo.
  • the cell is a subject (e.g., a human subject). In some embodiments, the subject is a human.
  • kits for delivering a dsRNA, conjugate, vector, carrier, or pharmaceutical composition to a subject comprising administering to the subject a dsRNA described herein, a conjugate described herein, a vector described herein, a carrier described herein, a cell described herein, or a pharmaceutical composition described herein, to thereby deliver the dsRNA, conjugate, vector, carrier, or pharmaceutical composition to the subject.
  • the subject is a human.
  • a cell comprising delivering into the cell a dsRNA described herein, a conjugate described herein, a vector described herein, a carrier described herein, a cell described herein, or a pharmaceutical composition described herein, to thereby reduce or inhibit expression of FASN (e.g., hFASN) in the cell.
  • the subject is a human.
  • a dsRNA described herein e.g., a conjugate described herein, a vector described herein, a carrier described herein, a cell described herein, or a pharmaceutical composition described herein, to thereby reduce or inhibit expression of FASN (e.g., hFASN) in the cell in the subject.
  • the subject is a human.
  • a FASN e.g., hFASN
  • methods of treating, ameliorating, or preventing a FASN (e.g., hFASN) associated disease in a subject comprising administering to the subject a dsRNA described herein, a conjugate described herein, a vector described herein, a carrier described herein, a cell described herein, or a pharmaceutical composition described herein, to thereby treat, ameliorate, or prevent the FASN (e.g., hFASN) associated disease in the subject.
  • the FASN (e.g., hFASN) associated disease is fatty liver, liver inflammation, nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFLD).
  • the FASN (e.g., hFASN) associated disease is obesity- induced metabolic syndrome, insulin insensitivity, obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, alcoholic fatty liver disease (AFLD), cirrhosis, metabolic dysfunction associated steatotic liver disease (MASLD), metabolic-associated steatohepatitis (MASH), metabolic dysfunction and alcohol associated steatotic liver disease (MetALD), steatotic liver disease (SLD), or cryptogenic SLD.
  • the subject is a human.
  • a liver disease in a subject comprising administering to the subject a dsRNA described herein, a conjugate described herein, a vector described herein, a carrier described herein, a cell described herein, or a pharmaceutical composition described herein, to thereby treat, ameliorate, or prevent the liver disease in the subject.
  • the liver disease is fatty liver, liver inflammation, NASH, NAFLD, obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, cirrhosis, MASLD, MASH, MetALD, SLD, or cryptogenic SLD.
  • the subject is a human.
  • a FASN e.g., hFASN
  • methods of diagnosing a FASN (e.g., hFASN) associated disease in a subject comprising (a) isolating and purifying DNA, RNA, or protein, or having DNA, RNA, or protein isolated and purified, from a sample obtained from the subject; and (b) detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA, RNA, or protein, wherein the presence of the one or more somatic mutation indicates that the subject has a FASN (e.g., hFASN) associated disease.
  • the FASN (e.g., hFASN) associated disease is a liver disease.
  • the FASN (e.g., hFASN) associated disease is fatty liver, liver inflammation, NASH, NAFLD, obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, cirrhosis, MASLD, MASH, MetALD, SLD, or cryptogenic SLD.
  • the sample is a blood, tissue, or cell sample.
  • the sample is biopsy.
  • the sample is a liver biopsy.
  • the subject is a human.
  • at least one of the one or more somatic mutation is a loss of function mutation.
  • at least one of the one or more somatic mutation is a gain of function mutation.
  • kits for diagnosing a liver disease in a subject comprising (a) isolating and purifying DNA, RNA, or protein, or having DNA, RNA, or protein isolated and purified, from a sample obtained from the subject; and (b) detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA, RNA, or protein, wherein the presence of the one or more somatic mutation indicates that the subject has a liver disease.
  • the liver disease fatty liver, liver inflammation, NASH, NAFLD, obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, cirrhosis, MASLD, MASH, MetALD, SLD, or cryptogenic SLD.
  • (a) comprises isolating and purifying DNA, or having DNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of the one or more somatic FASN mutation in the DNA.
  • the method further comprises administering to the subject an inhibitory nucleic acid molecule that inhibits expression of FASN if a FASN somatic mutation is detected in the DNA, RNA, or protein.
  • kits for selecting a subject for administration of an inhibitory nucleic acid molecule that inhibits expression of FASN comprising (a) isolating and purifying DNA, RNA, or protein, or having DNA, RNA, or protein isolated and purified, from a sample obtained from the subject; and (b) detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA, RNA, or protein, wherein the subject is selected for administration of the inhibitory nucleic acid molecule if the one or more somatic mutation is present.
  • a FASN e.g., hFASN
  • methods of treating, ameliorating, or preventing a FASN (e.g., hFASN) associated disease in a subject comprising (a) isolating and purifying DNA, RNA, or protein, or having DNA, RNA, or protein isolated and purified, from a sample obtained from the subject; (b) detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA, RNA, or protein, and (c) administering to the subject an inhibitory nucleic acid that inhibits expression of FASN if the one or more FASN somatic mutation is detected in the DNA, RNA, or protein.
  • a FASN e.g., hFASN
  • the FASN (e.g., hFASN) associated disease is a liver disease.
  • the liver disease is fatty liver, liver inflammation, NASH, NAFLD, obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, cirrhosis, MASLD, MASH, MetALD, SLD, or cryptogenic SLD.
  • the sample is a blood, tissue, or cell sample.
  • the sample is biopsy.
  • the sample is a liver biopsy.
  • the subject is a human.
  • at least one of the one or more somatic mutation is a loss of function mutation.
  • the inhibitory nucleic acid molecule comprises a dsRNA agent described herein, a conjugate described herein, a vector described herein, a carrier described herein, or a pharmaceutical composition described herein.
  • the liver disease is fatty liver, liver inflammation, NASH, NAFLD, obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, cirrhosis, MASLD, MASH, MetALD, SLD, or cryptogenic SLD.
  • (a) comprises isolating and purifying DNA, or having DNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of the one or more somatic FASN mutation in the DNA.
  • the sample is a blood, tissue, or cell sample.
  • the sample is biopsy.
  • the sample is a liver biopsy.
  • the subject is a human.
  • at least one of the one or more somatic mutation is a loss of function mutation.
  • at least one of the one or more somatic mutation is a gain of function mutation.
  • in vitro methods of screening a sample from a subject for one or more somatic FASN mutation comprising (a) isolating and purifying DNA, RNA, or protein from a sample obtained from the subject; and (b) detecting the presence or absence of one or more somatic FASN mutation in the DNA, RNA, or protein.
  • the sample is a blood, tissue, or cell sample.
  • the sample is biopsy.
  • the sample is a liver biopsy.
  • the subject is a human.
  • at least one of the one or more somatic mutation is a loss of function mutation.
  • FIG. 1A-1H is a bar graph showing the percent of hFASN mRNA remaining in Hep3B cells after 24 hour in vitro treatment with the indicated dsRNA agent (normalized to GAPDH and relative to control treated cells set to 100%). For the sake of additional clarity, it is noted that each dsRNA agent has two bars, the left bar shows the results utilizing 20nM of the dsRNA agent and the right bar shows the result utilizing 0.5nM of the dsRNA agent. [00103] FIG.
  • FIG. 2 is a bar graph showing the percent of mFASN mRNA remaining in liver cells from mice treated with the indicated dsRNA agent (normalized to GAPDH).
  • FIG. 3 is a bar graph showing the percent of mFASN mRNA remaining in liver cells from mice treated with the indicated dsRNA agent (normalized to GAPDH). 5.
  • DETAILED DESCRIPTION [00105] The inventors have, inter alia, discovered that FASN is increasingly expressed in the liver under conditions of increased fat accumulation (e.g., in NASH). The inventors have further discovered, inter alia, RNAi agents that inhibit expression of FASN (e.g., hFASN).
  • RNAi agents described herein are useful for the treatment of FASN mediated diseases such as liver diseases (e.g., fatty liver disease, NASH, nonalcoholic fatty liver disease (NAFLD)).
  • liver diseases e.g., fatty liver disease, NASH, nonalcoholic fatty liver disease (NAFLD)
  • the current disclosure provides RNAi agents (e.g., dsRNAi agents comprising a sense strand and an antisense strand) capable of inhibiting FASN expression (e.g., in a cell, in a cell in a subject); and their use in, inter alia, pharmaceutical compositions, and methods of treating diseases (e.g., liver diseases).
  • RNAi Agents 5.2.1 Antisense Strand 5.2.1.1 Targeting Region 5.2.1.2 Overall Length 5.2.1.3 Exemplary Antisense Strands 5.2.2 Sense Strand 5.2.2.1 Antisense Strand Complementarity 5.2.2.2 Overall Length 5.2.2.3 Exemplary Sense Strands 5.2.3 dsRNA Agents 5.2.3.1 Single & Multiple Nucleic Acid Molecules 5.2.3.2 Length of Double Stranded Region 5.2.3.3 Nucleotide Overhangs & Blunt Ends 5.2.3.4 Exemplary Structural Combinations of Sense & Antisense Strands 5.2.3.5 Exemplary Antisense Strands & Sense Strands 5.2.3.6 Exemplary dsRNA Agents 5.3 Modified RNAi Agents 5.3.1 Nature of Nucleotide Modifications 5.3.1.1 Modified Nucleosides 5.3.1.1(i) Sugar Modifications 5.3.1.1(i)(a) Non-Bicyclic Sugar Modifications
  • any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.
  • administering refers to the physical introduction of an agent, e.g., a therapeutic agent (or a precursor of the therapeutic agent that is metabolized or altered within the body of the subject to produce the therapeutic agent in vivo) to a subject, using any of the various methods and delivery systems known to those skilled in the art. Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.
  • agent is used generically to describe any macro or micro molecule.
  • moieties include, but are not limited polypeptides, proteins, peptides, polynucleotides (e.g., DNA, RNA), small molecules, carbohydrates, lipids, synthetic polymers (e.g., polymers of PEG).
  • polypeptides proteins, peptides, polynucleotides (e.g., DNA, RNA), small molecules, carbohydrates, lipids, synthetic polymers (e.g., polymers of PEG).
  • RNA molecule e.g., part of an RNAi agent (e.g., described herein), part of a dsRNA agent (e.g., described herein)
  • a target nucleic acid sequence e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)
  • bicyclic sugar refers to a modified sugar (e.g., ribose) moiety comprising two rings, wherein the second ring is formed via a bridge connecting two of the atoms in the first ring thereby forming a bicyclic structure.
  • the first ring of the bicyclic sugar moiety is a furanosyl moiety.
  • the furanosyl sugar moiety is a ribosyl moiety.
  • BNA bicyclic nucleoside
  • BNA is a nucleoside comprising a bicyclic sugar.
  • the term “blunt end” refers to a dsRNA molecule that does not contain any unpaired nucleotides at the end (e.g., 3′ terminus, 5′ terminus) of the dsRNA molecule (i.e., no nucleotide overhang(s)).
  • the dsRNA molecule can have, for example, a blunt end at the 3′ end, 5′ end, or both the 3′ and 5′ end of the molecule.
  • the term “complementary” in reference to a first nucleotide sequence (e.g., a sense strand or a target mRNA) in relation to a second nucleotide sequence (e.g., an antisense strand), refers to the ability of a nucleic acid molecule comprising the first nucleotide sequence to hybridize to a nucleic acid molecule comprising the second nucleotide sequence and form a double stranded region (through base pair hydrogen bonds) under suitable in vivo or vitro conditions (e.g., under certain standard conditions, under mammalian (e.g., human) physiological conditions).
  • Complementary sequences include, e.g., Watson-Crick base pairs.
  • complementary nucleobase pairs include adenine (A) and thymine (T); adenine (A) and uracil (U); and cytosine (C) and guanine (G).
  • Complementary nucleobase pairs include natural and modified nucleotides, and nucleotide mimics, at least to the extent that the above hybridization requirements are fulfilled. As such, determinations of complementarity (as described herein) are independent of nucleotide chemical modifications (e.g., as described herein).
  • conjugation refers to chemical conjugation of an agent (e.g., a nucleic acid molecule) with a moiety (e.g., carbohydrate, small molecule, polypeptide, polynucleotide, lipid, synthetic polymer (e.g., polymers of polyethylene glycol (PEG)), etc.).
  • agent e.g., a nucleic acid molecule
  • moiety e.g., carbohydrate, small molecule, polypeptide, polynucleotide, lipid, synthetic polymer (e.g., polymers of polyethylene glycol (PEG)), etc.
  • PEG polyethylene glycol
  • the term “differing by no more than X nucleotides” and the like (e.g., differing by not more than X nucleotides” in reference to a nucleotide sequence means that the nucleotide sequence comprises no more than X (wherein X is a specified number (e.g., 3, 2, 1, 0)) nucleotide variations (as defined herein) relative to a reference sequence.
  • the phrase “wherein the nucleotide sequence of the antisense strand differs by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO: X” means that the nucleotide sequence comprises no more than 3 nucleotide variations relative to the nucleotide sequence set forth in the cited SEQ ID NO: X.
  • the term “disease” refers to any abnormal condition that impairs physiological function. The term is used broadly to encompass any disorder, illness, abnormality, pathology, sickness, condition, or syndrome in which physiological function is impaired, irrespective of the nature of the etiology.
  • double stranded RNA agent or “dsRNA agent” refers to a complex of two RNA molecules comprising a double stranded region comprising two anti- parallel and at least partially (e.g., substantially, fully) complementary nucleic acid sequences that form the double stranded region.
  • the dsRNA agent comprises a sense strand and an antisense strand.
  • fatty acid synthase or “FASN” refers to the enzyme that functions, inter alia, to catalyze the synthesis of fatty acids (principally the long-chain saturated fatty acid palmitate) from acetyl-CoA and malonyl-CoA.
  • the term FASN includes human FASN (hFASN).
  • the mRNA sequence of reference hFASN gene is set forth in SEQ ID NO: 1 (NCBI Ref.: NM_004104.5).
  • the amino acid sequence of a reference hFASN protein is set forth in SEQ ID NO: 3 (NCBI Ref.: NP_004095.4).
  • the term FASN includes naturally occurring variants of FASN.
  • non-human primate e.g., rhesus macaque, Macaca fascicularis (cynomolgus monkey)
  • GenBank e.g., GenBank, UniProt, OMIM
  • OMIM Macaca fascicularis
  • the term “fully complementary” means that in a hybridized pair of a first nucleic acid molecule and a second nucleic acid molecule, 100% (all), of the bases in a contiguous sequence of the first nucleic acid molecule will hybridize with the same number of bases in a contiguous sequence of the second nucleic acid molecule.
  • the contiguous sequence may comprise all or a part of the first and/or second nucleic acid molecule.
  • the term “heterologous,” when used to describe a first element in reference to a second element means that the first element and second element do not exist in nature disposed as described.
  • a nucleic acid molecule comprising a “heterologous moiety” means a nucleic acid molecule that is joined to a moiety (e.g., carbohydrate, small molecule, polypeptide, polynucleotide, lipid, synthetic polymer (e.g., polymers of PEG), etc.) that is not joined to the nucleic acid molecule in nature.
  • a moiety e.g., carbohydrate, small molecule, polypeptide, polynucleotide, lipid, synthetic polymer (e.g., polymers of PEG), etc.
  • isolated with reference to a polypeptide, protein, or polynucleotide refers to a polypeptide, protein, or polynucleotide that is substantially free of other cellular components with which it is associated in the natural state.
  • nucleotide variation refers to a nucleic acid molecule that comprises at least one substitution, addition, deletion, or inversion of one or more nucleotide compared to a reference nucleic acid molecule.
  • variant or variant with reference to a peptide or protein refers to a peptide or protein that comprises at least one substitution, addition, deletion, or inversion of an amino acid residue compared to a reference peptide or protein.
  • modified agent refers to any agent (or any component thereof (e.g., any nucleic acid molecule thereof)) (e.g., described herein, e.g., an antisense strand, a sense strand, a dsRNA agent, RNAi agent, etc.) that comprises one or more modified nucleotide (as defined herein).
  • modified nucleotide refers to a nucleotide comprising a chemical modification, e.g., a modified sugar moiety, a modified nucleobase, and/or a modified internucleoside linkage, or any combination thereof.
  • exemplary modifications are provided herein, see, e.g., ⁇ 5.3, 5.3.1.
  • RNAi agent e.g., described herein, e.g., a sense strand, an antisense strand, a dsRNA agent
  • inclusion of a deoxynucleotide - which is acknowledged as a naturally occurring form of nucleotide - if present within an RNAi agent or component thereof e.g., described herein, e.g., a sense strand, an antisense strand, a dsRNA agent
  • RNAi agent e.g., described herein, e.g., a sense strand, an antisense strand, a dsRNA agent
  • the term “moiety” is used generically to describe any macro or micro molecule that can be operably connected to a protein described herein.
  • moieties include, but are not limited small molecules, polypeptides, polynucleotides (e.g., DNA, RNA), carbohydrates, lipids, synthetic polymers (e.g., polymers of PEG).
  • nucleic acid molecule e.g., a dsRNA molecule (e.g., a dsRNA molecule described herein)).
  • non-complementary nucleotide mismatch refers to a nucleotide within a region of complementarity (as described herein) that is not complementary to the corresponding nucleotide in the target nucleic acid molecule.
  • obtaining a sample refers to the acquisition of a sample. The term includes the direct acquisition from a subject and the indirect acquisition through one or more third parties wherein one of the third parties directly acquired the sample from the subject.
  • operably connected refers to the linkage of two moieties in a functional relationship.
  • a polypeptide is operably connected to another polypeptide when they are linked (either directly or indirectly via a peptide linker) in frame such that both polypeptides are functional (e.g., a fusion protein described herein).
  • a transcription regulatory polynucleotide e.g., a promoter, enhancer, or other expression control element is operably linked to a polynucleotide that encodes a protein if it affects the transcription of the polynucleotide that encodes the protein.
  • operably connected can also refer to the conjugation of a moiety to e.g., a polynucleotide or polypeptide (e.g., the conjugation of a PEG polymer to a protein).
  • “partially complementary” means that in a hybridized pair of a first nucleic acid molecule and a second nucleic acid molecule, at least 70%, but not all, of the bases in a contiguous sequence of the first nucleic acid molecule will hybridize with the same number of bases in a contiguous sequence of the second nucleic acid molecule.
  • the contiguous sequence may comprise all or a part of a first or second nucleic acid molecule.
  • identity between two sequences (e.g., protein (amino acid sequences) or polynucleotide (nucleic acid sequences)) can be accomplished using a mathematical algorithm. Determinations of identity (as described herein) are independent of nucleotide chemical modifications (e.g., as described herein). For example, (mC) is identical to (C) for the purposes of determining identity.
  • Gapped BLAST can be utilized as described in Altschul SF et al., (1997) Nuc Acids Res 25: 3389-3402, which is herein incorporated by reference in its entirety.
  • PSI BLAST can be used to perform an iterated search which detects distant relationships between molecules (Id.).
  • the default parameters of the respective programs e.g., of XBLAST and NBLAST
  • NCBI National Center for Biotechnology Information
  • Another specific, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11-17, which is herein incorporated by reference in its entirety.
  • the term “pharmaceutical composition” means a composition that is suitable for administration to an animal, e.g., a human subject, and comprises a therapeutic agent and a pharmaceutically acceptable carrier or diluent.
  • a “pharmaceutically acceptable carrier or diluent” means a substance intended for use in contact with the tissues of human beings and/or non-human animals, and without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable therapeutic benefit/risk ratio.
  • the term “plurality” means 2 or more (e.g., 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 9 or more, or 10 or more).
  • polynucleotide and “nucleic acid molecule” are used interchangeably herein and refer to a polymer of DNA or RNA.
  • the nucleic acid molecule can be single- stranded or double-stranded; contain natural, non-natural, or altered nucleotides; and contain a natural, non-natural, or altered internucleoside linkage, such as a phosphoroamidate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified nucleic acid molecule.
  • Nucleic acid molecules include, but are not limited to, all nucleic acid molecules which are obtained by any means available in the art, including, without limitation, recombinant means, e.g., the cloning of nucleic acid molecules from a recombinant library or a cell genome, using ordinary cloning technology and polymerase chain reaction, and the like, and by synthetic means.
  • recombinant means e.g., the cloning of nucleic acid molecules from a recombinant library or a cell genome
  • synthetic means e.g., the cloning of nucleic acid molecules from a recombinant library or a cell genome, using ordinary cloning technology and polymerase chain reaction, and the like, and by synthetic means.
  • recombinant means e.g., the cloning of nucleic acid molecules from a recombinant library or a cell genome, using ordinary cloning technology and polymerase chain reaction, and the like, and
  • any of the RNA polynucleotides encoded by a DNA identified by a particular sequence identification number may also comprise the corresponding RNA (e.g., mRNA) sequence encoded by the DNA, where each thymidine (T) of the DNA sequence is substituted with uracil (U).
  • RNA e.g., mRNA
  • T thymidine
  • U uracil
  • the terms “protein” and “polypeptide” refers to a polymer of at least 2 (e.g., at least 5) amino acids linked by a peptide bond.
  • the term “polypeptide” does not denote a specific length of the polymer chain of amino acids. It is common in the art to refer to shorter polymers of amino acids (e.g., approximately 2-50 amino acids) as peptides; and to refer to longer polymers of amino acids (e.g., approximately over 50 amino acids) as polypeptides.
  • the terms “peptide” and “polypeptide” and “protein” are used interchangeably herein.
  • the protein is folded into its three-dimensional structure.
  • proteins folded into their three-dimensional structure are also provided herein as well as polypeptides in the primary structure. Proteins can include more than one polypeptide (e.g., customarily referred to as the quaternary structure).
  • region of complementarity refers to a portion of a first nucleic acid molecule comprising a nucleotide sequence that is at least partially complementary to the nucleotide sequence of at least a portion of a second nucleic acid molecule.
  • RNA and “polyribonucleotide” are used interchangeably herein and refer to macromolecules that include multiple ribonucleotides that are polymerized via phosphodiester bonds. Ribonucleotides are nucleotides in which the sugar is ribose. RNA may contain modified nucleotides; and contain natural, non-natural, or altered internucleoside linkages, such as a phosphoroamidate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified nucleic acid molecule.
  • RNAi agent refers to an agent that contains one or more RNA molecules which can mediate the targeted cleavage of an RNA molecule (e.g., an mRNA molecule) via an RNA-induced silencing complex (RISC) pathway.
  • RISC RNA-induced silencing complex
  • the RNAi agent is thereby capable of e.g., modulating, e.g., inhibiting, the expression of a target gene (e.g., FASN) in a cell, e.g., a cell within a subject, such as a mammalian subject.
  • a target gene e.g., FASN
  • the RNAi agent is a dsRNA agent comprising a sense strand and an antisense strand that form a double stranded region, wherein optionally the sense strand and the antisense strand each independently comprise or consist of from about 19-23 nucleotides.
  • sample encompasses a variety of biological specimens obtained from a subject.
  • sample types include, e.g., blood, red blood cells, and other liquid samples of biological origin (including, but not limited to, whole-blood, red blood cells (e.g., isolated from whole blood), peripheral blood mononuclear cells (PBMCs), serum, plasma, urine, saliva, amniotic fluid, stool, synovial fluid, etc.), nasopharyngeal swabs, solid tissue samples such as biopsies (or cells derived therefrom and the progeny thereof), tissue cultures (or cells derived therefrom and the progeny thereof), and cell cultures (or cells derived therefrom and the progeny thereof).
  • PBMCs peripheral blood mononuclear cells
  • nasopharyngeal swabs solid tissue samples such as biopsies (or cells derived therefrom and the progeny thereof), tissue cultures (or cells derived therefrom and the progeny thereof), and cell cultures (or cells derived therefrom and the progeny thereof).
  • RNA molecule refers to an RNA molecule (e.g., part of an RNAi agent (e.g., described herein), part of a dsRNA agent (e.g., described herein)) that comprises a region that is at least partially (e.g., substantially, fully) complementary to a region of the antisense strand (as defined herein).
  • the sense strand is often referred to as such with reference to the orientation of the sequence of the sense strand being the same with respect to a target RNA (e.g., mRNA sequence).
  • a target RNA e.g., mRNA sequence.
  • the term “somatic mutation” refers to one or more nucleotide alteration (e.g., variation, modification (e.g., variation)) in a genomic DNA sequence (e.g., of a gene) that is acquired during the lifetime of a subject. It is understood in the art that somatic mutations are not present in the germline DNA of an individual and are therefore not inherited from a parent like germline polymorphisms.
  • Somatic mutations may occur spontaneously due to e.g., the infidelity of DNA replication occurring at each cell division creating substitutions, deletions, or additions of nucleotides into the DNA of a cell.
  • a somatic mutation may also be caused by environmental factors such as e.g., ultraviolet radiation, chemical exposure, or virial infections.
  • the term “subject” includes any animal, such as a human or other animal.
  • the subject is a vertebrate animal (e.g., mammal, bird, fish, reptile, or amphibian).
  • the subject is a human.
  • the method subject is a non-human mammal.
  • the subject is a non-human mammal is such as a non-human primate (e.g., monkeys, apes), ungulate (e.g., cattle, buffalo, sheep, goat, pig, camel, llama, alpaca, deer, horses, donkeys), carnivore (e.g., dog, cat), rodent (e.g., rat, mouse), or lagomorph (e.g., rabbit).
  • a non-human primate e.g., monkeys, apes
  • ungulate e.g., cattle, buffalo, sheep, goat, pig, camel, llama, alpaca, deer, horses, donkeys
  • carnivore e.g., dog, cat
  • rodent e.g., rat, mouse
  • lagomorph e.g., rabbit
  • the subject is a bird, such as a member of the avian taxa Galliformes (e.g., chickens, turkeys, pheasants, quail), Anseriformes (e.g., ducks, geese), Paleaognathae (e.g., ostriches, emus), Columbiformes (e.g., pigeons, doves), or Psittaciformes (e.g., parrots).
  • avian taxa Galliformes e.g., chickens, turkeys, pheasants, quail
  • Anseriformes e.g., ducks, geese
  • Paleaognathae e.g., ostriches, emus
  • Columbiformes e.g., pigeons, doves
  • Psittaciformes e.g., par
  • substantially complementary means that in a hybridized pair of a first nucleic acid molecule and a second nucleic acid molecule, at least 85%, but not all, of the bases in a contiguous sequence of the first nucleic acid molecule will hybridize with the same number of bases in a contiguous sequence of the second nucleic acid molecule.
  • the contiguous sequence may comprise all or a part of a first or second nucleic acid molecule.
  • the term “substantially all” means at least 95%, 96%, 97%, 98% or 99%, e.g., of the subject of said sentence.
  • the term “substantially all” preferably excludes 100%.
  • the term “substantially all of the nucleotides in the sense strand and/or antisense strand are modified” means that at least 95%, 96%, 97%, 98% or 99% of said nucleotides are modified.
  • the term “substantially all of the nucleotides of the agent are modified” means that at least 95%, 96%, 97%, 98% or 99% of said nucleotides are modified.
  • the term “substantially all of the nucleotides of the agent are unmodified” means that at least 95%, 96%, 97%, 98% or 99% of said nucleotides are unmodified.
  • the term “wherein the dsRNA agent is in the sodium salt form, sodium ions are present in the composition comprising the dsRNA agent as counterions for substantially all of the phosphodiester or phosphorothioate groups present in the dsRNA agent” means that wherein the dsRNA agent is in the sodium salt form, sodium ions are present in the composition comprising the dsRNA agent as counterions for at least 95%, 96%, 97%, 98% or 99% of the phosphodiester or phosphorothioate groups present in the dsRNA agent.
  • target nucleic acid sequence refers to a contiguous portion of the nucleotide sequence of a nucleic acid sequence (e.g., an mRNA molecule formed during the transcription of a target gene (e.g., FASN)).
  • target nucleic acid sequence is an mRNA molecule formed during the transcription of a target gene (e.g., FASN)).
  • target nucleic acid molecule comprises an mRNA that is a product of RNA processing of a primary transcription product.
  • the target portion of the sequence (e.g., mRNA) will be at least long enough to serve as a substrate for RNAi-directed cleavage at or near that portion of the nucleotide sequence of an mRNA molecule formed during the transcription of a FASN gene.
  • the target sequence is within the protein coding region of FASN.
  • the term “therapeutically effective amount” of a therapeutic agent refers to any amount of the therapeutic agent that, when used alone or in combination with another therapeutic agent, improves a disease condition, e.g., protects a subject against the onset of a disease (or infection); improves a symptom of disease or infection, e.g., decreases severity of disease or infection symptoms, decreases frequency or duration of disease or infection symptoms, increases disease or infection symptom-free periods; prevents or reduces impairment or disability due to the disease or infection; or promotes disease (or infection) regression.
  • a disease condition e.g., protects a subject against the onset of a disease (or infection); improves a symptom of disease or infection, e.g., decreases severity of disease or infection symptoms, decreases frequency or duration of disease or infection symptoms, increases disease or infection symptom-free periods; prevents or reduces impairment or disability due to the disease or infection; or promotes disease (or infection) regression.
  • a therapeutic agent to improve a disease condition can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays.
  • the terms “treat,” treating,” “treatment,” and the like refer to reducing or ameliorating a disease and/or symptom(s) associated therewith or obtaining a desired pharmacologic and/or physiologic effect. It will be appreciated that, although not precluded, treating a disease does not require that the disease, or symptom(s) associated therewith be completely eliminated.
  • the effect is therapeutic, i.e., without limitation, the effect partially or completely reduces, diminishes, abrogates, abates, alleviates, decreases the intensity of, or cures a disease and/or adverse symptom attributable to the disease.
  • the effect is preventative, i.e., the effect protects or prevents an occurrence or reoccurrence of a disease.
  • the presently disclosed methods comprise administering a therapeutically effective amount of a compositions as described herein.
  • RNAi agents useful in, inter alia, inhibiting expression of fatty acid synthase (FASN) (e.g., human FASN (hFASN)) (e.g., within a cell, e.g., within a cell in a subject, e.g., a mammalian subject, e.g., a human subject) (e.g., through the degradation of FASN (e.g., hFASN) mRNA).
  • FASN fatty acid synthase
  • hFASN human FASN
  • FASN fatty acid synthase
  • FASN is a key enzyme in the endogenous lipogenesis pathway.
  • FASN primarily catalyzes the synthesis of fatty acids (principally the long-chain saturated fatty acid palmitate) from acetyl-CoA and malonyl-CoA using NADPH as a reducing agent.
  • the mRNA sequence of a reference hFASN gene is set forth in SEQ ID NO: 1.
  • the reverse complement sequence of the hFASN mRNA is set forth in SEQ ID NO: 2.
  • the amino acid sequence of the hFASN protein encoded by the hFASN reference gene is set forth in SEQ ID NO: 3. See Table 1, herein.
  • the agent comprises one or more RNA molecule.
  • the agent e.g., RNAi agent, dsRNA agent
  • the agent e.g., RNAi agent, dsRNA agent
  • the agent comprises a sense strand.
  • the agent comprises one or more single stranded RNA (ssRNA) molecules.
  • the agent e.g., RNAi agent, dsRNA agent
  • the agent comprises a dsRNA agent comprising a sense strand and an antisense strand.
  • the agent e.g., RNAi agent
  • the agent e.g., RNAi agent
  • the sense strand and the antisense strand are part of a single nucleic acid molecule (e.g., a single nucleic acid molecule comprising a hairpin loop). In some embodiments, the sense strand and the antisense strand are separate nucleic acid molecules.
  • antisense Strands comprise a region of complementarity that comprises a nucleotide sequence that is at least partially (e.g., substantially, fully) complementary to the nucleotide sequence of a target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • a target nucleic acid molecule e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)
  • the nucleotide sequence of the region of complementarity is at least substantially complementary to the nucleotide sequence of the target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • the nucleotide sequence of the region of complementarity is fully complementary to the nucleotide sequence of the target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • the nucleotide sequence of the region of complementarity is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to the nucleotide sequence of the target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • a target mRNA e.g., a FASN mRNA
  • a portion of a target mRNA e.g., a FASN mRNA
  • the nucleotide sequence of the region of complementarity may be at least 70% complementary to the nucleotide sequence of the target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • the nucleotide sequence of the region of complementarity may be at least 75% complementary to the nucleotide sequence of the target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • the nucleotide sequence of the region of complementarity may be at least 80% complementary to the nucleotide sequence of the target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • the nucleotide sequence of the region of complementarity may be at least 85% complementary to the nucleotide sequence of the target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • the nucleotide sequence of the region of complementarity may be at least 90% complementary to the nucleotide sequence of the target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • the nucleotide sequence of the region of complementarity may be at least 95% complementary to the nucleotide sequence of the target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • the nucleotide sequence of the region of complementarity is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to the nucleotide sequence of the target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • a target mRNA e.g., a FASN mRNA
  • a portion of a target mRNA e.g., a FASN mRNA
  • the nucleotide sequence of the region of complementarity is at least 95%, 96%, 97%, 98%, 99%, or 100% (e.g., in some embodiments, preferably at least 95%, more preferably at least 98%) complementary to the nucleotide sequence of the target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • a target mRNA e.g., a FASN mRNA
  • a portion of a target mRNA e.g., a FASN mRNA
  • the nucleotide sequence of the region of complementarity is 100% complementary to the nucleotide sequence of the target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • a target mRNA e.g., a FASN mRNA
  • a portion of a target mRNA e.g., a FASN mRNA
  • the nucleotide sequence of the region of complementarity comprises or consists of one or more non-complementary nucleotide mismatches relative to the nucleotide sequence of the target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)).
  • the nucleotide sequence of the region of complementarity comprises or consists of no more than 5 (e.g., 4, 3, 2, 1, or 0) non-complementary nucleotide mismatches relative to the nucleotide sequence of the target nucleic acid molecule.
  • the nucleotide sequence of the region of complementarity comprises or consists of no more than 3 (e.g., 2, 1, or 0) non- complementary nucleotide mismatches relative to the nucleotide sequence of the target nucleic acid molecule. In some embodiments, the nucleotide sequence of the region of complementarity comprises or consists of no more than 2 (e.g., 1 or 0) non-complementary nucleotide mismatches relative to the nucleotide sequence of the target nucleic acid molecule.
  • the nucleotide sequence of the region of complementarity comprises or consists of no more than 1 (e.g., 0) non-complementary nucleotide mismatch relative to the nucleotide sequence of the target nucleic acid molecule. In some embodiments, the nucleotide sequence of the region of complementarity comprises 0 non-complementary nucleotide mismatches relative to the nucleotide sequence of the target nucleic acid molecule.
  • the region of complementarity comprises one or more (e.g., 2, 3, or more) non- complementary nucleotide mismatches relative to the nucleotide sequence of the target nucleic acid molecule, wherein the one or more non-complementary nucleotide mismatches are within the last 5 (e.g., 4, 3, 2, or 1) nucleotides from either the 5′- and/or 3′-end of the region of complementarity.
  • the last 5 e.g., 4, 3, 2, or 1
  • the region of complementarity comprises at least one but not more than 3 non-complementary nucleotide mismatches relative to the nucleotide sequence of the target nucleic acid molecule, wherein the one or more non-complementary nucleotide mismatches are within the last 5 (e.g., 4, 3, 2, or 1) nucleotides from either the 5′- and/or 3′-end of the region of complementarity.
  • the region of complementarity comprises one or more (e.g., 2, 3, or more) non-complementary nucleotide mismatches relative to the nucleotide sequence of the target nucleic acid molecule, wherein the one or more non-complementary nucleotide mismatches are within the last 3 (e.g., 2 or 1) nucleotides from either the 5′- and/or 3′-end of the region of complementarity.
  • the last 3 e.g., 2 or 1
  • the region of complementarity comprises at least one but not more than 3 non- complementary nucleotide mismatches relative to the nucleotide sequence of the target nucleic acid molecule, wherein the one or more non-complementary nucleotide mismatches are within the last 3 (e.g., 2 or 1) nucleotides from either the 5′- and/or 3′-end of the region of complementarity.
  • a target nucleic acid molecule e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)
  • a target mRNA e.g., a FASN mRNA
  • a portion of a target mRNA e.g., a FASN mRNA
  • the region of complementarity comprises or consists of from about 15-30 nucleotides, e.g., 15-29, 15-28, 15-27, 15- 26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18- 21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20- 30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides.
  • 15-30 nucleotides e.g., 15-29, 15-28, 15-27, 15- 26, 15-25, 15-24,
  • the region of complementarity comprises from about 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-25, 19- 24, 19-23, 19-22, 19-21, 19-20, 20-25, 20-24,20-23, 20-22, 20-21, 21-25, 21-24, 21-23, 21-22, 22- 25, 22-24, 22-23, 23-25, 23-24 or 24-25 nucleotides.
  • the region of complementarity comprises from about 19-21 (e.g., 19-20) nucleotides.
  • the region of complementarity comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides.
  • the region of complementarity comprises or consists of about 19, 20, 21, 22, or 23 nucleotides. In some embodiments, the region of complementarity comprises or consists of about 19 nucleotides. In some embodiments, the region of complementarity comprises or consists of about 20 nucleotides. In some embodiments, the region of complementarity comprises or consists of about 21 nucleotides. In some embodiments, the region of complementarity comprises or consists of about 22 nucleotides. In some embodiments, the region of complementarity comprises or consists of about 23 nucleotides. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.
  • the target nucleic acid molecule is part (e.g., a contiguous portion) of a larger nucleic acid molecule.
  • the target nucleic acid molecule is a portion (e.g., a contiguous portion) of a target mRNA (e.g., a FASN mRNA).
  • the target nucleic acid molecule is a contiguous nucleotide sequence of a target mRNA (e.g., a FASN mRNA) of sufficient length to allow it to be a substrate for cleavage directed by an RNAi agent (e.g., an RNAi agent described herein, e.g., a dsRNA agent (e.g., described herein)) (i.e., cleavage through a RISC pathway).
  • an RNAi agent e.g., an RNAi agent described herein, e.g., a dsRNA agent (e.g., described herein)
  • the target nucleic acid molecule is a target mRNA (e.g., a FASN mRNA).
  • the target nucleic acid molecule is at least a portion (e.g., a portion) of a target mRNA (e.g., a FASN mRNA). In some embodiments, the target nucleic acid molecule is at least a portion (e.g., a portion) of an mRNA (e.g., a FASN mRNA) formed in the expression of a target gene (e.g., a mammalian, primate, human, non-human primate, mouse, and/or rat gene) (e.g., a FASN gene).
  • a target gene e.g., a mammalian, primate, human, non-human primate, mouse, and/or rat gene
  • the target nucleic acid molecule is at least a portion (e.g., a portion) of a FASN (e.g., hFASN) mRNA. In some embodiments, the target nucleic acid molecule is at least a portion (e.g., a portion) of an mRNA formed in the expression of a FASN (e.g., hFASN) gene. In some embodiments, the target nucleic acid molecule comprises at least a portion (e.g., a portion) of the nucleotide sequence set forth in SEQ ID NO: 1 (or a variant or fragment thereof).
  • the target nucleic acid molecule comprises at least a portion (e.g., a portion) of an mRNA encoding a target protein. In some embodiments, the target nucleic acid molecule comprises at least a portion (e.g., a portion) of an mRNA encoding a FASN (e.g., hFASN) protein. In some embodiments, the target nucleic acid molecule comprises at least a portion (e.g., a portion) of an mRNA sequence encoding a protein comprising the amino acid sequence set forth in SEQ ID NO: 3 (or a variant or fragment thereof).
  • the target nucleic acid molecule comprises or consists of from about 19-30 nucleotides, e.g., 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21- 29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, 21-22, 22-30, 22-29, 22-28, 22-27, 22-26, 22- 25, 22-24, 22-23, 23-30, 23-29, 23-28, 23-27, 23-26, 23-27, 23-26, 23-25, or 23-24 nucleotides.
  • the target nucleic acid molecule comprises or consists of from about 19-25 nucleotides. In some embodiments, the target nucleic acid molecule comprises or consists of from about 19-23 nucleotides. In some embodiments, the target nucleic acid molecule comprises or consists of from about 21-25 nucleotides. In some embodiments, the target nucleic acid molecule comprises or consists of from about 21-23 nucleotides. In some embodiments, the target nucleic acid molecule comprises or consists of about 19, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the target nucleic acid molecule comprises or consists of about 19 nucleotides.
  • the target nucleic acid molecule comprises or consists of about 20 nucleotides. In some embodiments, the target nucleic acid molecule comprises or consists of about 21 nucleotides. In some embodiments, the target nucleic acid molecule comprises or consists of about 23 nucleotides. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.
  • the antisense strand comprises or consists of from about 15- 30 nucleotides (e.g., 15-29, 15-28, 15-27, 15- 26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18- 20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20- 29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides).
  • 15- 30 nucleotides e.g., 15-29, 15-28, 15-27, 15- 26, 15-25, 15-24,
  • the antisense strand comprises or consists of from about 18-25 nucleotides (e.g., 18-24, 18-23, 18-22, 18-21, 18- 20, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-25, 20-24,20-23, 20-22, 20-21, 21-25, 21-24, 21-23, 21-22, 22- 25, 22-24, 22-23, 23-25, 23-24 or 24-25 nucleotides).
  • 18-25 nucleotides e.g., 18-24, 18-23, 18-22, 18-21, 18- 20, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-25, 20-24,20-23, 20-22, 20-21, 21-25, 21-24, 21-23, 21-22, 22- 25, 22-24, 22-23, 23-25, 23-24 or 24-25 nucleotides.
  • the antisense strand comprises or consists of from about 19-25 nucleotide (e.g., 19-20, 19-21, 19-22, 19-23, 19-24, 19-25, 20-21, 20-22, 20-23, 20-24, 20-25, 21-22, 21-23, 21-24, 21-25, 22- 23, 22-24, 22-25, 23-24, 23-25, 24-25 nucleotides).
  • the antisense strand comprises or consists of from about 15-30, 16-30, 17-30, 18-30, 19-3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19-22, 19-23, 19-24, or 19-25 nucleotides.
  • the antisense strand comprises or consists of not more than about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the antisense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the antisense strand comprises or consists of about 21 nucleotides. In some embodiments, the antisense strand comprises or consists of about 23 nucleotides. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.
  • the antisense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2 or Table 3.
  • 15 e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))
  • 3 e.g., 0, 1, 2, or 3
  • the antisense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2 or Table 3.
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2 or Table 3.
  • 21 e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))
  • 3 e.g., 0, 1, 2, or 3
  • the antisense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2 or Table 3.
  • the antisense strand comprises from about 15-23 (e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19- 20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2 or Table 3.
  • 15-23 e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21
  • the antisense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2 or Table 3.
  • 19-23 e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2 or Table 3.
  • the antisense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2 or Table 3.
  • the nucleotide sequence of the antisense strand comprises the nucleotide sequence of any one of the antisense strands set forth in Table 2 or Table 3 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the antisense strand set forth in Table 2 or Table 3.
  • the nucleotide sequence of the antisense strand comprises the nucleotide sequence of any one of the antisense strands set forth in Table 2 or Table 3. [0030] Table 2 and Table 3 further identify the target nucleic acid molecule within the cited reference FASN mRNA transcript (SEQ ID NO: 1) targeted by each of the antisense strands.
  • the disclosure further provides antisense strands comprising at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2 or Table 3 and further comprising additional nucleotide sequences (e.g., comprising from about 1-10, 1-9, 1- 8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2 nucleotides) at least partially complementary to the region contiguous (e.g., either at the 3′ end, the 5′ end, or both the 3′ and 5′ end) of the FASN mRNA transcript targeted by the select antisense strand.
  • additional nucleotide sequences e.g., comprising from about 1-10, 1-9, 1-
  • the antisense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 232-459 or 916-1143.
  • the antisense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in SEQ ID NOS: 232-459 or 916-1143.
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 232-459 or 916-1143.
  • the antisense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 232-459 or 916-1143.
  • the antisense strand comprises from about 15-23 (e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19- 20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 232-459 or 916-1143.
  • 15-23 e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22,
  • the antisense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 232-459 or 916-1143.
  • 19-23 e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 232-459 or 916-1143.
  • the antisense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 232-459 or 916-1143.
  • the nucleotide sequence of the antisense strand comprises the nucleotide sequence set forth in any one of SEQ ID NOS: 232-459 or 916-1143 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 232-459 or 916-1143.
  • the nucleotide sequence of the antisense strand comprises the nucleotide sequence set forth in any one of SEQ ID NOS: 232-459 or 916-1143.
  • Table 2 and Table 3 further identify the target nucleic acid molecule within the cited reference FASN mRNA transcript (SEQ ID NO: 1) targeted by each of the antisense strands.
  • the disclosure further provides antisense strands comprising at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 232-459 or 916-1143 and further comprising additional nucleotide sequences (e.g., comprising from about 1-10, 1-9, 1- 8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2 nucleotides) at least partially complementary to the region contiguous (e.g., either at the 3′ end, the 5′ end, or both
  • the antisense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • 3 e.g., 0, 1, 2, or 3
  • the antisense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • 19 e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))
  • 3 e.g., 0, 1, 2, or 3
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • 21 e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))
  • 3 e.g., 0, 1, 2, or 3
  • the antisense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • the antisense strand comprises from about 15-23 (e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19- 20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • 15-23 e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19,
  • the antisense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20- 23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • 19-23 e.g., 19-22, 19-21, 19-20, 20- 23, 20-22, 20-21, 21-23, 21-22, 22-23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • the antisense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • the nucleotide sequence of the antisense strand comprises the nucleotide sequence of any one of the antisense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the antisense strand set forth in Table 2 or Table 3.
  • the nucleotide sequence of the antisense strand comprises the nucleotide sequence of any one of the antisense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • Table 2 and Table 3 further identify the target nucleic acid molecule within the cited reference FASN mRNA transcript (SEQ ID NO: 1) targeted by each of the antisense strands.
  • the disclosure further provides antisense strands comprising at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3 and further comprising additional nucleotide sequences (e.g., comprising from about 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2 nucleotides) at least partially complementary to the region contiguous (e.g., either at
  • antisense strands set forth in Table 2 are not described as being modified (e.g., comprising chemically modified nucleotides), conjugated, etc., the disclosure includes any antisense strand set forth in Table 2 that is unmodified, unconjugated, modified (e.g., as described herein), or conjugated (e.g., as described herein).
  • the antisense strands set forth in Table 3 are modified (e.g., comprising chemically modified nucleotides), conjugated, etc.
  • the disclosure includes any antisense strand set forth in Table 3 that is unmodified, unconjugated, alternatively modified (e.g., as described herein), or conjugated (e.g., as described herein).
  • sense strands comprise a region of complementarity that comprises a nucleotide sequence that is at least partially (e.g., substantially, fully) complementary to the nucleotide sequence of at least a portion of an antisense strand.
  • pairs of sense and antisense strands can hybridize to form a double stranded region (e.g., under conditions in which the pairs will be used).
  • the nucleotide sequence of the region of complementarity is at least substantially complementary to the nucleotide sequence of at least a portion of an antisense strand.
  • the nucleotide sequence of the region of complementarity is fully complementary to the nucleotide sequence of at least a portion of an antisense strand.
  • the nucleotide sequence of the region of complementarity is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to the nucleotide sequence of at least a portion of an antisense strand.
  • the nucleotide sequence of the region of complementarity may be at least 70% complementary to the nucleotide sequence of at least a portion of an antisense strand.
  • the nucleotide sequence of the region of complementarity may be at least 75% complementary to the nucleotide sequence of at least a portion of an antisense strand.
  • the nucleotide sequence of the region of complementarity may be at least 80% complementary to the nucleotide sequence of at least a portion of an antisense strand.
  • the nucleotide sequence of the region of complementarity may be at least 85% complementary to the nucleotide sequence of at least a portion of an antisense strand.
  • the nucleotide sequence of the region of complementarity may be at least 90% complementary to the nucleotide sequence of at least a portion of an antisense strand.
  • the nucleotide sequence of the region of complementarity may be at least 95% complementary to the nucleotide sequence of at least a portion of an antisense strand. In some embodiments, the nucleotide sequence of the region of complementarity is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to the nucleotide sequence of at least a portion of an antisense strand. In some embodiments, the nucleotide sequence of the region of complementarity is at least 95%, 96%, 97%, 98%, 99%, or 100% complementary to the nucleotide sequence of at least a portion of an antisense strand.
  • the nucleotide sequence of the region of complementarity comprises or consists of one or more non-complementary nucleotide mismatches relative to the nucleotide sequence of the at least a portion of an antisense strand. In some embodiments, the nucleotide sequence of the region of complementarity comprises or consists of no more than 5 (e.g., 4, 3, 2, 1, or 0) non-complementary nucleotide mismatches relative to the nucleotide sequence of the at least a portion of an antisense strand.
  • the nucleotide sequence of the region of complementarity comprises or consists of no more than 3 (e.g., 2, 1, or 0) non-complementary nucleotide mismatches relative to the nucleotide sequence of the at least a portion of an antisense strand. In some embodiments, the nucleotide sequence of the region of complementarity comprises or consists of no more than 2 (e.g., 1 or 0) non- complementary nucleotide mismatches relative to the nucleotide sequence of the at least a portion of an antisense strand.
  • the nucleotide sequence of the region of complementarity comprises or consists of no more than 1 (e.g., 0) non-complementary nucleotide mismatches relative to the nucleotide sequence of the at least a portion of an antisense strand. In some embodiments, the nucleotide sequence of the region of complementarity comprises 0 non-complementary nucleotide mismatches relative to the nucleotide sequence of the at least a portion of an antisense strand.
  • the region of complementarity comprises one or more (e.g., 2, 3, or more) non-complementary nucleotide mismatches relative to the nucleotide sequence of the at least a portion of an antisense strand, wherein the one or more non-complementary nucleotide mismatch is within the last 5 (e.g., 4, 3, 2, or 1) nucleotides from either the 5′- and/or 3′-end of the region of complementarity.
  • the last 5 e.g., 4, 3, 2, or 1
  • the region of complementarity comprises at least one but not more than 3 (e.g., 1, 2, or 3) non-complementary nucleotide mismatches relative to the nucleotide sequence of the at least a portion of an antisense strand, wherein the one or more non-complementary nucleotide mismatch is within the last 5 (e.g., 4, 3, 2, or 1) nucleotides from either the 5′- and/or 3′-end of the region of complementarity.
  • 3 e.g., 1, 2, or 3
  • the region of complementarity comprises at least one but not more than 3 (e.g., 1, 2, or 3) non-complementary nucleotide mismatches relative to the nucleotide sequence of the at least a portion of an antisense strand, wherein the one or more non-complementary nucleotide mismatch is within the last 5 (e.g., 4, 3, 2, or 1) nucleotides from either the 5′- and/or 3′-
  • the region of complementarity comprises from about 15-30 nucleotides, e.g., 15-29, 15-28, 15-27, 15- 26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15- 19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18- 20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20- 29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides.
  • the region of complementarity comprises from about 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-25, 19- 24, 19-23, 19-22, 19-21, 19-20, 20-25, 20-24,20-23, 20-22, 20-21, 21-25, 21-24, 21-23, 21-22, 22- 25, 22-24, 22-23, 23-25, 23-24 or 24-25 nucleotides.
  • the region of complementarity comprises from about 19-21 (e.g., 19-20) nucleotides.
  • the region of complementarity comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides.
  • the region of complementarity comprises or consists of about 19, 20, or 21 nucleotides. In some embodiments, the region of complementarity comprises or consists of about 19 nucleotides. In some embodiments, the region of complementarity comprises or consists of about 20 nucleotides. In some embodiments, the region of complementarity comprises or consists of about 21 nucleotides. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.
  • the sense strand comprises or consists of from about 15-30 nucleotides (e.g., 15-29, 15-28, 15-27, 15- 26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15- 19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18- 20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20- 29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides).
  • 15-30 nucleotides e.g., 15-29, 15-28, 15-27, 15- 26, 15-25, 15-24, 15-23,
  • the sense strand comprises or consists of from about 18-25 nucleotides (e.g., 18-24, 18-23, 18-22, 18-21, 18-20, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-25, 20-24,20-23, 20-22, 20-21, 21-25, 21-24, 21-23, 21- 22, 22- 25, 22-24, 22-23, 23-25, 23-24 or 24-25 nucleotides).
  • 18-25 nucleotides e.g., 18-24, 18-23, 18-22, 18-21, 18-20, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-25, 20-24,20-23, 20-22, 20-21, 21-25, 21-24, 21-23, 21- 22, 22- 25, 22-24, 22-23, 23-25, 23-24 or 24-25 nucleotides.
  • the sense strand comprises or consists of from about 19-25 nucleotide (e.g., 19-20, 19-21, 19-22, 19-23, 19-24, 19-25, 20-21, 20-22, 20-23, 20-24, 20-25, 21-22, 21-23, 21-24, 21-25, 22-23, 22-24, 22- 25, 23-24, 23-25, 24-25 nucleotides).
  • the sense strand comprises or consists of from about 15-30, 16-30, 17-30, 18-30, 19-3020-30, 21-30, 22-30, 23-30, 24-30, 25-30, 36-30, 27-30, 28-30-, 29-30, 19-20, 19-21, 19-22, 19-23, 19-24, or 19-25 nucleotides.
  • the sense strand comprises or consists of not more than about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the sense strand comprises or consists of about 19, 20, 21, 22, 23 nucleotides. In some embodiments, the sense strand comprises or consists of about 19, 20, 21 nucleotides. In some embodiments, the sense strand comprises or consists of about 20 nucleotides. In some embodiments, the sense strand comprises or consists of about 21 nucleotides.
  • the sense strand comprises or consists of about 21 nucleotides. In some embodiments, the sense strand comprises or consists of about 23 nucleotides. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.
  • the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2 or Table 3.
  • 15 e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))
  • 3 e.g., 0, 1, 2, or 3
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2 or Table 3.
  • 19 e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
  • 19 e.g., 19, 20, 21, 22, 23 (e.g., 23)
  • 3 e.g., 0, 1, 2, or 3
  • the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2 or Table 3.
  • the sense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2 or Table 3.
  • the sense strand comprises from about 15-23 (e.g., 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17-22, 17- 21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19-20, 20- 23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2 or Table 3.
  • 15-23 e.g., 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17-22, 17- 21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18
  • the sense strand comprises from about 19- 23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2 or Table 3.
  • the sense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2 or Table 3.
  • the nucleotide sequence of the sense strand comprises the nucleotide sequence of any one of the sense strands set forth in Table 2 or Table 3 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the sense strand set forth in Table 2 or Table 3.
  • the nucleotide sequence of the sense strand comprises the nucleotide sequence of any one of the sense strands set forth in Table 2 or Table 3.
  • Table 2 and Table 3 further identify the target nucleic acid molecule within the reference FASN mRNA transcript at least partially identical to each of the sense strands.
  • the disclosure further provides sense strands comprising at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2 or Table 3 and further comprising additional nucleotide sequences (e.g., comprising from about 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2 nucleotides) at least partially identical to the region contiguous (e.g., either at the 3′ end, the 5′ end, or both the 3′ and 5′ end) of the FASN mRNA transcript identical to the select sense strand.
  • additional nucleotide sequences e.g., comprising from about 1-10, 1-9, 1-8, 1-7,
  • the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 4-231 or 688-915.
  • 15 e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))
  • contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 4-231 or 688-915.
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in SEQ ID NOS: 4-231 or 688-915.
  • 19 e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))
  • contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in SEQ ID NOS: 4-231 or 688-915.
  • the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 4-231 or 688-915.
  • the sense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 4-231 or 688-915.
  • the sense strand comprises from about 15-23 (e.g., 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17-22, 17- 21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19-20, 20- 23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 4-231 or 688-915.
  • 15-23 e.g., 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17-22, 17- 21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21,
  • the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 4-231 or 688-915.
  • 19-23 e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 4-231 or 688-915.
  • the sense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 4-231 or 688-915.
  • the nucleotide sequence of the sense strand comprises the nucleotide sequence set forth in any one of SEQ ID NOS: 4-231 or 688-915 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 4-231 or 688-915.
  • the nucleotide sequence of the sense strand comprises the nucleotide sequence set forth in any one of SEQ ID NOS: 4-231 or 688- 915.
  • Table 2 and Table 3 further identify the target nucleic acid molecule within the reference FASN mRNA transcript at least partially identical to each of the sense strands.
  • disclosure further provides sense strands comprising at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence set forth in any one of SEQ ID NOS: 4-231 or 688-915 and further comprising additional nucleotide sequences (e.g., comprising from about 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2 nucleotides) at least partially identical to the region contiguous (e.g., either at the 3′ end, the 5′ end, or both the 3′ and 5′ end) of the FASN mRNA transcript identical to the select sense strand.
  • additional nucleotide sequences e.g., comprising from about 1-10, 1-9, 1-8, 1
  • the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • 3 e.g., 0, 1, 2, or 3
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • 19 e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))
  • contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • 21 e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))
  • 3 e.g., 0, 1, 2, or 3
  • the sense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • the sense strand comprises from about 15-23 (e.g., 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17-22, 17- 21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19-20, 20- 23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • 15-23 e.g., 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17-22, 17- 21, 17-20, 17-19, 17-18, 18-
  • the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21- 23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • 19-23 e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21- 23, 21-22, 22-23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • the sense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3.
  • the nucleotide sequence of the sense strand comprises the nucleotide sequence of any one of the sense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the sense strand set forth in Table 2 or Table 3.
  • the nucleotide sequence of the sense strand comprises the nucleotide sequence of any one of the sense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3. [0059] As described above, Table 2 and Table 3 further identify the target nucleic acid molecule within the reference FASN mRNA transcript at least partially identical to each of the sense strands.
  • disclosure further provides sense strands comprising at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands of any one of dsRNA agents 1-228 set forth in Table 2 or Table 3 and further comprising additional nucleotide sequences (e.g., comprising from about 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2 nucleotides) at least partially identical to the region contiguous (e.g., either at the 3′ end, the 5′ end, or both the 3′ and 5′ end) of the FASN mRNA transcript identical to the select sense strand.
  • additional nucleotide sequences e.g., comprising from about 1
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095- 1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060- 2095, 2066-2091, 2160-2195, 2160-2190, 2167-2187, 2220-2270, 2225-2263
  • the sense strand comprises at least 19 (e.g., 20, 21) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514- 558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048- 1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950-2010, 1955- 2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160-2190, 2167-2187, 2220-2270, 2225-2263, 2
  • the sense strand comprises at least 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436- 456, 510-565, 510-560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791-1811, 1945- 2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160-2190, 2167-2187, 2220-2270, 2225-2263, 2300-2340, 2311-2336, 2415
  • the sense strand comprises from about 15-23 (e.g., 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17-22, 17- 21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19-20, 20- 23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119
  • 15-23 e.
  • the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510- 560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045- 1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950- 2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091,
  • the sense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751- 771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575- 1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160-2190, 2167-2187, 2220-2270, 2225
  • Table 2 and Table 3 further identify the target nucleic acid molecule within the reference FASN mRNA transcript at least partially identical to each of the sense strands.
  • the disclosure further provides sense strands comprising at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751- 771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 14
  • sense strands set forth in Table 2 are not described as being modified (e.g., comprising chemically modified nucleotides), conjugated, etc., the disclosure includes any sense strand set forth in Table 2 that is unmodified, unconjugated, modified (e.g., as described herein), or conjugated (e.g., as described herein).
  • sense strands set forth in Table 3 are described as being modified (e.g., comprising chemically modified nucleotides), conjugated, etc., the disclosure includes any sense strand set forth in Table 3 that is unmodified, unconjugated, alternatively modified (e.g., as described herein), or conjugated (e.g., as described herein).
  • the agent comprises a dsRNA agent comprising an antisense strand (e.g., described herein, e.g., described in ⁇ 5.2.1) and a sense strand (e.g., described herein, e.g., described in ⁇ 5.2.2) that hybridize to form a double stranded region (e.g., under conditions in which the dsRNA will be used (e.g., under physiological (e.g., mammalian, e.g., human) conditions within a cell)).
  • a dsRNA agent comprising an antisense strand (e.g., described herein, e.g., described in ⁇ 5.2.1) and a sense strand (e.g., described herein, e.g., described in ⁇ 5.2.2) that hybridize to form a double stranded region (e.g., under conditions in which the dsRNA will be used (e.g., under physiological (e.g., mammalian,
  • antisense strands comprise a region of complementarity that comprises a nucleotide sequence that is at least partially (e.g., substantially, fully) complementary to the nucleotide sequence of a target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)); and the sense strands comprise a region of complementarity that comprises a nucleotide sequence that is at least partially (e.g., substantially, fully) complementary to the nucleotide sequence of at least a portion of an antisense strand.
  • a target nucleic acid molecule e.g., a target mRNA (e.g., a FASN mRNA), a portion of a target mRNA (e.g., a FASN mRNA)
  • the sense strands comprise a region of complementarity that comprises a nucleo
  • the sense strand and the antisense strand can be part of a single larger nucleic acid molecule (connected as a single stranded nucleic acid molecule) or separate nucleic acid molecules (only connected through the double stranded region).
  • the sense strand and the antisense strand are separate nucleic acid molecules.
  • sense strand and the antisense strand are part of a single larger nucleic acid molecule.
  • the nucleic acid molecule may comprise a hairpin loop between the antisense strand and the sense strand to allow for formation of the double stranded region.
  • the hairpin loop comprises at least 1 (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 23, 25 or more) unpaired nucleotides (non-complementary nucleotide mismatches).
  • the hairpin loop comprises at least one but less than 25, 23, 20, 10, 9, 8, 7, 6, 5, 4, 3, or 2 unpaired nucleotides (non-complementary nucleotide mismatches).
  • the hairpin loop comprises about 25, 23, 20, 9, 8, 7, 6, 5, 4, 3, or 1 unpaired nucleotide (non-complementary nucleotide mismatch).
  • a suitable cell e.g., a mammalian cell, e.g., a human cell
  • the nucleic acid molecule may be cleaved into a dsRNA molecule wherein the two strands of the dsRNA molecule are no longer part of the same nucleic acid molecule e.g., by a Type III endonuclease (e.g., Dicer) (see, e.g., Sharp et al.
  • the double stranded region is about 18-25 base pairs in length (e.g., 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-25, 19- 24, 19-23, 19-22, 19-21, 19-20, 20-25, 20-24,20-23, 20-22, 20-21, 21-25, 21-24, 21-23, 21-22, 22- 25, 22-24, 22-23, 23-25, 23-24 or 24-25 base pairs in length (e.g., 19-21 base pairs in length)).
  • the double stranded region is about 15-30, 15-29, 15-28, 15- 27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 19-30, 19- 29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-20, 19-21, 23-30, 23-29, 23-28, 23- 27, 23-26, 23-25, 23-24, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. In some embodiments, the double stranded region is about 19-21 (e.g., 19-20) base pairs in length.
  • the double stranded region is not more than about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 base pairs in length. In some embodiments, the double stranded region is about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 base pairs in length. In some embodiments, the double stranded region is about 19, 20, or 21 base pairs in length. In some embodiments, the double stranded region is about 19 base pairs in length. In some embodiments, the double stranded region is about 20 base pairs in length. In some embodiments, the double stranded region is about 21 base pairs in length. In some embodiments, the double stranded region is about 23 base pairs in length.
  • the dsRNA agent comprises one or more (e.g., 1 or 2) nucleotide overhang.
  • the nucleotides of a nucleotide overhang can include one or more a modified (e.g., chemically modified) nucleotide (e.g., described herein, e.g., described in ⁇ 5.3, 5.3.1).
  • the nucleotide overhang comprises from about 1-5 nucleotides, e.g., 1-4, 1-3, 1-2, 2-5, 2-4, 2-3, 3-5, 3-4, 4-5 nucleotides. In some embodiments, the nucleotide overhang comprises or consists of about 1, 2, 3, 4, or 5 nucleotides. In some embodiments, the nucleotide overhang comprises or consists of about 1 nucleotide. In some embodiments, the nucleotide overhang comprises or consists of about 2 nucleotides. [0074] The nucleotide overhang(s) can be on the sense strand, the antisense strand, or both the sense strand and the antisense strand.
  • the sense strand comprises a nucleotide overhang.
  • the antisense strand comprises a nucleotide overhang.
  • the sense strand and the antisense strand both comprise a nucleotide overhang.
  • the nucleotide(s) of an overhang can be present on the 5'-end, 3'- end, or both the 5'-end, 3'- end of an antisense or sense strand.
  • the sense strand comprises a nucleotide overhang at the 5'-end.
  • the sense strand comprises a nucleotide overhang at the 3'-end.
  • the sense strand comprises a nucleotide overhang at the 5'-end and the 3′-end.
  • the antisense strand comprises a nucleotide overhang at the 5'-end.
  • the antisense strand comprises a nucleotide overhang at the 3'-end.
  • the antisense strand comprises a nucleotide overhang at the 5'-end and the 3′-end.
  • the antisense strand comprises a nucleotide overhang at the 3'-end; and the sense strand comprises a nucleotide overhang at the 3'-end.
  • the antisense strand comprises a nucleotide overhang at the 5'-end; and the sense strand comprises a nucleotide overhang at the 5'-end.
  • the dsRNA agent comprises one or more blunt end.
  • the dsRNA agent comprises a blunt end at the end of the agent comprising the 3′end of the sense strand and the 5′ end of the antisense strand.
  • the dsRNA agent comprises a blunt end at the end of the agent comprising the 5′end of the sense strand and the 3′ end of the antisense strand.
  • both ends of the dsRNA agent are blunt ends.
  • the antisense strand and the sense strand contain the same number of nucleotides. In some embodiments, the antisense strand and the sense strand contain different numbers of nucleotides. In some embodiments, the nucleotide sequence of the sense strand is from about 1-5, 1-3, or 1-2 nucleotides shorter than the nucleotide sequence of the antisense strand. In some embodiments, the nucleotide sequence of the sense strand is about 1, 2, 3, 4, or 5 nucleotides shorter than the nucleotide sequence of the antisense strand.
  • the nucleotide sequence of the sense strand is about 2 nucleotides shorter than the nucleotide sequence of the antisense strand. In some embodiments, the nucleotide sequence of the antisense strand is from about 1-5, 1-3, or 1-2 nucleotides shorter than the nucleotide sequence of the sense strand. In some embodiments, the nucleotide sequence of the antisense strand is about 1, 2, 3, 4, or 5 nucleotides shorter than the nucleotide sequence of the sense strand. In some embodiments, the nucleotide sequence of the antisense strand is about 2 nucleotides shorter than the nucleotide sequence of the sense strand.
  • the sense strand comprises or consists of 21 nucleotides.
  • the antisense strand comprises or consists of 23 nucleotides.
  • the sense strand comprises or consists of 21 nucleotides; and the antisense strand comprises or consists of 23 nucleotides.
  • the double stranded region comprises or consists of 21 nucleotides.
  • the antisense strand comprises a 2-nucleotide overhang at the 3′end. In some embodiments, the 5′ end of the antisense strand and 3′ end of the sense strand form a blunt end.
  • the sense strand comprises or consists of 21 nucleotides; the antisense strand comprises or consists of 23 nucleotides; the double stranded region comprises or consists of 21 nucleotides; the antisense strand comprises a 2-nucleotide overhang at the 3′end; and the 5′ end of the antisense strand and 3′ end of the sense strand form a blunt end.
  • the sense strand comprises or consists of 19 nucleotides.
  • the antisense strand comprises or consists of 21 nucleotides.
  • the sense strand comprises or consists of 19 nucleotides; and the antisense strand comprises or consists of 21 nucleotides.
  • the double stranded region comprises or consists of 19 nucleotides.
  • the antisense strand comprises a 2-nucleotide overhang at the 3′end. In some embodiments, the 5′ end of the antisense strand and 3′ end of the sense strand form a blunt end.
  • the sense strand comprises or consists of 19 nucleotides; the antisense strand comprises or consists of 21 nucleotides; the double stranded region comprises or consists of 19 nucleotides; the antisense strand comprises a 2-nucleotide overhang at the 3′end; and the 5′ end of the antisense strand and 3′ end of the sense strand form a blunt end.
  • the sense strand comprises or consists of 21 nucleotides.
  • the antisense strand comprises or consists of 21 nucleotides.
  • the sense strand comprises or consists of 21 nucleotides; and the antisense strand comprises or consists of 21 nucleotides.
  • the double stranded region comprises or consists of 19 nucleotides.
  • the antisense strand comprises a 2-nucleotide overhang at the 3′end.
  • the sense strand comprises a 2- nucleotide overhang at the 3′end.
  • the sense strand comprises or consists of 21 nucleotides; the antisense strand comprises or consists of 21 nucleotides; the double stranded region comprises or consists of 19 nucleotides; the antisense strand comprises a 2- nucleotide overhang at the 3′end; and the sense strand comprises a 2-nucleotide overhang at the 3′end.
  • the sense strand comprises or consists of 20 nucleotides.
  • the antisense strand comprises or consists of 19 nucleotides.
  • the sense strand comprises or consists of 20 nucleotides; and the antisense strand comprises or consists of 19 nucleotides.
  • the double stranded region comprises or consists of 20 nucleotides.
  • the sense strand comprises a 1- nucleotide overhang at the 5′ end.
  • the 5′ end of the antisense strand and 3′ end of the sense strand form a blunt end.
  • the sense strand comprises or consists of 20 nucleotides;
  • the antisense strand comprises or consists of 19 nucleotides;
  • the double stranded region comprises or consists of 20 nucleotides;
  • the sense strand comprises a 1-nucleotide overhang at the 5′end; and the 5′ end of the antisense strand and 3′ end of the sense strand form a blunt end.
  • the sense strand comprises or consists of 21 nucleotides.
  • the antisense strand comprises or consists of 19 nucleotides.
  • the sense strand comprises or consists of 21 nucleotides; and the antisense strand comprises or consists of 19 nucleotides.
  • the double stranded region comprises or consists of 19 nucleotides.
  • the sense strand comprises a 1- nucleotide overhang at the 3′end. In some embodiments, the sense strand comprises a 1- nucleotide overhang at the 5′end.
  • the sense strand comprises or consists of 21 nucleotides; the antisense strand comprises or consists of 19 nucleotides; the double stranded region comprises or consists of 19 nucleotides; the sense strand comprises a 1- nucleotide overhang at the 3′end; and the sense strand comprises a 1-nucleotide overhang at the 5′ end.
  • the sense strand comprises or consists of 24 nucleotides.
  • the antisense strand comprises or consists of 23 nucleotides. In some embodiments, the sense strand comprises or consists of 24 nucleotides; and the antisense strand comprises or consists of 23 nucleotides.
  • the double stranded region comprises or consists of 21 nucleotides.
  • the antisense strand comprises a 2-nucleotide overhang at the 3′end.
  • the sense strand comprises a 3- nucleotide overhang at the 3′end.
  • the sense strand comprises or consists of 24 nucleotides; the antisense strand comprises or consists of 23 nucleotides; the double stranded region comprises or consists of 21 nucleotides; the antisense strand comprises a 2- nucleotide overhang at the 3′end; and the sense strand comprises a 3-nucleotide overhang at the 3′ end.
  • the sense strand comprises or consists of 19 nucleotides.
  • the antisense strand comprises or consists of 19 nucleotides.
  • the sense strand comprises or consists of 19 nucleotides; and the antisense strand comprises or consists of 19 nucleotides.
  • the double stranded region comprises or consists of 19 nucleotides.
  • the 5′ end of the antisense strand (and 3′ end of the sense strand) form a blunt end.
  • the 3′ end of the antisense strand (and 5′ end of the sense strand) form a blunt end.
  • the sense strand comprises or consists of 19 nucleotides; the antisense strand comprises or consists of 19 nucleotides; the double stranded region comprises or consists of 19 nucleotides; the 5′ end of the antisense strand (and 3′ end of the sense strand) form a blunt end; and the 3′ end of the antisense strand (and 5′ end of the sense strand) form a blunt end [0085]
  • the antisense strand and the sense strand are part of the same larger nucleic acid molecule, wherein the nucleic acid molecule comprises or consists of 44 nucleotides, the antisense portion comprises or consists of 21 nucleotides, the sense strand portion of the nucleic acid molecule comprises 19 nucleotides, the double stranded region comprises or consists of 19 nucleotides, the antisense strand comprises a 2-nucleotide overhang at the 3′end, and the intervening nucle
  • the antisense strand is an antisense strand described herein.
  • the sense strand is a sense strand described herein.
  • the antisense strand is an antisense strand described in ⁇ 5.2.1.
  • the sense strand is a sense strand described in ⁇ 5.2.2.
  • the antisense strand is an antisense strand described in ⁇ 5.2.1; and the sense strand is a sense strand described in ⁇ 5.2.2.
  • any sense strand described herein e.g., in ⁇ 5.2.2
  • any antisense strand in a dsRNA agent described herein e.g., in ⁇ 5.2.1
  • the entire contents of in ⁇ 5.2.1 and ⁇ 5.2.2 are incorporated by reference into the instant section in ⁇ 5.2.3.5.
  • the antisense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g.,
  • the antisense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)))
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nu
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no
  • the antisense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2,
  • the antisense strand comprises from about 15-23 (e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19- 20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises from about 15-23 (e.g., 15-22, 15- 21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17-22, 17- 21, 17-20, 17-19,
  • the antisense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises from about 19- 23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the sense strand comprises from about 19- 23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous
  • the antisense strand comprises from about from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2,
  • the antisense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises from about 21-23 (e.g., 21-22, 22- 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the sense strand comprises from about 21-23 (e.g., 21-22, 22- 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the antisense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g.,
  • the antisense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of at about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the antisense strand comprises or consists of about 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the antisense strand comprises or consists of about 23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • 3 e.g., 0, 1, 2, or 3
  • the antisense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of about 19 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • 3 e.g., 0, 1, 2, or 3
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of the antisense strands set forth in Table 2 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the antisense strand set forth in Table 2; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of any one of the sense strands set forth in Table 2 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the sense strand set forth in Table 2.
  • 3 e.g., 0, 1, 2, or 3
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of any one of the antisense strands set forth in Table 2; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of any one of the sense strands set forth in Table 2.
  • the antisense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20,
  • the antisense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contig
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • 21 e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21,
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • the antisense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or
  • the antisense strand comprises from about 15-23 (e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19- 20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises from about 15-23 (e.g., 15-22, 15- 21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17-22, 17- 21, 17-20, 17-19,
  • the antisense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises from about 19- 23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • 19-23 e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23 contiguous nucleotides differing by no
  • the antisense strand comprises from about from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or
  • the antisense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises from about 21-23 (e.g., 21-22, 22- 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • the antisense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • the antisense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of at about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • the antisense strand comprises or consists of about 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • the antisense strand comprises or consists of about 23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • 3 e.g., 0, 1, 2, or 3
  • the antisense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 2; and the sense strand comprises or consists of about 19 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • 3 e.g., 0, 1, 2, or 3
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of the antisense strands set forth in Table 2 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the antisense strand set forth in Table 2; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of the corresponding sense strand set forth in Table 2 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the corresponding sense strand set forth in Table 2.
  • 3 e.g., 0, 1, 2, or 3
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of any one of the antisense strands set forth in Table 2; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of the corresponding sense strand set forth in Table 2.
  • the antisense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises from about 15-23 (e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19- 20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises from about 15-23 (e.g., 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16- 18, 16-17, 17-23, 17-22
  • the antisense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20- 21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • 19-23 e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20- 21,
  • the antisense strand comprises from about from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22- 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4- 231.
  • the antisense strand comprises from about 21-23 (e.g., 21-22, 22- 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of at about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises or consists of about 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises or consists of about 23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of about 19 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the antisense strand set forth in any one of SEQ ID NOS: 4-231; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 232-459 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the sense strand set forth in any one of SEQ ID NOS: 4-231.
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the antisense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the antisense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the antisense strand comprises from about 15-23 (e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19- 20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises from about 15-23 (e.g., 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16- 18, 16-17, 17-23, 17-22
  • the antisense strand comprises from about from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23)
  • the antisense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the antisense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the antisense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of at about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the antisense strand comprises or consists of about 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the antisense strand comprises or consists of about 23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the antisense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the sense strand comprises or consists of about 19 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231).
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the antisense strand set forth in any one of SEQ ID NOS: 232-459; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 4-231) differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the sense strand set forth in any one of SEQ ID NOS: 4-231.
  • the antisense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g.,
  • the antisense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)))
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nu
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no
  • the antisense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2,
  • the antisense strand comprises from about 15-23 (e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19- 20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises from about 15-23 (e.g., 15-22, 15- 21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17-22, 17- 21, 17-20, 17-19,
  • the antisense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises from about 19- 23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the sense strand comprises from about 19- 23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous
  • the antisense strand comprises from about from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2,
  • the antisense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises from about 21-23 (e.g., 21-22, 22- 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the sense strand comprises from about 21-23 (e.g., 21-22, 22- 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the antisense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g.,
  • the antisense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the sense strand comprises or consists of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the sense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of at about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the sense strand comprises or consists of at about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0,
  • the antisense strand comprises or consists of about 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the sense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucle
  • the antisense strand comprises or consists of about 23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • 3 e.g., 0, 1, 2, or 3
  • the antisense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of about 19 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • 3 e.g., 0, 1, 2, or 3
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of the antisense strands set forth in Table 3 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the antisense strand set forth in Table 3; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of any one of the sense strands set forth in Table 3 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the sense strand set forth in Table 3.
  • 3 e.g., 0, 1, 2, or 3
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of any one of the antisense strands set forth in Table 3; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of any one of the sense strands set forth in Table 3.
  • the antisense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20,
  • the antisense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contig
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • 21 e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21,
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • the antisense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or
  • the antisense strand comprises from about 15-23 (e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19- 20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises from about 15-23 (e.g., 15-22, 15- 21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17-22, 17- 21, 17-20, 17-19,
  • the antisense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises from about 19- 23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • 19-23 e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23 contiguous nucleotides differing by no
  • the antisense strand comprises from about from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or
  • the antisense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises from about 21-23 (e.g., 21-22, 22- 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • the antisense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)
  • the antisense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • the sense strand comprises or consists of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • the sense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of at about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • the sense strand comprises or consists of at about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2,
  • the antisense strand comprises or consists of about 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • the antisense strand comprises or consists of about 23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • 3 e.g., 0, 1, 2, or 3
  • the antisense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in Table 3; and the sense strand comprises or consists of about 19 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • 3 e.g., 0, 1, 2, or 3
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of the antisense strands set forth in Table 3 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the antisense strand set forth in Table 3; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of the corresponding sense strand set forth in Table 3 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the corresponding sense strand set forth in Table 3.
  • 3 e.g., 0, 1, 2, or 3
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of any one of the antisense strands set forth in Table 3; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of the corresponding sense strand set forth in Table 3.
  • the antisense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • the sense strand comprises at least 15 (e.g.
  • the antisense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • 21 e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • 21 e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g.,
  • the antisense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • 23 e.g., 24, 25, 26, 27, 28, 29, 30 (e.g., 23)
  • the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26,
  • the antisense strand comprises from about 15-23 (e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19- 20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises from about 15-23 (e.g., 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16- 18, 16-17, 17-23, 17
  • the antisense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20- 21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • 19-23 e.g., 19-22, 19-21, 19-20, 20-23, 20-22,
  • the antisense strand comprises from about from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20- 21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20- 21, 21-23, 21-22, 22-23) con
  • the antisense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • the antisense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • the antisense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of at about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • the antisense strand comprises or consists of about 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • the antisense strand comprises or consists of about 23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688- 915.
  • 3 e.g., 0, 1, 2, or 3
  • the antisense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of about 19 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • 3 e.g., 0, 1, 2, or 3
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the antisense strand set forth in any one of SEQ ID NOS: 688-915; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 916-1143 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the sense strand set forth in any one of SEQ ID NOS: 688-915.
  • 3 e.g., 0, 1, 2, or 3
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of any one of the sense strands set forth in any one of SEQ ID NOS: 688-915.
  • the antisense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the antisense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24,
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • 21 e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21,
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the antisense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21
  • the antisense strand comprises from about 15-23 (e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19- 20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises from about 15-23 (e.g., 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16- 18, 16-17, 17-23, 17
  • the antisense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20- 23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises from about 19- 23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • 19-23 e.g., 19-22, 19-21, 19-20, 20- 23, 20
  • the antisense strand comprises from about from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22,
  • the antisense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the antisense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the antisense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of at about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the antisense strand comprises or consists of about 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the antisense strand comprises or consists of about 23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the antisense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 916-1143; and the sense strand comprises or consists of about 19 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the antisense strand set forth in any one of SEQ ID NOS: 232-459; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915) differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the sense strand set forth in any one of SEQ ID NOS: 688-915.
  • 3 e.g., 0, 1, 2, or 3
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of any one of any one of the antisense strands set forth in any one of SEQ ID NOS: 232-459; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of the corresponding sense strand (e.g., as set forth in one of SEQ ID NOS: 688-915).
  • the antisense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • the sense strand comprises at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
  • the antisense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • 19 e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23,
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • 21 e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30
  • the sense strand comprises at least 19 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,
  • the antisense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • 21 e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30
  • the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g.
  • the antisense strand comprises at least 23 (e.g., 24, 25, 26, 27, 28, 29, 30 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21))) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • 23 e.g., 24, 25, 26, 27, 28, 29, 30 (e.g., 23)
  • the sense strand comprises at least 21 (e.g., 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e
  • the antisense strand comprises from about 15-23 (e.g., 15- 22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17- 22, 17-21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19- 20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises from about 15-23 (e.g., 15-22, 15- 21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17-22, 17- 21, 17-20,
  • the antisense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21- 22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • 19-23 e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23 contig
  • the antisense strand comprises from about from about 21-23 (e.g., 21- 22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • 21-23 e.g., 21- 22, 22-23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of
  • the antisense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • the antisense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • 3 e.g., 0, 1, 2, or 3
  • the antisense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises or consists of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • the sense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 21)) contiguous nucleotides
  • the antisense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises or consists of at about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • the antisense strand comprises or consists of about 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 21)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • 3 e.g., 0, 1, 2, or 3
  • the antisense strand comprises or consists of about 23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • 3 e.g., 0, 1, 2, or 3
  • the antisense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228; and the sense strand comprises or consists of about 19 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • 3 e.g., 0, 1, 2, or 3
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence of the antisense strand of any one of dsRNA agents 1-228 differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the antisense strand set forth in any one of the dsRNA agents 1-228; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from the sense strand set forth in the corresponding (the same) dsRNA agent.
  • 3 e.g., 0, 1, 2, or 3
  • the nucleotide sequence of the antisense strand comprises or consists of the nucleotide sequence the antisense strand of any one of dsRNA agents 1-228; and the nucleotide sequence of the sense strand comprises or consists of the nucleotide sequence of the sense strand of the corresponding (the same) dsRNA agent.
  • the sense strand comprises at least 15 (e.g., 16, 17, 18, 19, 20, 21) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751- 771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575- 1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160-2190, 2167-2187, 2220-2270
  • the sense strand comprises at least 19 (e.g., 20, 21) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751- 771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575- 1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160-2190, 2167-2187, 2220-2270, 2225- 2263, 2
  • the sense strand comprises at least 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791- 1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160-2190, 2167-2187, 2220-2270, 2225-2263, 2300-2340, 2311-2336, 2415
  • 3
  • the sense strand comprises at least 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510- 560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045- 1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950- 2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160-2190, 2167-2187, 2220-2270, 2225-2263, 2300-2340, 2311-2336, 2415
  • 3
  • the sense strand comprises at least 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751- 771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575- 1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160-2190, 2167-2187, 2220-2270, 2225- 2263, 2300-2340, 2311-2336,
  • the sense strand comprises from about 15-23 (e.g., 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 15-16, 16-22, 16-20, 16-19, 16-18, 16-17, 17-23, 17-22, 17- 21, 17-20, 17-19, 17-18, 18-23, 18-22, 18-21, 18-20, 18-19, 19-23, 19-22, 19-21, 19-20, 20- 23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045- 1080, 1048-1075, 1050-1080, 1055-1075, 1095-10
  • the sense strand comprises from about 19-23 (e.g., 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-23, 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510- 560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045- 1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950- 2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091,
  • the sense strand comprises from about from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751- 771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575- 1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160-2190, 2167-2187, 2220-2270,
  • the sense strand comprises from about 21-23 (e.g., 21-22, 22-23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990- 1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791- 1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160-2190, 2167-2187, 2220-2270, 2225-2263, 2300
  • the sense strand comprises or consists of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250- 285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095- 1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060- 20
  • the sense strand comprises or consists of about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 19, 20, 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510- 565, 510-560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284- 1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-21
  • the sense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997- 1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791-1811, 1945- 2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160
  • the sense strand comprises or consists of about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 21, 22, 23 (e.g., 23)) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791- 1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160
  • the sense strand comprises or consists of about 23, 24, 25, 26, 27, 28, 29, 30 (e.g., 23) contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510- 565, 510-560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284- 1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160- 2190, 2167-2187, 2220-22
  • the sense strand comprises or consists of about 23 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250- 285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095- 1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791-1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060- 2095, 2066-2091, 2160-2195, 2160-2190, 2167-2187, 2220-2270, 2225-2263, 2300-2340, 2311-
  • the sense strand comprises or consists of about 21 contiguous nucleotides differing by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides from nucleotides 250-285, 253-282, 430-440, 436-456, 510-565, 510-560, 514-558, 745-775, 751-771, 830-895, 830-890, 836-888, 990-1025, 997-1017, 1045-1080, 1048-1075, 1050-1080, 1055-1075, 1095-1025, 1099-1119, 1280-1310, 1284-1304, 1400-1430, 1405-1425, 1575-1620, 1583-1610, 1651-1671, 1791- 1811, 1945-2015, 1950-2010, 1955-2001, 1990-2030, 1995-2025, 2060-2095, 2066-2091, 2160-2195, 2160-2190, 2167-2187, 2220-2270, 2225-2263, 2300-2340, 2311-233
  • exemplary unmodified dsRNA agents comprising a sense and antisense strand (e.g., suitable for targeting hFASN, suitable for inhibiting hFASN expression)) are set forth in Table 2. More specifically, Table 2 sets forth the nucleotide sequence of exemplary sense strands, antisense strands, and dsRNA agent pairs of sense and antisense strands.
  • the disclosure encompasses dsRNA agents comprising any sense strand and any antisense set forth in Table 2 (e.g., that are at least partially complementary (e.g., as could be determined by a person of ordinary skill in the art)). It is to be understood that while the nucleotide sequence of the sense strands and antisense strands in Table 2 are set forth as unmodified (not containing any modified nucleotides), the disclosure encompasses the sense and antisense sense strands set forth in Table 2 comprising one or more modified nucleotide (e.g., as described herein).
  • nucleotide sequence of exemplary modified versions of the dsRNA agents set forth in Table 2 are set forth in Table 3. More specifically, Table 3 sets forth the nucleotide sequence of exemplary sense strands, antisense strands, and dsRNA agent pairs of sense and antisense strands. It is to be understood that while the sense and antisense strands are set forth in pairs in Table 3, the disclosure encompasses dsRNA agents comprising any sense strand and any antisense set forth in Table 3 (e.g., that are at least partially complementary (e.g., as could be determined by a person of ordinary skill in the art)).
  • nucleotide sequence of the sense strands and antisense strands in Table 3 are set forth as modified (i.e., contain at least one modified nucleotide), the disclosure encompasses the sense and antisense sense strands set forth in Table 3 comprising other nucleotide modifications (e.g., as described herein) or that are unmodified.
  • the dsRNA agent is in a free acid form.
  • the dsRNA agent is in a salt form.
  • the dsRNA agent is in a sodium salt form.
  • sodium ions are present in the composition comprising the dsRNA agent as counterions for substantially all of the phosphodiester or phosphorothioate groups present in the dsRNA agent.
  • the agent (or any component thereof (e.g., any nucleic acid molecule thereof)) (e.g., described herein, e.g., an antisense strand, a sense strand, a dsRNA agent, RNAi agent, etc.) comprises one or more modified nucleotide(s) (as defined herein).
  • the modified agent may have one or more different (e.g., improved) properties relative to a corresponding unmodified agent.
  • the modified agent may exhibit decreased immunostimulatory activity (e.g., when administered to a subject), increased stability (e.g., in vivo, in a cell, when administered to a subject), and/or increased inhibition of expression of a target nucleic acid molecule (e.g., a target mRNA (e.g., a FASN mRNA)), or any combination thereof.
  • a target nucleic acid molecule e.g., a target mRNA (e.g., a FASN mRNA)
  • Nucleotide modifications can include modification to any one of more of the nucleoside and/or the internucleoside linkage.
  • Nucleoside modifications include modification to the sugar (e.g., ribose) moiety and/or the nucleobase.
  • the modified agent (or component thereof) comprises one or more nucleotides comprising a modified sugar moiety.
  • the modified agent (or component thereof) e.g., antisense strand, sense strand, dsRNA agent, etc.
  • the modified agent (or component thereof) e.g., antisense strand, sense strand, dsRNA agent, etc.
  • the modified agent (or component thereof) (e.g., antisense strand, sense strand, dsRNA agent, etc.) comprises one or more nucleotides comprising one, two, or three of a modified sugar moiety, a modified nucleobase, and/or a modified internucleoside linkage.
  • exemplary nucleotide modifications are described below and also known in the art, see, e.g., WO2021257782, WO2013075035, WO2022246251, and WO2022271573, the entire contents of each of which is incorporated by reference herein for all purposes.
  • the modified agent (or any component thereof) (e.g., antisense strand, sense strand, dsRNA agent, etc.) comprises one or more nucleotide comprising a modified nucleoside.
  • nucleoside modifications can include modification of the sugar (e.g., ribose) moiety and/or modification of the nucleobase.
  • the modified agent (or any component thereof) (e.g., antisense strand, sense strand, dsRNA agent, etc.) comprises one or more nucleotides comprising a modified sugar (e.g., ribose) moiety.
  • the modified sugar (e.g., ribose) moiety can comprise, for example, a substituent at any one or more position of the sugar (e.g., ribose), including e.g., positions 2′, 4′, and/or 5′.
  • the modified sugar comprises a substituent at 2′ position of the sugar (e.g., ribose). In some embodiments, the modified sugar (e.g., ribose) comprises a substituent at 5′ position of the sugar (e.g., ribose). In some embodiments, the modified sugar (e.g., ribose) comprises a substituent at 5′ position of the sugar (e.g., ribose).
  • the agent (or any component thereof) comprises any one or more of the following substituents (e.g., at any position of the sugar (e.g., ribose) (e.g., at position 2′)): a group for improving the stability of the agent, a group for improving the pharmacokinetic properties of the agent, or a group for improving the pharmacodynamic properties of the agent, an RNA cleaving group, a reporter group, an intercalator, or other substituents having similar properties.
  • substituents e.g., at any position of the sugar (e.g., ribose) (e.g., at position 2′)
  • substituents e.g., at any position of the sugar (e.g., ribose) (e.g., at position 2′)
  • substituents e.g., at any position of the sugar (e.g., ribose) (e.g., at position 2′)
  • substituents include, for example, but are not limited to, substitution (e.g., at any position of the sugar (e.g., ribose) (e.g., at position 2′)) with any one of the following: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O- alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted C 1 to C 10 alkyl or C2 to C10 alkenyl and alkynyl.
  • Additional exemplary substitutions include, for example, but are not limited to, substitution with any one of the following: O[(CH 2 )nO]m, CH 3 , O(CH 2 )nOCH 3 , O(CH 2 )nNH 2 , O(CH 2 ) n CH 3 , O(CH 2 ) n ONH 2 , and O(CH 2 ) n ON[(CH 2 ) n CH 3 )] 2 , where n and m are from 1 to about 10.
  • the modified sugar e.g., ribose
  • the modified sugar comprises any one of the following modifications: 2′-O-methyl (2′-OMe), 2′O-methoxyethyl (2′-O-MOE), 2′deoxy-2′- fluoro (2′-F), 2′-arabino-fluoro (2′-Ara-F), 2′-O-benzyl, 2′-O-methyl-4-pyridine (2-O-methyl- 4-pyridine (2′-O-CH2Py(4)).
  • the agent comprises any of the following substituents at the 2′-position of the sugar (e.g., ribose): C1 to C10 lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , OCN, Cl, Br, CN, CF 3 , OCF 3 , SOCH 3 , SO 2 CH 3 , ONO 2 , NO 2 , N 3 , NH 2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, or a substituted silyl.
  • the sugar e.g., ribose
  • the agent (or any component thereof) comprises a 2′-methoxyethoxy (2′-O—CH 2 CH 2 OCH 3 , also known as 2′-O-(2-methoxyethyl) or 2′-MOE) (see, e.g., Martin et al., Helv. Chim. Acta, 1995, 78:486- 504, the entire contents of which is incorporated by reference herein for all purposes) (i.e., an alkoxy-alkoxy group).
  • 2′-methoxyethoxy 2′-O—CH 2 CH 2 OCH 3
  • 2′-MOE 2′-methoxyethoxy
  • the agent (or any component thereof) comprises a 2′-dimethylaminooxyethoxy, i.e., a O(CH 2 ) 2 ON(CH 3 ) 2 group, also known as 2′-DMAOE; a 2′-dimethylaminoethoxyethoxy (also known in the art as 2′-O-dimethylaminoethoxyethyl or 2′-DMAEOE), i.e., 2′-O—CH 2 —O—CH 2 —N(CH 3 ) 2 ; a 5′-Me-2′-F nucleotide, a 5′-Me-2′- OMe nucleotide, a 5′-Me-2′-deoxynucleotide, (both R and S isomers in these three families); a 2′-alkoxyalkyl; and 2′-NMA (N-methylacetamide).
  • 2′-dimethylaminooxyethoxy i.e.,
  • Exemplary US patents that describe the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920; the entire contents of each of the foregoing are hereby incorporated herein by reference for all purposes.
  • the modified sugar (e.g., ribose) moiety comprises a non- bicyclic modified sugar (e.g., ribose) moiety.
  • the modified sugar (e.g., ribose) moiety comprises a furanosyl ring comprising one or more substituent groups none of which bridges two atoms of the furanosyl ring to form a bicyclic structure.
  • one or more non-bridging substituent of a non-bicyclic modified sugar moiety is branched.
  • non-bicyclic modified sugar moiety comprises a substituent group at the 2′-position of the sugar (e.g., ribose).
  • 2′- substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to: 2′-O-methyl (2′-OMe), 2′O-methoxyethyl (2′-O-MOE), 2′deoxy-2′-fluoro (2′-F), 2′-arabino-fluoro (2′-Ara-F), 2′-O- benzyl, 2′-O-methyl-4-pyridine (2-O-methyl-4-pyridine (2′-O-CH 2 Py(4)), and 2′-O-N-alkyl acetamide (e.g., 2′-O-N-methyl acetamide (“NMA”), 2′-O-N-dimethyl acetamide, 2′-O-N- ethyl acetamide, and 2′-O-N-propyl acetamide).
  • NMA 2′-O-N-methyl acetamide
  • NMA 2′-O-N-dimethyl acetamide
  • the 2′-substituent group is a halo, allyl, amino, azido, SH, CN, OCN, CF 3 , O CF 3 , O-C 1 -C 10 alkoxy, O- C 1 -C 10 substituted alkoxy, O-C 1 -C 10 alkyl, O-C 1 - C 10 substituted alkyl, S-alkyl, N(R m )-alkyl, O-alkenyl, S-alkenyl, N(R m )-alkenyl, O-alkynyl, S-alkynyl, N(Rm)-alkynyl, O-alkylenyl-O- alkyl, alky
  • these 2'- substituent groups can be further substituted with one or more substituent groups independently selected from among: hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO2), thiol, thioalkoxy, thioalkyl, halogen, alkyl, aryl, alkenyl and alkynyl.
  • a non-bridging 2′-substituent group selected from: F,
  • non-bicyclic modified sugar moiety comprises a substituent group at the 3′-position of the sugar (e.g., ribose). Examples of substituent groups suitable for the 3′-position of modified sugar moieties include but are not limited to alkoxy (e.g., methoxy), alkyl (e.g., methyl, ethyl).
  • non-bicyclic modified sugar moiety comprises a substituent group at the 4′-position of the sugar (e.g., ribose).
  • 4′-substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to alkoxy (e.g., methoxy), alkyl, and those described in Manoharan et al., WO 2015/106128.
  • non-bicyclic modified sugar moiety comprises a substituent group at the 5′-position of the sugar (e.g., ribose).
  • substituent groups suitable for the 5′-position of modified sugar moieties include, but are not limited to, vinyl (e.g., 5'-vinyl), alkoxy (e.g., methoxy (e.g., 5′-methoxy)), and alkyl (e.g., methyl (R or S) (e.g., 5′-methyl (R or S)), ethyl).
  • non-bicyclic modified sugar moieties comprise more than one non-bridging sugar substituent, for example, 2'-F-5'-methyl sugar moieties and the modified sugar moieties and modified nucleosides described in Migawa et al., WO 2008/101157 and Rajeev et al., US2013/0203836, the entire contents of each of which is incorporated herein by reference for all purposes.
  • modified furanosyl sugar moieties and nucleosides incorporating such modified furanosyl sugar moieties are further defined by isomeric configuration.
  • a 2′- deoxyfuranosyl sugar moiety may be in seven isomeric configurations other than the naturally occurring ⁇ -D- deoxyribosyl configuration.
  • modified sugar moieties are described in, e.g., WO 2019/157531, the entire contents of which are incorporated by reference herein for all purposes.
  • the sugar (e.g., ribose) modification comprises an unlocked nucleotide (UNA).
  • UNA is unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked sugar (e.g., ribose) residue.
  • the bonds between C1′-C4′ have been removed (i.e., the covalent carbon- oxygen-carbon bond between the C1′ and C4′ carbons).
  • the C2′-C3′ bond i.e., the covalent carbon-carbon bond between the C2′ and C3′ carbons
  • the sugar e.g., ribose
  • UNAs and methods of making are known in the art.
  • the modified sugar (e.g., ribose) moiety comprises a substituent that bridges two atoms of the furanosyl ring to form a second ring, resulting in a bicyclic sugar (e.g., ribose) moiety.
  • the bicyclic sugar (e.g., ribose) moiety comprises a bridge between the 4' and the 2' furanose ring atoms.
  • 4′ to 2′ bridging sugar substituents include but are not limited to: 4'-CH 2 -2', 4'-(CH 2 ) 2 -2', 4'- (CH 2 )3-2', 4'-CH 2 -O-2' (“LNA”), 4'-CH 2 -S-2', 4'-(CH 2 )2-O-2' (“ENA”), 4'-CH(CH 3 )-O-2' (referred to as “constrained ethyl” or “cEt”), 4′-CH 2 - O-CH 2 -2′, 4′-CH 2 -N(R)-2′, 4'- CH(CH 2 OCH 3 )-O-2' (“constrained MOE” or “cMOE”) and analogs thereof (see, e.g., Seth et al., U
  • the modified sugar comprises a constrained ethyl nucleotide comprising a 4′-CH(CH 3 )—O-2′ bridge.
  • the constrained ethyl nucleotide is in the S conformation (S-cEt).
  • the modified sugar e.g., ribose
  • CRNs are nucleotide analogs with a linker connecting the C2′ and C4′ carbons of ribose or the C3 and —C 5 ′ carbons of ribose.
  • Representative publications that teach the preparation of certain of the above include, but are not limited to, US2013/0190383; and WO2013/036868, the entire contents of each of which are hereby incorporated herein by reference.
  • bicyclic sugar moieties and nucleosides incorporating such bicyclic sugar moieties are further defined by isomeric configuration.
  • an LNA nucleoside (described herein) may be in the ⁇ -L configuration or in the ⁇ -D configuration.
  • bicyclic nucleosides include both isomeric configurations. Any of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example ⁇ -L-ribofuranose and ⁇ -D-ribofuranose (see, e.g., WO 99/14226, the entire contents of which are incorporated herein by reference for all purposes).
  • Additional representative U.S. Patents and U.S. Patent Publications that teach the preparation of bicyclic nucleosides include, but are not limited to, the following: U.S. Pat. Nos.
  • the modified agent (or any component thereof) (e.g., antisense strand, sense strand, dsRNA agent, etc.) comprises one or more nucleotides comprising a modified nucleobase.
  • “unmodified” nucleobases refer to the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U). Modified nucleobases include other synthetic and natural nucleobases.
  • Modified nucleobases include, but are not limited to, 5-substituted pyrimidines, 6- azapyrimidines, alkyl or alkynyl substituted pyrimidines, alkyl substituted purines, and N-2, N-6 and 0-6 substituted purines.
  • nucleobases include tricyclic pyrimidines, such as 1,3-diazaphenoxazine-2-one, l,3-diazaphenothiazine-2- one and 9-(2-aminoethoxy)-l,3-diazaphenoxazine-2-one (G-clamp).
  • Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2- pyridone.
  • Further nucleobases include those disclosed in Merigan et al., U.S.
  • the modified nucleobase comprises a pseudouridine, 2′thiouridine (s2U), N6′-methyladenosine, 5′methylcytidine (m 5 C), 5′fluoro-2′deoxyuridine, N-ethylpiperidine 7-EAA triazole modified adenine, N-ethylpiperidine 6′triazole modified adenine, 6-phenylpyrrolo-cytosine (PhpC), 2′,4′-difluorotoluyl ribonucleoside (rF), or 5′nitroindole.
  • the modified nucleobase comprises a 5-substituted pyrimidine; 6-azapyrimidine; or N-2, N-6 and 0-6 substituted purines (including 2- aminopropyladenine, 5-propynyluracil and 5-propynylcytosine).
  • 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., dsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp.276-278) and are exemplary base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications.
  • the modified agent (or any component thereof) (e.g., antisense strand, sense strand, dsRNA agent, etc.) comprises one or more modified internucleoside linkage.
  • Modified internucleoside linkages compared to naturally occurring phosphate linkages, can be used to alter, typically increase, nuclease resistance of an agent (e.g., described herein).
  • the naturally occurring internucleoside linkage of RNA and DNA is a 3' to 5' phosphodiester linkage.
  • the modified internucleoside linkage contains a normal 3′-5′ linkage.
  • the modified internucleoside linkage contains a 2′-5′ linkage. In some embodiments, the modified internucleoside linkage has an inverted polarity wherein the adjacent pairs of nucleoside units are linked e.g., 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′.
  • the two main classes of modified internucleoside linking can be defined by the presence or absence of a phosphorous atom.
  • Modified Phosphorous Containing Internucleoside Linkages [00175] In some embodiments, the modified internucleoside linkage comprises a phosphorous atom.
  • modified phosphorus-containing internucleoside linkages include but are not limited to phosphorothioates (PS (Rp isomer or Sp isomer)) (e.g., 5′phosphorothioate), phosphotriesters, phosphoramidates (e.g., 3′-amino phosphoramidate and aminoalkylphosphoramidates), chiral phosphorothioates, phosphorodithioates (PS2), aminoalkylphosphotriesters, methyl and other alkyl phosphonates (e.g., methylphosphonate (MP), 3′-alkylene phosphonates), methpxypropyl-phosphonates (MOP), 5′-(E)- vinylphosphonates, 5′methyl phosphonates, (S)-5′C-methyl with phosphates, phosphinates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, boranophosphate
  • the modified internucleoside linkage does not contain a phosphorous atom.
  • Modified internucleoside linkages that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages.
  • morpholino linkages formed in part from the sugar portion of a nucleoside
  • siloxane backbones sulfide, sulfoxide and sulfone backbones
  • formacetyl and thioformacetyl backbones methylene formacetyl and thioformacetyl backbones
  • alkene containing backbones sulfamate backbones
  • sulfonate and sulfonamide backbones amide backbones; and others having mixed N, O, S, and CH 2 component parts.
  • Methods of preparing polynucleotides comprising modified internucleoside linkages do not contain a phosphorous atom are known in the art. See, e.g., U.S. Pat. Nos.
  • the modified agent comprises one or more RNA mimetic in which both the sugar and the internucleoside linkage of the nucleotide units are replaced with novel groups.
  • the nucleobase units are maintained for hybridization with an appropriate nucleic acid target (e.g., a target mRNA).
  • the RNA mimetic is a peptide nucleic acid (PNA).
  • PNAs the ribose moiety of the RNA nucleotide is replaced with an amide containing moiety (e.g., an aminoethylglycine).
  • nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide.
  • Representative US patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, the entire contents of each of which are hereby incorporated herein by reference. Additional PNA compounds suitable for use in the agents described herein are described in, for example, in Nielsen et al., Science, 1991, 254, 1497- 1500, the entire contents of which is incorporated by reference herein for all purposes. [00181] Potentially stabilizing modifications to the terminal ends of the agents (e.g., described herein) can also be incorporated to agents described herein.
  • N- (acetylaminocaproyl)-4-hydroxyprolinol Hyp-C6-NHAc
  • N-(caproyl-4-hydroxyprolinol Hyp-C6)
  • N-(acetyl-4-hydroxyprolinol Hyp-NHAc
  • thymidine-2′-O-deoxythymidine ether
  • N-(aminocaproyl)-4-hydroxyprolinol Hyp-C6-amino
  • 2-docosanoyl-uridine-3′′- phosphate inverted base dT(idT) and others.
  • nucleotides of the agent or any component (e.g., nucleic acid molecule) thereof) (e.g., described herein, e.g., an antisense strand, a sense strand, a dsRNA agent, RNAi agent) are modified.
  • nucleotides of the agent or any component (e.g., nucleic acid molecule) thereof) (e.g., described herein, e.g., an antisense strand, a sense strand, a dsRNA agent, RNAi agent, etc.) are modified.
  • At least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 of the nucleotides of the agent (or any component (e.g., nucleic acid molecule) thereof) e.g., described herein, e.g., an antisense strand, a sense strand, a dsRNA agent, RNAi agent, etc.
  • the agent or any component (e.g., nucleic acid molecule) thereof)
  • any component e.g., nucleic acid molecule
  • substantially all of the nucleotides of the agent (or any component (e.g., nucleic acid molecule) thereof) are modified.
  • all of the nucleotides of the agent (or any component (e.g., nucleic acid molecule) thereof) are modified.
  • At least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides of the sense and/or antisense strand are modified.
  • at least 50% of the nucleotides of the sense strand and/or antisense strand may be modified.
  • at least 55% of the nucleotides of the sense strand and/or antisense strand may be modified.
  • at least 60% of the nucleotides of the sense strand and/or antisense strand may be modified.
  • At least 65% of the nucleotides of the sense strand and/or antisense strand may be modified.
  • at least 70% of the nucleotides of the sense strand and/or antisense strand may be modified.
  • at least 75% of the nucleotides of the sense strand and/or antisense strand may be modified.
  • at least 80% of the nucleotides of the sense strand and/or antisense strand may be modified.
  • at least 85% of the nucleotides of the sense strand and/or antisense strand may be modified.
  • at least 90% of the nucleotides of the sense strand and/or antisense strand may be modified.
  • At least 90% of the nucleotides of the sense strand and/or antisense strand may be modified.
  • at least 95% of the nucleotides of the sense strand and/or antisense strand may be modified.
  • substantially all (or all) of the nucleotides in the sense strand and/or antisense strand are modified.
  • at least one of the modified nucleotides comprises a modified sugar (e.g., ribose moiety).
  • at least one of the modified nucleotides comprises a modified nucleobase.
  • the sense strand comprises at least one modified internucleoside linkage and/or the antisense strand comprises at least one modified internucleoside linkage.
  • not more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 of the nucleotides of the of the agent (or any component (e.g., nucleic acid molecule) thereof) e.g., described herein, e.g., an antisense strand, a sense strand, a dsRNA agent, RNAi agent, etc.
  • an antisense strand, a sense strand, a dsRNA agent, RNAi agent, etc. are unmodified.
  • nucleotides of the agent or any component (e.g., nucleic acid molecule) thereof) (e.g., described herein, e.g., an antisense strand, a sense strand, a dsRNA agent, RNAi agent, etc.) are unmodified.
  • not more than 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides of the agent (or any component (e.g., nucleic acid molecule) thereof) e.g., described herein, e.g., an antisense strand, a sense strand, a dsRNA agent, RNAi agent, etc.
  • the agent or any component (e.g., nucleic acid molecule) thereof)
  • any component e.g., nucleic acid molecule
  • At least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides of the agent (or any component (e.g., nucleic acid molecule) thereof) e.g., described herein, e.g., an antisense strand, a sense strand, a dsRNA agent, RNAi agent
  • the agent or any component (e.g., nucleic acid molecule) thereof)
  • any component e.g., nucleic acid molecule
  • nucleotides of the agent or any component (e.g., nucleic acid molecule) thereof) (e.g., described herein, e.g., an antisense strand, a sense strand, a dsRNA agent, RNAi agent, etc.) are unmodified.
  • At least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 of the nucleotides of the agent (or any component (e.g., nucleic acid molecule) thereof) are unmodified.
  • substantially all of the nucleotides of the agent (or any component (e.g., nucleic acid molecule) thereof) are unmodified.
  • all of the nucleotides of the agent (or any component (e.g., nucleic acid molecule) thereof) are unmodified.
  • not more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 of the nucleotides of the of the agent (or any component (e.g., nucleic acid molecule) thereof) e.g., described herein, e.g., an antisense strand, a sense strand, a dsRNA agent, RNAi agent, etc.
  • any component e.g., nucleic acid molecule
  • not more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 of the nucleotides of the agent (or any component (e.g., nucleic acid molecule) thereof) e.g., described herein, e.g., an antisense strand, a sense strand, a dsRNA agent, RNAi agent, etc.
  • the agent or any component (e.g., nucleic acid molecule) thereof) (e.g., described herein, e.g., an antisense strand, a sense strand, a dsRNA agent, RNAi agent, etc.) are modified.
  • RNAi agent e.g., antisense strand, sense strand, dsRNA agent (e.g., described herein)
  • the RNAi agent comprises one or more non-naturally internucleoside linkage.
  • RNAi agent e.g., antisense strand, sense strand, dsRNA agent (e.g., described herein)
  • the internucleoside linkages of the RNAi agent are non-naturally occurring.
  • RNAi agent e.g., antisense strand, sense strand, dsRNA agent (e.g., described herein)
  • the agent e.g., described herein
  • the agent comprises a heterologous moiety (e.g., operably connected to the agent).
  • conjugates comprising an agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand) and a heterologous moiety (e.g., operably connected to the agent).
  • an agent e.g., described herein
  • the conjugate an comprise a modified agent (e.g., described herein, see, e.g., ⁇ 5.3).
  • the heterologous moiety modifies one or more property of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand) to which it is conjugated.
  • the heterologous moiety enhances the distribution and/or uptake (e.g., into a cell, e.g., into a cell in a subject) of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand) (e.g., as compared to an agent that lacks the heterologous moiety).
  • the agent e.g., described herein
  • the agent e.g., described herein
  • the agent e.g., described herein
  • the heterologous moiety alters (e.g., extends) the lifetime (e.g., in vivo) of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand) (e.g., as compared to an agent that lacks the heterologous moiety).
  • the heterologous moiety provides an enhanced affinity for a selected target, e.g., a selected molecule, cell type, compartment (e.g., cell type, tissue, organ or region of the body) (e.g., as compared to an agent that lacks the heterologous moiety).
  • the heterologous moiety enhances the activity (e.g., in a cell, e.g., in a cell in a subject) of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand) (e.g., as compared to an agent that lacks the heterologous moiety).
  • Activity can include, e.g., degradation of a target mRNA (e.g., a FASN mRNA), inhibition of expression of a target gene (e.g., a FASN gene), and/or reduction in the expression of a target gene (e.g., a FASN gene).
  • the heterologous moiety imparts a new property on the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand) to which it is conjugated.
  • agent e.g., described herein
  • fluorophores or reporter groups that enable detection of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand).
  • the heterologous moieties can impart multiple (e.g., any combination of the foregoing) properties of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand).
  • the agent e.g., described herein
  • the heterologous moiety does not take part in, does not alter, and/or does not interfere with, the creation of a double strand region.
  • Heterologous moieties include for example, but are not limited to, carbohydrates, peptides, proteins (e.g., antibodies or functional fragments or variants thereof; ligands (e.g., of a target receptor)), lipids, polymers, small molecules, intercalators, reporter molecules, polyamines, polyamides, vitamin moieties, polyethylene glycols, thioethers, polyethers, cholesterols, thiocholesterols, cholic acid moieties, folate, lipophilic groups, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins, fluorophores, and dyes.
  • the heterologous moiety is a carbohydrate, peptide, protein (e.g., antibody or functional fragment or variant thereof, e.g., ligand (e.g., of a target receptor)), lipid, polymer, small molecule, or any combination thereof.
  • the heterologous moiety comprises an active drug substance.
  • the heterologous moiety does not contain an active drug substance.
  • Exemplary heterologous moieties e.g., targeting moieties
  • lipid moieties such as a cholesterol moiety (see, e.g., Letsinger et al., Proc. Natl. Acid. Sci. USA, 1989, 86: 6553-6556); cholic acid (see, e.g., Manoharan et al., Biorg. Med. Chem. Let., 1994, 4:1053-1060), a thioether, e.g., beryl-S- tritylthiol (see, e.g., Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306-309; Manoharan et al., Biorg. Med.
  • thiocholesterols see, e.g., Oberhauser et al., Nucl. Acids Res., 1992, 20:533-538
  • aliphatic chains e.g., dodecandiol or undecyl residues
  • phospholipids e.g., dihexadecyl-rac-glycerol or triethyl-ammonium l,2-di-O-hexadecyl-rac-glycero-3- phosphonate
  • phospholipids e.g., dihexadecyl-rac-glycerol or triethyl-ammonium l,2-di-O-hexadecyl-rac-glycero-3- phosphonate
  • the heterologous moiety is a targeting moiety.
  • the targeting moiety enhances distribution of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand) to a target cell (or population of cells), tissue, and/or organ (e.g., as compared to an agent that lacks the targeting moiety).
  • the targeting moiety enhances the uptake of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand) into a target cell (or population of cells) (e.g., as compared to an agent that lacks the targeting moiety).
  • the targeting moiety provides enhanced affinity for a selected target, e.g., molecule, cell, cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, (e.g., as compared to an agent that lacks the targeting moiety).
  • the targeting moiety specifically binds to a target molecule (e.g., protein, carbohydrate, lipid, etc.) expressed on the surface of a target cell, tissue, and/or organ.
  • the target molecule is a protein, carbohydrate, or lipid.
  • the target molecule is a receptor.
  • Hepatocyte Targeting Moieties [00200] In some embodiments, the targeting moiety specifically binds to a target molecule (e.g., protein, carbohydrate, lipid, etc.) expressed by hepatocytes (e.g., on the surface of the surface of hepatocytes).
  • the targeting moiety specifically binds to a target molecule protein (e.g., receptor) expressed on the surface of hepatocytes.
  • the targeting moiety comprises a carbohydrate. Exemplary carbohydrate targeting moieties are described in WO2019055633, the entire contents of which is incorporated by reference herein for all purposes.
  • the carbohydrate is a monosaccharide. In some embodiments, the carbohydrate is a polysaccharide.
  • the targeting moiety comprises at least one (e.g., at least 2, 3, 4, or more) N-acetylgalactosamine (GalNAc) or GalNAc derivative.
  • the targeting moiety comprise a plurality (e.g., 2, 3, 4, 5, or 6) of GalNAc moieties and/or GalNAc derivatives. In some embodiments, the targeting moiety comprise a plurality (e.g., 2, 3, 4, 5, or 6) of GalNAc moieties and/or GalNAc derivatives each independently attached to a plurality of nucleotides of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand) through a plurality of linkers (e.g., monovalent linkers).
  • the agent e.g., described herein
  • linkers e.g., monovalent linkers
  • the GalNAc targeting moiety serves to target the agent to hepatocytes through specific binding to the asialoglycoprotein receptor.
  • Exemplary GalNAc conjugates which comprise one or more GalNAc and/or derivative thereof, are known the art. See, e.g., in U.S. Patent No.8,106,022, the entire contents of which is hereby incorporated herein by reference for all purposes. Additional exemplary GalNAc targeting moieties are described below.
  • the targeting moiety e.g., GalNAc targeting moiety
  • the targeting moiety comprises the GalNAc targeting moiety set forth in below in Formula II: .
  • the targeting moiety comprises the GalNAc targeting moiety and linker set forth below in Formula I:
  • the targeting moiety comprises N-[tris(GalNAc)-amido- dodecanoyl)]-4-hydroxyprolinol [Hyp-(GalNAc-alkyl)3]. [00208] In one embodiment, the targeting moiety comprises (2S,4R)-1-[29-[[2- (acetylamino)-2-deoxy- ⁇ -D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2- deoxy- ⁇ -D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]- 1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2- hydroxymethylpyrrolidine.
  • the agent e.g., described herein
  • the agent e.g., described herein
  • the heterologous moiety e.g., targeting moiety
  • the agent e.g., described herein
  • the agent e.g., described herein
  • the agent is indirectly attached to the heterologous moiety (e.g., targeting moiety).
  • the agent e.g., described herein
  • the agent e.g., described herein
  • RNAi agent e.g., RNAi agent, dsRNA agent, antisense strand, sense strand
  • a linker e.g., RNAi agent, dsRNA agent, antisense strand, sense strand
  • Suitable linkers for use in the conjugates described herein are known in the art and can be evaluated by a person of ordinary skill in the art using standard methods. Exemplary linkers and components thereof for use in the conjugates described herein are also described below.
  • Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NR8, C(O), C(O)NH, SO, SO2, SO2NH or a chain of atoms, such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkeny
  • the linker is about 1-24 atoms, 2- 24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18, 7-17, 8-17, 6-16, 7-17, or 8-16 atoms.
  • the linker comprises ethylene glycol, nucleosides, or amino acid units.
  • the linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino.
  • the linker comprises groups selected from alkyl, amino, oxo, amide and ether groups.
  • the linker comprises groups selected from alkyl and amide groups.
  • the linker comprises groups selected from alkyl and ether groups. In some embodiments, the linker comprises at least one phosphorus moiety. In some embodiments, the linker comprises at least one phosphate group. In some embodiments, the linker comprises at least one neutral linking group. Exemplary linkers include but are not limited to pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N- maleimidomethyl) cyclohexane-1-carboxylate (SMCC), 6-aminohexanoic acid (AHEX or AHA).
  • ADO 8-amino-3,6-dioxaoctanoic acid
  • SMCC succinimidyl 4-(N- maleimidomethyl) cyclohexane-1-carboxylate
  • AHEX or AHA 6-aminohexanoic acid
  • linkers include but are not limited to substituted or unsubstituted Ci-Cw alkyl, substituted or unsubstituted C2-C10 alkenyl or substituted or unsubstituted C2- C10 alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.
  • the linker is bifunctional.
  • a bifunctional linker comprises at least two functional groups.
  • One of the functional groups is selected to react with a particular site on an agent (e.g., described herein) and the other is selected to react with a heterologous moiety (e.g., described herein).
  • Examples of functional groups used in a bifunctional linkers include but are not limited to electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups.
  • bifunctional linking moieties comprise one or more groups selected from amino, hydroxyl, carboxylic acid, thiol, alkyl, alkenyl, and alkynyl.
  • the linker is a monovalent linker, a bivalent linker, a trivalent linker, or a tetravalent linker.
  • the linker comprises or consists of the linker set forth above in Formula I. 5.4.2.1 Cleavable Linkers
  • the linker is non-cleavable.
  • the linker is cleavable. Cleavable linkers contain at least one (or a plurality of) cleavable bonds that are susceptible to one or more cleavage agent.
  • cleavable linkers include, but are not limited to, redox cleavable linkers, phosphate based cleavable linkers, acid cleavable linkers, ester-based cleavable linkers, and peptide-based cleavable linkers.
  • a cleavable bond is selected from among: an amide, an ester, an ether, one or both esters of a phosphodiester, a phosphate ester, a carbamate, or a disulfide.
  • Cleavable linkers may be advantageous when a stable conjugate is desired under a first set of conditions but under a second set of conditions it is advantageous to release the agent (e.g., described herein) from the heterologous moiety (e.g., described herein).
  • a sufficiently stable conjugate outside of a cell e.g., within a subject (e.g., within the blood or serum of a subject)
  • a cell e.g., a target cell (e.g., a target cell within a subject)
  • the linker upon entry into a cell (e.g., a target cell (e.g., a target cell within a subject)) have the linker cleaved to release the agent (e.g., described herein) from the heterologous moiety (e.g., described herein).
  • the linker is not cleaved (or is cleaved at a lower rate) under a first condition relative to under a second condition.
  • the first condition is within the blood (e.g., of a subject) (or in an in vitro system sufficient to mimic the conditions of the blood within a subject) and the second condition is with a cell (e.g., a cell within a subject) (or in an in vitro system sufficient to mimic the conditions of a cell within a subject).
  • the suitability of a cleavable linker can be assessed by standard methods known in the art. In general, the suitability of a cleavable linker can be evaluated by testing the ability of a cleavage agent (or condition) to cleave the candidate linker (e.g., the cleavage bond(s)).
  • the linker is a redox cleavable linker that is cleaved upon reduction or oxidation.
  • a reductively cleavable linker is a disulphide (-S-S-) containing linker. Redox cleavable linkers can be evaluated using methods analogous to those described above.
  • the linker is a phosphate-based cleavable linker.
  • a phosphate-based cleavable linker is cleaved by agents that degrade or hydrolyze the phosphate group.
  • agents that degrade or hydrolyze the phosphate group.
  • enzymes such as phosphatases are capable of cleaving phosphate groups.
  • phosphate-based linkers include those comprising any of the following - O-P(O)(ORk)-O-, -OP(S)(ORk)-O-, -O-P(S)(SRk)-O-, -S-P(O)(ORk)-O-, -O-P(O)(ORk)-S-, - S-P(O)(ORk)-S-, -OP(S)(ORk)-S-, -S-P(S)(ORk)-O-, -O-P(O)(Rk)-O-, -O-P(S)(Rk)-O-, -S- P(O)(
  • Exemplary embodiments include are -OP(O)(OH)-O-, -O-P(S)(OH)-O-, -O-P(S)(SH)- O-, -S-P(O)(OH)-O-, -O-P(O)(OH)-S-, -S-P(O)(OH)-S-, -O-P(S)(OH)-S-, -S-P(S)(OH)-O-, - O-P(O)(H)-O-, -O-P(S)(H)-O-, -S-P(O)(H)-O, -S-P(O)(H)-O-, -S-P(O)(H)-S-, or -O-P(S)(H)- S-.
  • the linker is an acid cleavable linker.
  • An acid cleavable linker is cleaved under acidic conditions.
  • the acid cleavable linker can be cleaved in an acidic environment with a pH of about 6.5 or less (e.g., about 6.0, 5.5, 5.0, or less).
  • the acid cleavable linker can be cleaved by enzymes that can act as a general acid.
  • specific low pH organelles such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linkers.
  • acid cleavable linkers include but are not limited to hydrazones, esters, and esters of amino acids.
  • ester-based cleavable linker is cleaved by enzymes such as esterases and amidases in cells.
  • ester-based cleavable include, but are not limited to, esters of alkylene, alkenylene and alkynylene groups.
  • the cleavable bonds of ester cleavable linkers have the general formula - C(O)O- or -OC(O)-.
  • Ester-based cleavable linkers can be evaluated using methods analogous to those described above. [00223]
  • the linker is a peptide-based cleavable linker.
  • a peptide- based cleavable linker is cleaved by enzymes such as peptidases and proteases (e.g., present in cells (e.g., cells within a subject)).
  • Peptide-based cleavable linkers comprise peptide bonds formed between amino acids to yield polypeptides (e.g., dipeptides, tripeptides, etc.).
  • polypeptides e.g., dipeptides, tripeptides, etc.
  • peptide bonds i.e., the amide bond
  • Peptide-based cleavable linkers can be evaluated using methods analogous to those described above.
  • the heterologous moiety may be attached at any suitable position to the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand).
  • the heterologous moiety is conjugated to the 5 ⁇ end of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand).
  • the heterologous moiety is conjugated to the 3 ⁇ end of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand).
  • a first heterologous moiety is conjugated to the 5 ⁇ end of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand) and a second heterologous moiety is conjugated to the 3 ⁇ end of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand).
  • the first and second heterologous moieties can be the same or different.
  • the heterologous moiety is conjugated to an internal site of the agent (e.g., described herein) (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand).
  • the agent e.g., RNAi agent, dsRNA agent
  • the heterologous moiety is conjugated to the 5 ⁇ end of the antisense strand.
  • the heterologous moiety is conjugated to the 3 ⁇ end of the antisense strand.
  • a first heterologous moiety is conjugated to the 5 ⁇ end of the antisense strand and a second heterologous moiety is conjugated to the 3 ⁇ end of the antisense strand.
  • the first and second heterologous moieties can be the same or different.
  • the heterologous moiety is conjugated to an internal site of the antisense strand. [00227]
  • the heterologous moiety may be attached to the 3′ end of the sense and/or antisense strand.
  • the heterologous moiety may be attached to the 5′ end of the sense and/or antisense strand.
  • the heterologous moiety may be attached to at an internal site of the sense and/or antisense strand.
  • the heterologous moiety may be attached to the 3′ end of the sense and antisense strand.
  • the heterologous moiety may be attached to the 5′ end of the sense and antisense strand.
  • the heterologous moiety may be attached to at an internal site of the sense and antisense strand.
  • the agent e.g., RNAi agent, dsRNA agent
  • the heterologous moiety comprises a sense strand.
  • the heterologous moiety is conjugated to the 5 ⁇ end of the sense strand.
  • the heterologous moiety is conjugated to the 3 ⁇ end of the sense strand.
  • a first heterologous moiety is conjugated to the 5 ⁇ end of the sense strand and a second heterologous moiety is conjugated to the 3 ⁇ end of the sense strand.
  • the first and second heterologous moieties can be the same or different.
  • the heterologous moiety is conjugated to an internal site of the sense strand.
  • the agent e.g., RNAi agent
  • the heterologous moiety is conjugated to the 5 ⁇ end of the sense strand.
  • the heterologous moiety is conjugated to the 3 ⁇ end of the sense strand.
  • a first heterologous moiety is conjugated to the 5 ⁇ end of the sense strand and a second heterologous moiety is conjugated to the 3 ⁇ end of the sense strand.
  • the first and second heterologous moieties can be the same or different.
  • the heterologous moiety is conjugated to an internal site of the sense strand.
  • the heterologous moiety is conjugated to the 5 ⁇ end of the sense strand.
  • the heterologous moiety is conjugated to the 3 ⁇ end of the sense strand.
  • a first heterologous moiety is conjugated to the 5 ⁇ end of the sense strand and a second heterologous moiety is conjugated to the 3 ⁇ end of the sense strand.
  • the first and second heterologous moieties can be the same or different.
  • the heterologous moiety is conjugated to an internal site of the sense strand.
  • a first heterologous moiety is conjugated to the 5 ⁇ end of the sense strand and a second heterologous moiety is conjugated to the 5 ⁇ end of the antisense strand.
  • a first heterologous moiety is conjugated to the 3 ⁇ end of the sense strand and a second heterologous moiety is conjugated to the 3 ⁇ end of the antisense strand.
  • a first heterologous moiety is conjugated to the 5 ⁇ end of the sense strand and a second heterologous moiety is conjugated to the 3 ⁇ end of the antisense strand. In some embodiments, a first heterologous moiety is conjugated to the 3 ⁇ end of the sense strand and a second heterologous moiety is conjugated to the 5 ⁇ end of the antisense strand.
  • the first and second heterologous moieties can be the same or different.
  • a first heterologous moiety is conjugated to an internal site of the sense strand and a second heterologous moiety is conjugated to the 5 ⁇ end of the antisense strand.
  • a first heterologous moiety is conjugated to an internal site of the sense strand and a second heterologous moiety is conjugated to the 3 ⁇ end of the antisense strand. In some embodiments, a first heterologous moiety is conjugated to an internal site of the antisense strand and a second heterologous moiety is conjugated to the 3 ⁇ end of the antisense strand. In some embodiments, a first heterologous moiety is conjugated to an internal site of the antisense strand and a second heterologous moiety is conjugated to the 5 ⁇ end of the antisense strand.
  • the first and second heterologous moieties can be the same or different.
  • RNAi agent e.g., RNAi agent, dsRNA agent, antisense strand, sense strand
  • the agent e.g., RNAi agent, dsRNA agent, antisense strand, sense strand
  • a linker e.g., as shown in the following schematic, wherein X is O or S (and further described in ⁇ 5.4.2).
  • the targeting moiety comprises N-[tris(GalNAc)-amido- dodecanoyl)]-4-hydroxyprolinol [Hyp-(GalNAc-alkyl)3].
  • the targeting moiety comprises (2S,4R)-1-[29-[[2- (acetylamino)-2-deoxy- ⁇ -D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2- deoxy- ⁇ -D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]- 1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2- hydroxymethylpyrrolidine.
  • the agent e.g., RNAi agent, e.g., dsRNA agent
  • a target gene e.g., FASN
  • the agent e.g., RNAi agent, e.g., dsRNA agent
  • inhibits expression of a target gene e.g., FASN
  • the agent e.g., RNAi agent, e.g., dsRNA agent
  • a target gene e.g., FASN
  • a subject e.g., a mammalian subject, e.g., a primate, human, non- human primate, mouse, rat, etc.
  • the agent e.g., RNAi agent, e.g., dsRNA agent
  • RNAi agent e.g., dsRNA agent
  • a target gene e.g., FASN
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • a subject e.g., a mammalian subject,
  • the agent e.g., RNAi agent, e.g., dsRNA agent
  • RNAi agent e.g., dsRNA agent
  • a target gene e.g., FASN
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • a subject e.g., a mammalian subject,
  • the agent e.g., RNAi agent, e.g., dsRNA agent
  • RNAi agent e.g., dsRNA agent
  • a target gene e.g., FASN
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • the agent e.g., RNAi agent, e.g., dsRNA agent
  • RNAi agent e.g., dsRNA agent
  • a target gene e.g., FASN
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • the agent e.g., RNAi agent, e.g., dsRNA agent
  • RNAi agent e.g., dsRNA agent
  • a target gene e.g., FASN
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • the agent e.g., RNAi agent, e.g., dsRNA agent
  • RNAi agent e.g., dsRNA agent
  • a target gene e.g., FASN
  • a subject e.g., a mammalian subject, e.g., a primate, human, non- human primate, mouse, rat, etc.
  • the agent e.g., RNAi agent, e.g., dsRNA agent
  • RNAi agent e.g., dsRNA agent
  • a target gene e.g., FASN
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • the agent e.g., RNAi agent, e.g., dsRNA agent
  • RNAi agent e.g., dsRNA agent
  • a target gene e.g., FASN
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • the agent e.g., RNAi agent, e.g., dsRNA agent
  • a target gene e.g., FASN
  • a subject e.g., a mammalian subject, e.g., a primate, human, non-human primate, mouse, rat, etc.
  • the agent e.g., RNAi agent, e.g., dsRNA agent
  • mediates degradation of a target mRNA e.g., a FASN (e.g., hFASN) mRNA).
  • Any one or more of the above activities can be evaluated in vitro, ex vivo, or in vivo. Any one or more of the above activities can be evaluated by standard methods known in the art. For example, by PCR (e.g., qPCR), branched DNA assays, or by a protein-based methods (such as immunofluorescence analysis (using, e.g., western blotting or flow cytometric techniques). In some embodiments, inhibition of gene (e.g., FASN (e.g., hFASN)) expression is determined by qPCR.
  • FASN e.g., hFASN
  • RNAi agent e.g., described herein
  • RNAi agent e.g., dsRNA agent, antisense strand, sense strand
  • chemical synthesis e.g., solid phase synthesis
  • RNAi agent e.g., RNAi agent, dsRNA agent, antisense strand, sense strand
  • methods of making an agent described herein e.g., RNAi agent, dsRNA agent, antisense strand, sense strand.
  • agent described herein e.g., RNAi agent, dsRNA agent, antisense strand, sense strand
  • single stranded nucleic acid molecules e.g., described herein
  • antisense strands, sense strands can be prepared using solution-phase or solid-phase organic synthesis or both.
  • dsRNA agents can be prepared using a two-step procedure, wherein the individual strands of the dsRNA agent are prepared separately and subsequently annealed.
  • the individual strands of the dsRNA agent can be prepared using solution-phase or solid-phase organic synthesis or both.
  • the agents e.g., described herein
  • the dsRNA agent can be prepared in a solution (e.g., an aqueous or organic solution) that is appropriate for formulation.
  • the dsRNA agent can be precipitated and redissolved in pure double-distilled water, and lyophilized.
  • conjugates can be synthesized utilizing standard methods known in the art. See, e.g., Dong Y, Siegwart DJ, Anderson DG. Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev. 2019 Apr;144:133-147. doi: 10.1016/j.addr.2019.05.004. Epub 2019 May 15. PMID: 31102606; PMCID: PMC6745264, the entire contents of which is incorporated herein by reference for all purposes.
  • one or more of the agents described herein are contained in a vector (e.g., a non-viral vector (e.g., a plasmid), a viral vector).
  • a vector e.g., a non-viral vector (e.g., a plasmid), a viral vector.
  • vectors e.g., non-viral vectors (e.g., plasmids) viral vectors) comprising one or more agent described herein (e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand) (see, e.g., ⁇ 5.2, 5.3).
  • agent described herein e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand
  • agent described herein e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand
  • the vector used can be any vector that is suitable for cloning nucleic acid molecules that can be used for transcription of the nucleic acid molecule of interest (e.g., an agent described herein (e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand) (see, e.g., ⁇ 5.2, 5.3).
  • the vector is a viral vector.
  • Viral vectors include both RNA and DNA based vectors.
  • the vectors can be designed to meet a variety of specifications.
  • viral vectors can be engineered to be capable or incapable of replication in prokaryotic and/or eukaryotic cells.
  • the vector is replication deficient.
  • the vector is replication competent.
  • Vectors can be engineered or selected that either will (or will not) integrate in whole or in part into the genome of host cells, resulting (or not (e.g., episomal expression)) in stable host cells comprising the desired nucleic acid in their genome.
  • Exemplary viral vectors include, but are not limited to, adenovirus vectors, adeno- associated virus vectors, lentivirus vectors, retrovirus vectors, poxvirus vectors, parapoxivirus vectors, vaccinia virus vectors, fowlpox virus vectors, herpes virus vectors, adeno-associated virus vectors, alphavirus vectors, lentivirus vectors, rhabdovirus vectors, measles virus, Newcastle disease virus vectors, picornaviruses vectors, anellovectors, or lymphocytic choriomeningitis virus vectors.
  • the viral vector is an adenovirus vector, adeno-associated virus vector, lentivirus vector, anellovector (as described, for example, in U.S. Pat. No. 11,446,344, the entire contents of which is incorporated by reference herein for all purposes).
  • the vector is an adenoviral vector (e.g., human adenoviral vector, e.g., HAdV or AdHu).
  • the adenovirus vector has the E1 region deleted, rendering it replication-deficient in human cells. Other regions of the adenovirus such as E3 and E4 may also be deleted.
  • Exemplary adenovirus vectors include, but are not limited to, those described in e.g., W02005071093 or WQ2006048215, the entire contents of each of which is incorporated by reference herein for all purposes.
  • the adenovirus-based vector used is a simian adenovirus, thereby avoiding dampening of the immune response after vaccination by pre-existing antibodies to common human entities such as AdHu5.
  • simian adenovirus vectors include AdCh63 (see, e.g., W02005071093, the entire contents of which is incorporated by reference herein for all purposes) or AdCh68.
  • Viral vectors can be generated through the use of a packaging/producer cell line (e.g., a mammalian cell line) using standard methods known to the person of ordinary skill in the art.
  • a nucleic acid construct e.g., a plasmid
  • the transgene e.g., an agent described herein
  • ITRs inverted terminal repeats
  • a plasmid encoding e.g., viral replication and structural proteins along with one or more helper plasmids
  • a host cell e.g., a host cell line
  • a host cell line i.e., the packing/producer cell line
  • helper plasmid may also be needed that include helper genes from another virus (e.g., in the instance of adeno-associated viral vectors).
  • Eukaryotic expression plasmids are commercially available from a variety of suppliers, for example the plasmid series: pcDNATM, pCR3.1 TM, pCMVTM, pFRTTM, pVAX1 TM, pCITM, NanoplasmidTM, and Pcaggs.
  • the person of ordinary skill in the art is aware of numerous transfection methods and any suitable method of transfection may be employed (e.g., using a biochemical substance as carrier (e.g., lipofectamine), by mechanical means, or by electroporation,).
  • the cells are cultured under conditions suitable and for a sufficient time for plasmid expression.
  • the viral particles may be purified from the cell culture medium using standard methods known to the person of ordinary skill in the art. For example, by centrifugation followed by e.g., chromatography or ultrafiltration.
  • the vector is a plasmid. A person of ordinary skill in the art is aware of suitable plasmids for expression of the DNA of interest.
  • Suitable plasmid DNA may be generated to allow efficient production of the encoded RNA in cell lines, e.g., in insect cell lines, for example using vectors as described in W02009150222A2 and as defined in PCT claims 1 to 33, the disclosure relating to claim 1 to 33 of W02009150222A2 the entire contents of which is incorporated by reference herein for all purposes.
  • a cell e.g., host cell
  • population of cells e.g., a population of host cells
  • agent described herein e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein see, e.g., ⁇ 5.6
  • a conjugate described herein see, e.g., ⁇ 5.4
  • a carrier described herein see, e.g., ⁇ 5.8
  • a pharmaceutical composition described herein see, e.g., ⁇ 5.10), and/or a cell described herein (see, e.g., ⁇ 5.8); or any combination thereof.
  • the cell or population of cells is in vitro. In some embodiments, the cell or population of cells is in vivo. In some embodiments, the cell or population of cells is ex vivo. In some embodiments, the cell or population of cells are derived from a subject (e.g., a human subject. In some embodiments, the subject is a human, mouse, rat, primate, or non-human primate.
  • a subject e.g., a human subject. In some embodiments, the subject is a human, mouse, rat, primate, or non-human primate.
  • one or more of the agents described herein e.g., RNAi agents, double stranded RNA (dsRNA) agents, sense strands, antisense strands (or a conjugate comprising the same)
  • a vector comprising any of the foregoing is formulated within one or more carrier.
  • carriers comprising any one or more of the agents described herein e.g., RNAi agents, double stranded RNA (dsRNA) agents, sense strands, antisense strands (or a conjugate comprising the same)
  • a vector comprising any of the foregoing comprising any of the foregoing.
  • any of the foregoing e.g., one or more of the agents described herein (e.g., RNAi agents, double stranded RNA (dsRNA) agents, sense strands, antisense strands (or a conjugate comprising the same) or a vector comprising any of the foregoing
  • RNAi agents double stranded RNA (dsRNA) agents
  • sense strands sense strands
  • antisense strands or a conjugate comprising the same
  • a vector comprising any of the foregoing can be encapsulated within a carrier, chemically conjugated to a carrier, associated with the carrier.
  • the term “associated” refers to the essentially stable combination of an agent described herein (or a conjugate comprising the same) (or a vector comprising the same) with one or more molecules of a carrier (e.g., one or more lipids of a lipid-based carrier, e.g., an LNP, liposome, lipoplex, and/or nanoliposome) into larger complexes or assemblies without covalent binding.
  • a carrier e.g., one or more lipids of a lipid-based carrier, e.g., an LNP, liposome, lipoplex, and/or nanoliposome
  • the term “encapsulation” refers to the incorporation of an agent described herein (or a conjugate comprising the same) (or a vector comprising the same) into a carrier (e.g., a lipid-based carrier, e.g., an LNP, liposome, lipoplex, and/or nanoliposome) wherein the agent described herein (or the conjugate comprising the same) (or the vector comprising the same) is entirely contained within the interior space of the carrier (e.g., the lipid-based carrier, e.g., the LNP, liposome, lipoplex, and/or nanoliposome).
  • a carrier e.g., a lipid-based carrier, e.g., an LNP, liposome, lipoplex, and/or nanoliposome
  • Exemplary carriers includes, but are not limited to, lipid-based carriers (e.g., lipid nanoparticles (LNPs), liposomes, lipoplexes, and nanoliposomes).
  • the carrier is a lipid-based carrier.
  • the carrier is an LNP.
  • the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and/or a PEG lipid. Lipid based carriers are further described below in ⁇ 5.9.1.
  • an agent described herein e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)
  • a vector comprising any of the foregoing is encapsulated or associated with one or more lipids (e.g., cationic lipids and/or neutral lipids), thereby forming lipid-based carriers such as lipid nanoparticles (LNPs), liposomes, lipoplexes, or nanoliposomes.
  • lipids e.g., cationic lipids and/or neutral lipids
  • an agent described herein e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)
  • a vector comprising any of the foregoing is encapsulated in one or more lipids (e.g., cationic lipids and/or neutral lipids), thereby forming lipid-based carriers such as lipid nanoparticles (LNPs), liposomes, lipoplexes, or nanoliposomes.
  • lipids e.g., cationic lipids and/or neutral lipids
  • an agent described herein e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)
  • a vector comprising any of the foregoing is associated with one or more lipids (e.g., cationic lipids and/or neutral lipids), thereby forming lipid-based carriers such as lipid nanoparticles (LNPs), liposomes, lipoplexes, or nanoliposomes.
  • lipids e.g., cationic lipids and/or neutral lipids
  • an agent described herein e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)
  • dsRNA double stranded RNA
  • sense strand sense strand
  • antisense strand or a conjugate comprising the same
  • LNPs e.g., as described herein
  • RNAi agents double stranded RNA (dsRNA) agents, sense strands, antisense strands (or a conjugate comprising the same)
  • dsRNA double stranded RNA
  • antisense strands or a conjugate comprising the same
  • a vector comprising any of the foregoing may be completely or partially located in the interior space of the LNPs, liposomes, lipoplexes, and/or nanoliposomes, within the lipid layer/membrane, or associated with the exterior surface of the lipid layer/membrane.
  • RNAi agent double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)
  • dsRNA double stranded RNA
  • antisense strand or a conjugate comprising the same
  • a vector comprising any of the foregoing is to protect the agent from an environment which may contain enzymes or chemicals or conditions that degrade the agent from molecules or conditions that cause the rapid excretion of the agent.
  • RNAi agent double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)
  • dsRNA double stranded RNA
  • nanoliposomes may promote the uptake of the agent, and hence, may enhance the therapeutic effect of the agent (e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)) (or a vector comprising any of the foregoing).
  • RNAi agent double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)
  • dsRNA double stranded RNA
  • sense strand antisense strand
  • nanoliposomes or a vector comprising any of the foregoing
  • LNPs, liposomes, lipoplexes, and/or nanoliposomes may be particularly suitable for a pharmaceutical composition described herein, e.g., for intramuscular and/or intradermal administration.
  • an agent described herein e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)
  • a vector comprising any of the foregoing is formulated into a lipid-based carrier (or lipid nanoformulation).
  • the lipid-based carrier or lipid nanoformulation
  • the lipid-based carrier is a liposome or a lipid nanoparticle (LNP).
  • the lipid-based carrier is an LNP.
  • the lipid-based carrier (or lipid nanoformulation) comprises a cationic lipid (e.g., an ionizable lipid), a non-cationic lipid (e.g., phospholipid), a structural lipid (e.g., cholesterol), and a PEG-modified lipid.
  • the lipid-based carrier (or lipid nanoformulation) contains one or more agent described herein (e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)) (or a vector comprising any of the foregoing), or a pharmaceutically acceptable salt thereof.
  • suitable compounds to be used in the lipid-based carrier include all the isomers and isotopes of the compounds described above, as well as all the pharmaceutically acceptable salts, solvates, or hydrates thereof, and all crystal forms, crystal form mixtures, and anhydrides or hydrates.
  • the lipid-based carrier may further include a second lipid.
  • the second lipid is a cationic lipid, a non-cationic (e.g., neutral, anionic, or zwitterionic) lipid, or an ionizable lipid.
  • the lipid-based carrier may contain positively charged (cationic) lipids, neutral lipids, negatively charged (anionic) lipids, or a combination thereof.
  • the lipid-based carrier (or lipid nanoformulation) comprises one or more cationic lipids, e.g., a cationic lipid that can exist in a positively charged or neutral form depending on pH, or an amine-containing lipid that can be readily protonated.
  • the cationic lipid is a lipid capable of being positively charged, e.g., under physiological conditions.
  • Exemplary cationic lipids include one or more amine group(s) which bear the positive charge.
  • the lipid- based carrier (or lipid nanoformulation) comprises more than one cationic lipid.
  • the lipid-based carrier (or lipid nanoformulation) comprises a cationic lipid having an effective pKa over 6.0.
  • the lipid-based carrier (or lipid nanoformulation) further comprises a second cationic lipid having a different effective pKa (e.g., greater than the first effective pKa) than the first cationic lipid.
  • cationic lipids that can be used in the lipid-based carrier (or lipid nanoformulation) include, for example those described in Table 4 of WO 2019/217941, the entire contents of which are incorporated by reference herein for all purposes.
  • the cationic lipid is an ionizable lipid (e.g., a lipid that is protonated at low pH, but that remains neutral at physiological pH).
  • the lipid-based carrier (or lipid nanoformulation) may comprise one or more additional ionizable lipids, different than the ionizable lipids described herein.
  • Exemplary ionizable lipids include, but are not limited to,
  • Examples of other ionizable lipids that can be used in lipid-based carrier (or lipid nanoformulation) include, without limitation, one or more of the following formulas: X of US 2016/0311759; I of US 20150376115 or in US 2016/0376224; Compound 5 or Compound 6 in US 2016/0376224; I, IA, or II of US 9,867,888; I, II or III of US 2016/0151284; I, IA, II, or IIA of US 2017/0210967; I-c of US 2015/0140070; A of US 2013/0178541; I of US 2013/0303587 or US 2013/0123338; I of US 2015/0141678; II, III, IV, or V of US 2015/0239926; I of US 2017/0119904; I or II of WO 2017/117528; A of US 2012/0149894; A of US 2015/0057373; A of WO 2013/116126; A of US 2013/00
  • the lipid-based carrier (or lipid nanoformulation) further includes biodegradable ionizable lipids, for instance, (9Z,l2Z)-3-((4,4- bis(octyloxy)butanoyl)oxy)-2-((((3- (diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,l2-dienoate, also called 3- ((4,4-bis(octyloxy)butanoyl)oxy)-2-(((3- (diethylamino)propoxy)carbonyl)oxy)methyl)propyl (9Z,l2Z)-octadeca-9,l2-dienoate).
  • biodegradable ionizable lipids for instance, (9Z,l2Z)-3-((4,4- bis(octyloxy)butanoyl)oxy)-2-((((3- (diethylamino)propoxy)carbon
  • the lipid-based carrier (or lipid nanoformulation) further comprises one or more non-cationic lipids.
  • the non-cationic lipid is a phospholipid.
  • the non-cationic lipid is a phospholipid substitute or replacement.
  • the non-cationic lipid is a negatively charged (anionic) lipid. replacement.
  • the non-cationic lipid is a negatively charged (anionic) lipid.
  • Exemplary' non-cationic lipids include, but are not limited to, distearoyl-sn-glycero- phosphoethanolamine, distearoylphosphatidylchohne (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane- 1 - carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristo
  • acyl groups in these lipids are preferably acyl groups derived from fatty acids having C10-C24 carbon chains, e.g., lauroyl, myristoyl, paimitoyl, stearoyl, or oleoyl.
  • Additional exemplary lipids include, without limitation, those described in Kim et al. (2020) dx.doi.org/10.1021/acs.nanolett.0c01386, the entire contents of which are incorporated by reference herein for all purposes.
  • Such lipids include, in some embodiments, plant lipids found to improve liver transfection with mRNA (e.g, DGTS).
  • the lipid-based carrier may comprise a combination of distearoylphosphatidylchohne/ cholesterol, dipalmitoylphosphatidylcholine/cholesterol, dimyrystoylphosphatidylchohne/cholesterol, 1 ,2- Dioleoyl-sn-glycero-3-phosphocholine (DOPC)/ cholesterol, or egg sphingomyelin/ cholesterol .
  • DOPC Dioleoyl-sn-glycero-3-phosphocholine
  • non-cationic lipids include, without limitation, nonphosphorous lipids such as, e.g., stearyl amine, dodecylamine, hexadecylamine, acetyl palmitate, glycerol ricinoleate, hexadecyl stearate, isopropyl myristate, amphoteric acrylic polymers, triethanolamine-lauryl sulfate, alkyl-aryl sulfate polyethyloxylated fatty acid amides, dioctadecyl dimethyl ammonium bromide, ceramide, sphingomyelin, and the like.
  • non-catiomc lipids are described in WO 2017/099823 or US 2018/0028664, the entire contents of each of which are incorporated by reference herein for all purposes.
  • the lipid-based carrier (or lipid nanoformulation) further comprises one or more non-cationic lipid that is oleic acid or a compound of Formula I, II, or IV of US 2018/0028664, the entire contents of which are incorporated by reference herein for all purposes.
  • the non-cationic lipid content can be, for example, 0-30% (mol) of the total lipid components present. In some embodiments, the non-cationic lipid content is 5-20% (mol) or 10-15% (mol) of the total lipid components present.
  • the lipid-based carrier (or lipid nanoformulation) further comprises a neutral lipid, and the molar ratio of an ionizable lipid to a neutral lipid ranges from about 2:1 to about 8:1 (e.g., about 2: l, 3: 1, 4:1, 5: 1, 6: 1, 7:1, or 8:1).
  • the lipid-based carrier does not include any phospholipids.
  • the lipid-based carrier (or lipid nanoformulation) can further include one or more phospholipids, and optionally one or more additional molecules of similar molecular shape and dimensions having both a hydrophobic moiety and a hydrophilic moiety (e.g., cholesterol).
  • the lipid-based carrier (or lipid nanoformulation) described herein may further comprise one or more structural lipids.
  • structural lipid refers to sterols (e.g, cholesterol) and also to lipids containing sterol moi eties.
  • Structural lipids can be selected from the group including but not limited to, cholesterol or cholesterol derivative, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid, alpha- tocopherol, hopanoids, phytosterols, steroids, and mixtures thereof.
  • the structural lipid is a sterol.
  • the structural lipid is a steroid.
  • the structural lipid is cholesterol.
  • the structural lipid is an analog of cholesterol.
  • the structural lipid is alpha-tocopherol.
  • structural lipids may be incorporated into the lipid-based carrier at molar ratios ranging from about 0. 1 to 1.0 (cholesterol phospholipid).
  • sterols when present, can include one or more of cholesterol or cholesterol denvatives, such as those described in WO 2009/127060 or US 2010/0130588, the entire contents of each of which are incorporated by reference herein for all purposes.
  • Additional exemplary sterols include phytosterols, including those described in Eygeris et al. (2020), Nano Lett. 2020;20(6):4543-4549, the entire contents of which are incorporated by reference herein for all purposes.
  • the structural lipid is a cholesterol derivative.
  • cholesterol derivatives include polar analogues such as 5a-cholestanol, 53- coprostanol, cholesteryl-(2’-hydroxy)-ethyl ether, cholesteryl-(4'- hydroxy)-butyl ether, and 6- ketocholestanol; non-polar analogues such as 5a-cholestane, cholestenone, 5a-cholestanone, 5p-cholestanone, and cholesteryl decanoate; and mixtures thereof.
  • the cholesterol derivative is a polar analogue, e.g, cholesteryl-(4'-hydroxy)-butyl ether.
  • exemplary cholesterol derivatives are described in WO 2009/127060 and US 2010/0130588, the entire contents of each of which are incorporated by reference herein for all purposes.
  • the lipid-based carrier (or lipid nanoformulation) further comprises sterol in an amount of 0-50 mol% (e.g., 0-10 mol %, 10-20 mol %, 20-50 mol%, 20- 30 mol %, 30-40 mol %, or 40-50 mol %) of the total lipid components.
  • the lipid-based carrier may include one or more polymers or co-polymers, e.g., poly(lactic-co-glycolic acid) (PFAG) nanoparticles.
  • PFAG poly(lactic-co-glycolic acid)
  • the lipid-based carrier may include one or more polyethylene glycol (PEG) lipid.
  • PEG polyethylene glycol
  • useful PEG-hpids include, but aarree nnoott limited to, l,2-Diacyl-sn-Glycero-3- Phosphoethanolamine-N- [Methoxy(Polyethylene glycol)-350] (mPEG 350 PE); 1 ,2-Diacyl-sn- Glycero-3- Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-550] (mPEG 550 PE); 1,2- Diacyl- sn-Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-750] (mPEG 750 PE); l,2-Diacyl-sn-Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-1000] (mPEG 1000 PE);
  • the PEG lipid is a polyethyleneglycol-diacylglycerol (i.e., polyethyleneglycol diacylglycerol (PEG-DAG), PEG-cholesterol, or PEG-DMB) conjugate.
  • PEG-DAG polyethyleneglycol diacylglycerol
  • PEG-DMB PEG-DMB conjugate
  • the lipid-based carrier includes one or more conjugated lipids (such as PEG-conjugated lipids or lipids conjugated to polymers described in Table 5 of WO 2019/217941, the entire contents of which are incorporated by reference herein for all purposes).
  • the one or more conjugated lipids is formulated with one or more ionic lipids (e.g., non-cationic lipid such as a neutral or anionic, or zwitterionic lipid); and one or more sterols (e.g., cholesterol).
  • the PEG conjugate can comprise a PEG-dilaurylglycerol (C12), a PEG- dimyristylglycerol (C14), a PEG-dipalmitoylglycerol (C16), a PEG-disterylglycerol (C18), PEG-dilaurylglycamide (C12), PEG-dimyristylglycamide (C14), PEG-dipalmitoylglycamide (Cl 6), and PEG-disterylglycamide (Cl 8).
  • a PEG-dilaurylglycerol C12
  • PEG- dimyristylglycerol C14
  • PEG-dipalmitoylglycerol C16
  • PEG-disterylglycerol C18
  • PEG-dilaurylglycamide C12
  • PEG-dimyristylglycamide C14
  • conjugated lipids when present, can include one or more of PEG-diacylglycerol (DAG) (such aass l-(monomethoxy-polyethyleneglycol)-2,3- dimynstoylglycerol (PEG-DMG)), PEG-dialkyloxypropyl (DAA), PEG-phospholipid, PEG- ceramide (Cer), a pegylated phosphatidylethanoloamine (PEG-PE), PEG succinate diacylglycerol (PEGS-DAG) (such aass 4-0-(2',3'-di(tetradecanoyloxy)propyl-l-0-(w- methoxy(polyethoxy)ethyl) butanedioate (PEG-S-DMG)), PEG dialkoxypropylcarbam, N- (carbonyl-methoxypolyethylene glycol 2000
  • DAG PEG-diacy
  • PEG-lipid conjugates are described, for example, in US 5,885,613, US 6,287,591, US 2003/0077829, US 2003/0077829, US 2005/0175682, US 2008/0020058, US 2011/0117125, US 2010/0130588, US 2016/0376224, US 2017/0119904, US 2018/0028664, and WO 2017/099823, the entire contents of each of which are incorporated by reference herein for all purposes.
  • the PEG-lipid is a compound of Formula III, III-a-I, III-a-2, III-b-1, III-b-2, or V of US 2018/0028664, which is incorporated herein by reference in its entirety.
  • the PEG-lipid is of Formula II of US 2015/0376115 or US 2016/0376224, the entire contents of each of which are incorporated by reference herein for all purposes.
  • the PEG-DAA conjugate can be, for example, PEG- dilauryloxypropyl, PEG- dimyristyloxypropyl, PEG-dipalmityloxypropyl, oorr PEG- distearyloxypropyl.
  • the PEG-lipid includes one of the following:
  • lipids conjugated with a molecule other than a PEG can also be used in place of PEG-lipid.
  • PEG-lipid conjugates polyoxazoline (POZ)-lipid conjugates, polyamidelipid conjugates (such as ATTA-lipid conjugates), and cationic-polymer lipid (GPL) conjugates can be used in place of or in addition to the PEG-lipid.
  • POZ polyoxazoline
  • GPL cationic-polymer lipid
  • Exemplary' conjugated lipids e.g., PEG-lipids, (POZ)-lipid conjugates, ATTA-lipid conjugates and cationic polymer-lipids, include those described in Table 2 of WO 2019/051289A9, the entire contents of which are incorporated by reference herein for all purposes.
  • the conjugated lipid (e.g., the PEGylated lipid) can be present in an amount of 0-20 mol% of the total lipid components present in the lipid-based carrier (or lipid nanoformulation). In some embodiments, the conjugated lipid (e.g., the PEGylated lipid) content is 0.5-10 mol% or 2-5 mol% of the total lipid components.
  • the lipid-based carrier (or lipid nanoformulation) described herein may be coated with a polymer layer to enhance stability in vivo (e.g, sterically stabilized LNPs).
  • Suitable polymers include, but are not limited to, polyethylene glycol), which may form a hydrophilic surface layer that improves the circulation half-life of liposomes and enhances the amount of lipid nanoformulations (e.g, liposomes or LNPs) that reach therapeutic targets. See, e.g., Working et al. J Pharmacol Exp Ther.
  • the lipid-based carrier comprises one of more of the agents described herein (e.g., RNAi agents, double stranded RNA (dsRNA) agents, sense strands, antisense strands (or a conjugate comprising the same)) (or a vector comprising any of the foregoing), optionally a non-cationic lipid (e.g., a phospholipid), a sterol, a neutral lipid, and optionally conjugated lipid (e.g, a PEGylated lipid) that inhibits aggregation of particles.
  • RNAi agents e.g., double stranded RNA (dsRNA) agents, sense strands, antisense strands (or a conjugate comprising the same)
  • a vector comprising any of the foregoing
  • optionally a non-cationic lipid e.g., a phospholipid
  • sterol e.g., a sterol
  • a neutral lipid e.
  • the lipid-based earner (or lipid nanoformulation) further comprises an agent (e.g, an agent described herein (e.g, RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)) (or a vector comprising any of the foregoing))).
  • an agent e.g, an agent described herein (e.g, RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)
  • dsRNA double stranded RNA
  • the ionizable lipid including the lipid compounds described herein is present in an amount from about 20 mol% to about 100 mol% (e.g., 20-90 mol%, 20-80 mol%, 20-70 mol%, 25-100 mol%, 30-70 mol%, 30-60 mol%, 30-40 mol%, 40-50 mol%, or 50-90 mol%) of the total lipid components; a non-cationic lipid (e.g., phospholipid) is present in an amount from about 0 mol% to about 50 mol% (e.g., 0-40 mol%, 0-30 mol%, 5-50 mol%, 5-40 mol%, 5-30 mol%, or 5-10 mol%) of the total lipid components, a conjugated lipid (e.g, a PEGylated lipid) in an amount from about 0.5 mol% to about 20 mol% (e.g., 1-10 mol% or 5-10%) of the total lipid components;
  • the lipid-based carrier (or lipid nanoformulation) comprises about 25-100 mol% of the ionizable lipid including the lipid compounds described herein, about 0-50 mol% phospholipid, about 0-50 mol% sterol, and about 0-10 mol% PEGylated lipid.
  • the lipid-based carrier comprises an agent described herein (e.g, RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)) (or a vector comprising any of the foregoing) that is formulated in a lipid nanoparticle, wherein the lipid nanoparticle comprises about 25-100 mol% of the ionizable lipid including the lipid compounds described herein, about 0-50 mol% phospholipid, about 0-50 mol% sterol, and about 0-10 mol% PEGylated lipid.
  • the encapsulation efficiency of the agent may be at least 70%.
  • the lipid-based carrier (or lipid nanoformulation) comprises about 25-100 mol% of the ionizable lipid including the lipid compounds described herein; about 0-40 mol% phospholipid (e.g., DSPC), about 0-50 mol% sterol (e.g, cholesterol), and about 0-10 mol% PEGylated lipid.
  • the lipid-based carrier comprises an agent described herein (e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)) (or a vector comprising any of the foregoing) that is formulated in a lipid nanoparticle, wherein the lipid nanoparticle comprises about 25-100 mol% of the ionizable lipid including the lipid compounds described herein; about 0-40 mol% phospholipid (e.g, DSPC), about 0-50 mol% sterol (e.g, cholesterol), and about 0-10 mol% PEGylated lipid.
  • the encapsulation efficiency of the agent may be at least 70%.
  • the lipid-based carrier (or lipid nanoformulation) comprises about 30-60 mol% (e.g, about 35-55 mol%, or about 40-50 mol%) of the ionizable lipid including the lipid compounds described herein, about 0-30 mol% (e.g., 5-25 mol%, or 10-20 mol%) phospholipid, about 15-50 mol% (e.g, 18.5-48.5 mol%, or 30-40 mol%) sterol, and about 0-10 mol% (e.g, 1-5 mol%, or 1.5-2.5 mol%) PEGylated lipid.
  • the lipid-based carrier comprises an agent described herein (e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)) (or a vector comprising any of the foregoing) that is formulated in a lipid nanoparticle, wherein the lipid nanoparticle comprises about 30-60 mol% (e.g., about 35-55 mol%, or about 40-50 mol%) of the ionizable lipid including the lipid compounds described herein, about 0-30 mol% (e.g, 5-25 mol%, or 10-20 mol%) phospholipid about 15-50 mol% (e g 18 5-48 5 mol% or 30-40 mol%) sterol and about 0- 10 mol% (e.g, 1-5 mol%, or 1.5-2.5 mol%) PEGylated lipid.
  • the encapsulation efficiency of the agent may be at least 70%
  • molar ratios of ionizable lipid/sterol/phospholipid (or another structural lipid)/PEG-lipid/additional components is varied in the following ranges: ionizable lipid (25-100%); phospholipid (DSPC) (0-40%); sterol (0-50%); and PEG lipid (0- 5%).
  • the lipid-based carrier comprises an agent described herein (e.g, RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)) (or a vector comprising any of the foregoing) that is formulated in a lipid nanoparticle, wherein the lipid nanoparticle comprises molar ratios of ionizable lipid/ sterol/ phospholipid (or another structural lipid)/PEG-lipid/additional components in the following ranges: ionizable lipid (25-100%); phospholipid (DSPC) (0-40%); sterol (0-50%); and PEG lipid (0-5%).
  • the encapsulation efficiency of the agent may be at least 70%.
  • the lipid-based carrier comprises, by mol% or wt% of the total lipid components, 50-75% ionizable lipid (including the lipid compound as described herein), 20-40% sterol (e.g, cholesterol or derivative), 0 to 10% non- cationic-lipid, and 1-10% conjugated lipid (e.g., the PEGylated lipid).
  • the lipid-based carrier comprises an agent described herein (e.g, RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)) (or a vector comprising any of the foregoing) that is formulated in a lipid nanoparticle, wherein the lipid nanoparticle compnses, by mol% or wt% of the total lipid components, 50-75% ionizable lipid (including the lipid compound as described herein), 20-40% sterol (e.g, cholesterol or derivative), 0 to 10% non-cationic-lipid, and 1-10% conjugated lipid (e.g, the PEGylated lipid).
  • the encapsulation efficiency of the agent may be at least 70%.
  • the lipid-based carrier (or lipid nanoformulation) comprises (i) an agent described herein (e.g., RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)) (or a vector comprising any of the foregoing); (ii) a cationic lipid comprising from 50 mol% to 65 mol% of the total lipid present in the lipid-based carrier; (iii) a non-cationic lipid comprising a mixture of a phospholipid and a cholesterol derivative thereof, wherein the phospholipid comprises from 3 mol% to 15 mol% of the total lipid present in the lipid-based carrier and the cholesterol or derivative thereof compnses from 30 mol% to 40 mol% of the total lipid present in the lipid- based earner; and (iv) a conjugated lipid comprising 0.5 mol% to 2 mol% of the total lipid present
  • the lipid-based carrier (or lipid nanoformulation) comprises (i) an agent described herein (e.g, RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)) (or a vector comprising any of the foregoing); (ii) a cationic lipid comprising from 50 mol % to 85 mol % of the total lipid present in the lipid-based carrier; (iii) a non-cationic lipid comprising from 13 mol % to 49.5 mol % of the total lipid present in the lipid-based earner; and (d) a conjugated lipid comprising from 0.5 mol % to 2 mol % of the total lipid present in the lipid-based carrier.
  • an agent described herein e.g, RNAi agent, double stranded RNA (dsRNA) agent, sense strand, antisense strand (or a conjugate comprising the same)
  • the phospholipid component in the mixture may be present from 2 mol% to 20 mol%, from 2 mol% to 15 mol%, from 2 mol% to 12 mol%, from 4 mol% to 15 mol%, from 4 mol% to 10 mol%, from 5 mol% to 10 mol%, (or any fraction of these ranges) of the total lipid components.
  • the lipid-based carrier or lipid nanoformulation is phospholipid-free.
  • the sterol component (e.g. cholesterol or derivative) in the mixture may comprise from 25 mol% to 45 mol%, from 25 mol% to 40 mol%, from 25 mol% to 35 mol%, from 25 mol% to 30 mol%, from 30 mol% to 45 mol%, from 30 mol% to 40 mol%, from 30 mol% to 35 mol%, from 35 mol% to 40 mol%, from 27 mol% to 37 mol%, or from 27 mol% to 35 mol% (or any fraction of these ranges) of the total lipid components.
  • the non-iomzable lipid components in the lipid-based carrier may be present from 5 mol% to 90 mol%, from 10 mol% to 85 mol%, or from 20 mol% to 80 mol% (or any fraction of these ranges) of the total lipid components.
  • the ratio of total lipid components to the agent can be varied as desired.
  • the total lipid components to the agent (mass or weight) ratio can be from about 10: 1 to about 30: 1.
  • the total lipid components to the agent ratio can be in the range of from about 1:1 to about 25:1, from about 10: 1 to about 14: 1, from about 3:1 to about 15:1, from about 4:1 to about 10:1, from about 5: 1 to about 9:1, or about 6:1 to about 9: 1.
  • the amounts of total lipid components and the agent can be adjusted to provide a desired N/P ratio, for example, N/P ratio of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 28 29 30 or higher
  • the lipid-based carrier (or lipid nanoformulation’s) overall lipid content can range from about 5 mg/ml to about 30 mg/mL.
  • Nitrogen: phosphate ratios is evaluated at values between 0. 1 and 100.
  • the efficiency of encapsulation of an agent describes the amount of agent that is encapsulated or otherwise associated with a lipid nanoformulation (e.g, liposome or LNP) after preparation, relative to the initial amount provided.
  • the encapsulation efficiency is desirably high (e.g, at least 70%. 80%. 90%. 95%, close to 100%).
  • the encapsulation efficiency may be measured, for example, by comparing the amount of agent in a solution containing the liposome or LNP before and after breaking up the liposome or LNP with one or more organic solvents or detergents.
  • An anion exchange resin may be used to measure the amount of free agent in a solution.
  • the encapsulation efficiency of a protein and/or nucleic acid may be at least 50%, for example 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%.
  • the encapsulation efficiency may be at least 70%.
  • the encapsulation efficiency may be at least 80%.
  • the encapsulation efficiency may be at least 90%.
  • the encapsulation efficiency may be at least 95%.
  • compositions comprising any one more agent described herein (e.g, an RNAi agent, a dsRNA agent, an antisense strand, a sense strand) (see, e.g., ⁇ 5.2, 5.3); a vector described herein (see, e.g., ⁇ 5.6); a conjugate described herein (see, e.g., ⁇ 5.4); a carrier described herein (see, e.g., ⁇ 5.8); and/or a cell described herein (see, e.g, ⁇ 5.8); or any combination thereof; and a pharmaceutically acceptable excipient (see, e.g., Remington’s Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, PA, the entire contents of which is incorporated by reference herein for all purposes).
  • agent described herein e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein see, e.g
  • compositions described herein compnsing providing any one more agent described herein (e.g. , an RNAi agent, a dsRNA agent, an antisense strand, a sense strand) (see, e.g, ⁇ 5.2, 5.3); a vector described herein (see, e.g, ⁇ 5.6); a conjugate described herein (see, e.g, ⁇ 5.4); a carrier described herein (see, e.g, ⁇ 5.8); and/or a cell described herein (see, e.g, ⁇ 5.8); and formulating it into a pharmaceutically acceptable composition by the addition of one or more pharmaceutically acceptable excipient.
  • agent described herein e.g. , an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein see, e.g, ⁇ 5.6
  • a conjugate described herein see, e.g, ⁇ 5.4
  • compositions comprising any one more agent described herein (e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand); vector described herein; conjugate described herein; carrier described herein; and/or cell described herein, wherein the pharmaceutical composition lacks a predetermined threshold amount or a detectable amount of a process impurity or contaminant, e.g., lacks a predetermined threshold amount or a detectable amount of a process-related impurity such as host cell proteins, host cell DNA, or a cell culture component (e.g., inducers, antibiotics, or media components); a product-related impurity (e.g, precursors, fragments, aggregates, degradation products); or a contaminant, e.g., endotoxin, bacteria, viral contaminant.
  • an RNAi agent e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • Acceptable excipients are preferably nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, or other organic acids; antioxidants including ascorbic acid or methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol;or m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine
  • a pharmaceutical composition may be formulated for any route of administration to a subject.
  • Non-limiting embodiments include parenteral administration, such as intramuscular, intradermal, subcutaneous, transcutaneous, or mucosal.
  • the pharmaceutical composition is formulated for administration by intramuscular, intradermal, or subcutaneous injection. In one embodiment, the pharmaceutical composition is formulated for administration by intramuscular injection. In one embodiment, the pharmaceutical composition is formulated for administration by intradermal injection. In one embodiment, the pharmaceutical composition is formulated for administration by subcutaneous injection.
  • injectables can be prepared in conventional forms, either as liquid solutions or suspensions. The injectables can contain one or more excipients.
  • Exemplary excipients include for example water saline dextrose glycerol or ethanol
  • the pharmaceutical compositions to be administered can also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, or other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate or cyclodextrins.
  • the pharmaceutical composition is formulated in a single dose.
  • the pharmaceutical compositions if formulated as a multi-dose.
  • compositions described herein include for example, aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents or other pharmaceutically acceptable substances.
  • aqueous vehicles which can be incorporated in one or more of the formulations described herein, include sodium chloride injection, Ringer’s injection, isotonic dextrose injection, sterile water injection, dextrose or lactated Ringer’s injection.
  • Nonaqueous parenteral vehicles which can be incorporated in one or more of the formulations described herein, include fixed oils of vegetable origin, cottonseed oil, com oil, sesame oil or peanut oil.
  • Antimicrobial agents in bacteriostatic or fungistatic concentrations can be added to the parenteral preparations described herein and packaged in multiple-dose containers, which include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride or benzethonium chlonde.
  • Isotonic agents which can be incorporated in one or more of the formulations described herein, include sodium chloride or dextrose Buffers, which can be incorporated in one or more of the formulations described herein, include phosphate or citrate.
  • Antioxidants which can be incorporated in one or more of the formulations described herein, include sodium bisulfate.
  • Local anesthetics which can be incorporated in one or more of the formulations described herein, include procaine hydrochloride.
  • Suspending and dispersing agents which can be incorporated in one or more of the formulations described herein, include sodium carboxymethylcelluose, hydroxypropyl methylcellulose or polyvinylpyrrolidone.
  • Emulsifying agents which can be incorporated in one or more of the formulations described herein, include Polysorbate 80 (TWEEN® 80).
  • a sequestering or chelating agent of metal ions which can be incorporated in one or more of the formulations described herein, is EDTA.
  • Pharmaceutical carriers which can be incorporated in one or more of the formulations described herein, also include ethyl alcohol, polyethylene glycol or propylene glycol for water miscible vehicles; orsodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.
  • the precise dose to be employed in a pharmaceutical composition will also depend on the route of administration, and the seriousness of the condition caused by it, and should be decided according to the judgment of the practitioner and each subject’s circumstances.
  • effective doses may also vary depending upon means of administration, target site, physiological state of the subject (including age, body weight, and health), other medications administered, or whether therapy is prophylactic or therapeutic.
  • Therapeutic dosages are preferably titrated to optimize safety and efficacy.
  • any one more agent described herein e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector descnbed herein see, e.g., ⁇ 5.6
  • a conjugate described herein see, e.g., ⁇ 5.4
  • a carrier described herein see, e.g., ⁇ 5.9
  • a host cell described herein see, e.g., ⁇ 5.8
  • a pharmaceutical composition described herein see, e.g., ⁇ 5.10; or any combination thereof.
  • the methods described herein comprise administering one or more of the foregoing to a subject.
  • exemplary subjects include mammals, e.g., humans, non-human mammals, e.g., non-human primates.
  • the subject is a human.
  • the dosage of any of the foregoing, to be administered to a subject in accordance with any of the methods described herein can be determined in accordance with standard techniques known to those of ordinary skill in the art, including the route of administration, the age and weight of the subject.
  • the agent described herein e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a subject is administered to a subject at a dose of from about 1-10 mg/kg, 2-10 mg.kg, 3-10 mg/kg, 4-10 mg/kg, 5-10 mg/kg, 6-10 mg/kg, 7-10 mg/kg, 8-10 mg/kg 9-10 mg/kg, 1-5 mg/kg, 1-4 mg.kg, 1-3 mg/kg, 1-2 mg/kg, 1-2.5 mg/kg, 2-5 mg.kg, 2-4 mg/kg, 2-3 mg/kg, or 2- 2.5mg/kg.
  • the agent described herein e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a subject is administered to a subject at a dose of about 1 mg/kg, 2 mg/kg, 2.5mg/kg, 3 mg.kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, or 10 mg/kg.
  • the agent described herein e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a subject at least once per month, once per month, at least twice per month, twice per month, at least once a week, or once per week.
  • RNAi agent e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector descnbed herein e.g., a conjugate described herein; a carrier descnbed herein; a host cell described herein; and/or a pharmaceutical composition described herein; or any combination thereof to e.g., a cell, subject, a cell within a subject.
  • RNAi agent e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein e.g., a dsRNA agent, an antisense strand, a sense strand
  • a pharmaceutical composition described herein or any combination thereof to a cell
  • the method comprising introducing into a cell any one more agent described herein (e.g, an RNAi agent, a dsRNA agent, an antisense strand, a sense strand); a vector described herein; a conjugate described herein; a carrier described herein; a host cell described herein; and/or a pharmaceutical composition described herein into the cell, to thereby deliver the agent (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand), conjugate, vector, carrier, or pharmaceutical composition into the cell.
  • agent e.g., RNAi agent, dsRNA agent, antisense strand
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is introduced in an amount and for a time sufficient to deliver the agent (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand), conjugate, vector, carrier, or pharmaceutical composition into the cell.
  • the cell is in vitro, ex vivo, or in vivo. In some embodiments, the cell is in vitro or ex vivo. In some embodiments, the cell is in vitro. In some embodiments, the cell is ex vivo. In some embodiments, the cell is in vivo.
  • RNAi agent e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein e.g., a dsRNA agent, an antisense strand, a sense strand
  • a pharmaceutical composition described herein or any combination thereof to a subject
  • the method comprising administering to a subject any one more agent described herein (e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand); a vector described herein; a conjugate described herein; a carrier described herein; a host cell described herein; and/or a pharmaceutical composition described herein into the cell, to thereby deliver the agent (e.g., RNAi agent, dsRNA agent, antisense strand, sense strand), conjugate, vector, carrier, or pharmaceutical composition to the subject.
  • agent e.g., RNAi agent, dsRNA agent, antisense
  • the agent e.g., RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is administered in an amount and for a time sufficient to deliver the agent (e.g, RNAi agent, dsRNA agent, antisense strand, sense strand), conjugate, vector, carrier, or pharmaceutical composition to the subject.
  • RNAi agent e.g, an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein e.g, a conjugate described herein; a carrier described herein; a host cell described herein; and/or a pharmaceutical composition described herein; or any combination thereof to a cell within a subj ect
  • the method comprising administering to a cell within a subj ect any one more agent described herein (e.g, an RNAi agent, a dsRNA agent, an antisense strand, a sense strand); a vector described herein; a conjugate described herein; a carrier described herein; a host cell descnbed herein; and/or a pharmaceutical composition described herein into the cell, to thereby deliver the agent (e.g, RNAi agent, dsRNA agent, antisense strand, sense strand), conjugate,
  • agent e.g, RNAi agent,
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is administered in an amount and for a time sufficient to deliver the agent (e.g, RNAi agent, dsRNA agent, antisense strand, sense strand), conjugate, vector, carrier, or pharmaceutical composition to the cell within the subject.
  • RNAi agent e.g. RNAi agent
  • dsRNA agent e.g., RNAi agent
  • antisense strand e.g., RNAi agent
  • sense strand e.g., RNAi agent
  • dsRNA agent e.g., RNAi agent
  • antisense strand e.g., RNAi agent
  • a vector described herein e.g., RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein e.g., RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein e.g., RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein e.g., RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is introduced in an amount and for a time sufficient to reduce or inhibit expression of FASN (e.g, hFASN) in the cell.
  • the cell is in vitro, ex vivo, or in vivo. In some embodiments, the cell is in vitro or ex vivo. In some embodiments, the cell is in vitro. In some embodiments, the cell is ex vivo. In some embodiments, the cell is in vivo.
  • the level of FASN (e.g, hFASN) expression in the cell is reduced by at least about 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% (e.g, as compared to suitable control) (e.g, as measured by an assay known in the art or described herein, e.g, qPCR).
  • the level of FASN (e.g, hFASN) expression in the cell is reduced by at least about 50% (e.g, as compared to suitable control) (e.g, as measured by an assay known in the art or described herein, e.g, qPCR).
  • the level of FASN (e.g, hFASN) expression in the cell is reduced by at least about 75% (e.g, as compared to suitable control) (e.g, as measured by an assay known in the art or described herein, e.g, qPCR). In some embodiments, the level of FASN (e.g, hFASN) expression in the cell is reduced by at least about 80% (e.g, as compared to suitable control) (e.g., as measured by an assay known in the art or described herein, e.g, qPCR).
  • the level of FASN (e.g, hFASN) expression in the cell is reduced by at least about 90% (e.g, as compared to suitable control) (e.g, as measured by an assay known in the art or described herein, e.g, qPCR). In some embodiments, the level of FASN (e.g, hFASN) expression in the cell is reduced by at least about 95% (e.g, as compared to suitable control) (e.g, as measured by an assay known in the art or described herein, e.g, qPCR).
  • RNAi agent e.g., a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein e.g., a conjugate described herein; a carrier described herein; a host cell described herein; and/or a pharmaceutical composition descnbed herein, to thereby reduce or inhibit expression of FASN (e.g., hFASN) in the cell in the subject.
  • agent described herein e.g, an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein e.g., a conjugate described herein; a carrier described herein; a host cell described herein; and/or a pharmaceutical composition descnbed herein
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is administered to the subject in an amount and for a time sufficient to reduce or inhibit expression of FASN (e.g, hFASN) in the cell in the subject.
  • FASN e.g, hFASN
  • the level of FASN (e.g, hFASN) expression in the cell is reduced by at least about 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% (e.g, as compared to suitable control) (e.g, as measured by an assay known in the art or described herein, e.g, qPCR).
  • suitable control e.g, as measured by an assay known in the art or described herein, e.g, qPCR.
  • dsRNA agents, conjugates, vectors, carriers, and pharmaceutical compositions for use in a method of reducing or inhibiting expression of FASN (e.g, hFASN) in a cell in a subject, the method comprising administenng to the subject a dsRNA agent described herein, a conjugate described herein, a vector described herein, a carrier described herein, or a pharmaceutical composition described herein, to thereby reduce or inhibit expression of FASN (e.g, hFASN) in the cell in the subject.
  • FASN e.g, hFASN
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is administered to the subject in an amount and for a time sufficient to reduce or inhibit expression of FASN (e.g, hFASN) in the cell in the subject.
  • FASN e.g, hFASN
  • the level of FASN (e.g, hFASN) expression in the cell is reduced by at least about 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% (e.g, as compared to suitable control) (e.g, as measured by an assay known in the art or described herein, e.g, qPCR).
  • suitable control e.g, as measured by an assay known in the art or described herein, e.g, qPCR.
  • dsRNA agents in the manufacture of a medicament for use in the reduction or inhibition of FASN (e.g, hFASN) expression in a cell in a subject.
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is administered to the subject in an amount and for a time sufficient to reduce or inhibit expression of FASN (e.g, hFASN) in the cell in the subject.
  • the level of FASN (e.g., hFASN) expression in the cell is reduced by at least about 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% (e.g, as compared to suitable control) (e.g, as measured by an assay known in the art or described herein, e.g, qPCR).
  • suitable control e.g, as measured by an assay known in the art or described herein, e.g, qPCR.
  • dsRNA agents in the manufacture of a medicament for use in a method of reducing or inhibiting expression of FASN (e.g, hFASN) in a cell in a subject, the method comprising administering to the subject a dsRNA agent described herein, a conjugate described herein, a vector described herein, a carrier described herein, or a pharmaceutical composition described herein, to thereby reduce or inhibit expression of FASN (e.g, hFASN) in the cell in the subject.
  • FASN e.g, hFASN
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is administered to the subj ect in an amount and for a time sufficient to reduce or inhibit expression of FASN (e.g, hFASN) in the cell in the subject.
  • FASN e.g, hFASN
  • the level of FASN (e.g, hFASN) expression in the cell is reduced by at least about 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% (e.g, as compared to suitable control) (e.g., as measured by an assay known in the art or described herein, e.g, qPCR).
  • suitable control e.g., as measured by an assay known in the art or described herein, e.g, qPCR.
  • RNAi agent e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein e.g., a conjugate described herein; a carrier described herein; a host cell described herein; and/or a pharmaceutical composition described herein, to thereby treat, ameliorate, or prevent a disease in the subject.
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is administered to the subject in an amount and for a time sufficient to treat, ameliorate, or prevent the disease in the subject.
  • a FASN e.g, hFASN
  • a FASN e.g, hFASN
  • administering to the subject any one more agent described herein (e.g, an RNAi agent, a dsRNA agent, an antisense strand, a sense strand); a vector described herein; a conjugate described herein; a carrier described herein; a host cell described herein; and/or a pharmaceutical composition described herein, to thereby treat, ameliorate, or prevent the FASN (e.g, hFASN) associated disease in the subject.
  • agent described herein e.g, an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein e.g, a conjugate described herein; a carrier described herein; a host cell described herein; and/or a pharmaceutical composition described herein
  • the agent e.g., RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is administered to the subj ect in an amount and for a time sufficient to treat, ameliorate, or prevent the FASN (e.g, hFASN) associated disease in the subject.
  • FASN e.g, hFASN
  • the FASN associated disease is fatty liver, liver inflammation, nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFLD).
  • NASH nonalcoholic steatohepatitis
  • NAFLD nonalcoholic fatty liver disease
  • the disease is obesity -induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, alcoholic fatty liver disease (AFLD), or cirrhosis.
  • the disease is metabolic dysfunction associated steatotic liver disease (MASLD), metabolic-associated steatohepatitis (MASH), metabolic dysfunction and alcohol associated steatotic liver disease (MetALD), steatotic liver disease (SLD), cryptogenic SLD. See, e.g, Rinella M.
  • dsRNA agents, conjugates, vectors, carriers, and pharmaceutical compositions for use in a method of treating, ameliorating, or preventing a FASN (e.g, hFASN) associated disease in a subject, the method comprising administering to the subject a dsRNA agent described herein, a conjugate described herein, a vector described herein, a carrier described herein, or a pharmaceutical composition described herein, to thereby treat, ameliorate, or prevent the FASN (e.g, hFASN) associated disease in the subject.
  • a FASN e.g, hFASN
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is administered to the subject in an amount and for a time sufficient to treat, ameliorate, or prevent the FASN (e.g, hFASN) associated disease in the subject.
  • FASN e.g, hFASN
  • the FASN associated disease is fatty liver, liver inflammation, NASH or NAFLD
  • the disease is obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, or cirrhosis.
  • the disease is MASLD, MASH, MetALD, SLD, cryptogenic SLD.
  • dsRNA agents in one aspect, uses of dsRNA agents, conjugates, vectors, carriers, and pharmaceutical compositions in the manufacture of a medicament for use in the treatment, amelioration, or prevention of a FASN (e.g, hFASN) associated disease in a subject.
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is administered in an amount and for a time sufficient to treat, ameliorate, or prevent the FASN (e.g, hFASN) associated disease in the subject.
  • the FASN associated disease is fatty liver, liver inflammation, NASH or NAFLD
  • the disease is obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, or cirrhosis.
  • the disease is MASLD, MASH, MetALD, SLD, cryptogenic SLD.
  • dsRNA agents in the manufacture of a medicament for use in a method of treating, ameliorating, or preventing a FASN (e.g, hFASN) associated disease in a subject, the method comprising administering to the subject a dsRNA agent described herein, a conjugate described herein, a vector described herein, a carrier described herein, or a pharmaceutical composition described herein, to thereby treat, ameliorate, or prevent the FASN (e.g., hFASN) associated disease in the subject.
  • a FASN e.g., hFASN
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • the agent e.g., RNAi agent, dsRNA agent, antisense strand, sense strand
  • the FASN e.g., hFASN
  • the FASN associated disease is fatty liver, liver inflammation, NASH or NAFLD
  • the disease is obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, or cirrhosis.
  • the disease is MASLD, MASH, MetALD, SLD, cry ptogenic SLD.
  • dsRNA agents for use in treating a disease in a subj ect, preferably a FASN (e.g. , hFASN) associated disease, more preferably a liver disease.
  • a FASN e.g. , hFASN
  • dsRNA agents for use for use in treating a disease in a subject (preferably a FASN (e.g.. hFASN) associated disease, more preferably a liver disease) by reducing or inhibiting expression of FASN (e.g, hFASN) in a cell.
  • a FASN e.g.. hFASN
  • hFASN hFASN associated disease
  • RNAi agent e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand
  • a vector described herein e.g., a conjugate described herein; a carrier described herein; a host cell described herein; and/or a pharmaceutical composition described herein, to thereby treat, ameliorate, or prevent the liver disease in the subject.
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is administered to the subject in an amount and for a time sufficient to treat, ameliorate, or prevent the liver disease in the subject.
  • the FASN associated disease is fatty liver, liver inflammation, NASH or NAFLD
  • the disease is obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, or cirrhosis.
  • the disease is MASLD, MASH, MetALD, SLD, cryptogenic SLD.
  • dsRNA agents, conjugates, vectors, carriers, and pharmaceutical compositions for use in a method of treating, ameliorating, or preventing a liver disease in a subject, the method comprising administering to the subject a dsRNA agent described herein, a conjugate described herein, a vector described herein, a carrier described herein, or a pharmaceutical composition described herein, to thereby treat, ameliorate, or prevent the liver disease in the subject.
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is administered to the subject in an amount and for a time sufficient to treat, ameliorate, or prevent the liver disease in the subject.
  • the FASN associated disease is fatty liver, liver inflammation, NASH or NAFLD
  • the disease is obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, or cirrhosis.
  • the disease is MASLD, MASH, MetALD, SLD, cryptogenic SLD.
  • dsRNA agents conjugates, vectors, carriers, and pharmaceutical compositions in the manufacture of a medicament for the treatment, amelioration, or prevention of a liver disease in a subject.
  • the agent e.g, RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, earner, or pharmaceutical composition is administered in an amount and for a time sufficient to treat, ameliorate, or prevent the liver disease in the subject.
  • the FASN associated disease is fatty liver, liver inflammation, NASH or NAFLD
  • the disease is obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, or cirrhosis.
  • the disease is MASLD, MASH, MetALD, SLD, cryptogenic SLD.
  • dsRNA agents in one aspect, are uses of dsRNA agents, conjugates, vectors, carriers, and pharmaceutical compositions in the manufacture of a medicament for use in a method of treating, ameliorating, or preventing a liver disease in a subject, the method comprising administering to the subject a dsRNA agent described herein, a conjugate described herein, a vector desenbed herein, a carrier desenbed herein, or a pharmaceutical composition described herein, to thereby treat, ameliorate, or prevent the liver disease in the subject.
  • the agent e.g., RNAi agent, dsRNA agent, antisense strand, sense strand
  • conjugate, vector, carrier, or pharmaceutical composition is administered to the subject in an amount and for a time sufficient to treat, ameliorate, or prevent the liver disease in the subject.
  • the FASN associated disease is fatty liver, liver inflammation, NASH or NAFLD.
  • the disease is obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, or cirrhosis.
  • the disease is MASLD, MASH, MetALD, SLD, cryptogenic SLD.
  • a liver disease in a subj ect comprising (a) isolating and purifying DNA, RNA, or protein, or having DNA, RNA, or protein isolated and purified, from a sample obtained from the subject: (b) detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA, RNA, or protein, wherein the presence of the somatic mutation indicates that the subject has a liver disease.
  • (a) comprises isolating and purifying DNA, or having DNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA.
  • (a) comprises isolating and purifying RNA, or having RNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the RNA
  • (a) comprises isolating and purifying protein, or having protein isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the protein.
  • the method further comprises (c) administenng to the subj ect an inhibitory nucleic acid molecule that inhibits expression of FASN if one or more somatic FASN mutation is detected in the DNA, RNA, or protein.
  • the inhibitory nucleic acid molecule comprises one or more RNA agent described herein (e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein, e.g., a vector described herein; a conjugate comprising the RNA agent described herein, e.g., a conjugate described herein; a carrier comprising the RNA agent described herein (or a vector or conjugate comprising the same), e.g., a carrier described herein; and/or a pharmaceutical composition comprising the RNA agent described herein (or a vector, conjugate, or carrier comprising the same), e.g, a pharmaceutical composition described herein).
  • the RNA agent is a dsRNA agent described herein comprising a sense strand and an antisense strand.
  • the method further comprises (c) withholding administration of an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if one or more somatic FASN mutation is not detected in the DNA, RNA, or protein.
  • the method further comprises (c) administering an alternative therapeutic agent for treatment of the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if a somatic FASN mutation in the sample is not detected.
  • the different therapeutic agent is a standard of care agent for the disease.
  • the subj ect is undergoing or has undergone treatment with a different therapeutic agent for the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN and/or function of FASN.
  • the treatment with the different therapeutic agent is discontinued if a somatic FASN mutation in the sample is detected and/or the inhibitory nucleic acid molecule that inhibits expression of FASN is administered to the subject.
  • the FASN associated disease is fatty liver, liver inflammation, NASH or NAFLD
  • the disease is obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, or cirrhosis.
  • the disease is MASLD, MASH, MetALD, SLD, cry ptogenic SLD.
  • kits for diagnosing and/or prognosticating a liver disease in a subject comprising (a) isolating and purifying DNA, RNA, or protein, or having DNA, RNA, or protein isolated and punfied, from a sample obtained from the subject; (b) detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA, RNA, or protein, wherein the presence of the somatic mutation indicates that the subject has a liver disease, is at risk of developing a liver disease, is at risk of developing a more severe form of a liver disease, and/or is at risk of developing a disease associated with a liver disease.
  • (a) comprises isolating and punfying DNA, or having DNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA.
  • (a) comprises isolating and purifying RNA, or having RNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the RNA.
  • (a) comprises isolating and purifying protein, or having protein isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the protein.
  • the method further comprises (c) administenng to the subj ect an agent (e.g., inhibitory nucleic acid molecule (e.g, an RNA agent (e.g, a dsRNA agent described herein)) that inhibits expression of FASN if one or more somatic FASN mutation is detected in the DNA, RNA, or protein.
  • an agent e.g., inhibitory nucleic acid molecule (e.g, an RNA agent (e.g, a dsRNA agent described herein)) that inhibits expression of FASN if one or more somatic FASN mutation is detected in the DNA, RNA, or protein.
  • the inhibitory nucleic acid molecule comprises one or more RNA agent described herein (e g an RNAi agent a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein, e.g., a vector described herein; a conjugate comprising the RNA agent described herein, e.g., a conjugate described herein; a carrier comprising the RNA agent described herein (or a vector or conjugate comprising the same), e.g., a carrier described herein; and/or a pharmaceutical composition comprising the RNA agent described herein (or a vector, conjugate, or carrier comprising the same), e.g., a pharmaceutical composition described herein).
  • the RNA agent is a dsRNA agent described herein comprising a sense strand and an antisense strand.
  • the method further comprises (c) withholding administration of an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if one or more somatic FASN mutation is not detected in the DNA, RNA, or protein.
  • the method further comprises (c) administering an alternative therapeutic agent for treatment of the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if a somatic FASN mutation in the sample is not detected.
  • the different therapeutic agent is a standard of care agent for the disease.
  • the subject is undergoing or has undergone treatment with a different therapeutic agent for the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN and/or function of FASN.
  • the treatment with the different therapeutic agent is discontinued if a somatic FASN mutation in the sample is detected and/or the inhibitory nucleic acid molecule that inhibits expression of FASN is administered to the subject.
  • the FASN associated disease is fatty liver, liver inflammation, NASH or NAFLD
  • the disease is obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, or cirrhosis.
  • the disease is MASLD, MASH, MetALD, SLD, cryptogenic SLD.
  • RNA, or protein wherein the presence of the somatic mutation indicates that the subject is at risk of developing a liver disease, is at risk of developing a more severe form of a liver disease, and/or is at risk of developing a disease associated with a liver disease.
  • (a) comprises isolating and punfying DNA, or having DNA isolated and purified from a sample obtained from the subject; and (b) comprises detecting or having detected, the presence or absence of one or more somatic FASN mutation in the DNA.
  • (a) comprises isolating and purifying RNA, or having RNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the RNA.
  • (a) comprises isolating and purifying protein, or having protein isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the protein.
  • the method further comprises (c) administering to the subj ect an agent (e.g., inhibitory nucleic acid molecule (e.g, an RNA agent (e.g, a dsRNA agent described herein)) that inhibits expression of FASN if one or more somatic FASN mutation is detected in the DNA, RNA, or protein.
  • an agent e.g., inhibitory nucleic acid molecule (e.g, an RNA agent (e.g, a dsRNA agent described herein)) that inhibits expression of FASN if one or more somatic FASN mutation is detected in the DNA, RNA, or protein.
  • the agent comprises a nucleic acid molecule, small molecule, protein, peptide.
  • the agent is a nucleic acid molecule.
  • the agent is an inhibitory nucleic acid molecule.
  • the inhibitory nucleic acid molecule composes one or more RNA agent described herein (e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein, e.g, a vector described herein; a conjugate comprising the RNA agent described herein, e.g., a conjugate described herein; a carrier comprising the RNA agent described herein (or a vector or conjugate comprising the same), e.g., a earner desenbed herein; and/or a pharmaceutical composition comprising the RNA agent described herein (or a vector, conjugate, or earner comprising the same), e.g, a pharmaceutical composition described herein).
  • the RNA agent is a dsRNA agent described herein comprising a sense strand and an antisense
  • the method further comprises (c) withholding administration of an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if one or more somatic FASN mutation is not detected in the DNA, RNA, or protein.
  • the method further comprises (c) administering an alternative therapeutic agent for treatment of the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if a somatic FASN mutation in the sample is not detected.
  • the different therapeutic agent is a standard of care agent for the disease.
  • the subj ect is undergoing or has undergone treatment with a different therapeutic agent for the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN and/or function of FASN.
  • the treatment with the different therapeutic agent is discontinued if a somatic FASN mutation in the sample is detected and/or the inhibitory nucleic acid molecule that inhibits expression of FASN is administered to the subject.
  • the FASN associated disease is fatty liver, liver inflammation, NASH or NAFLD
  • the disease is obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, or cirrhosis.
  • the disease is MASLD, MASH, MetALD, SLD, cry ptogenic SLD.
  • RNA agent e.g., a dsRNA agent described herein
  • methods of screening a subj ect for administration of an inhibitory nucleic acid molecule that inhibits expression of FASN comprising (a) isolating and purifying DNA, RNA, or protein, or having DNA, RNA, or protein isolated and purified, from a sample obtained from the subject; (b) detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA, RNA, or protein, wherein the subject is selected for administration of an agent (e.g, inhibitory nucleic acid molecule (e.g, an RNA agent (e.g, a dsRNA agent described herein)) that inhibits expression of FASN if the somatic mutation is present.
  • an agent e.g, inhibitory nucleic acid molecule (e.g, an RNA agent (e.g, a dsRNA agent described herein)
  • (a) comprises isolating and punfying DNA, or having DNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA.
  • (a) comprises isolating and purifying RNA, or having RNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the RNA.
  • (a) comprises isolating and purifying protein, or having protein isolated and purified, from a sample obtained from the subject, and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the protein.
  • the agent comprises a nucleic acid molecule, small molecule, protein, peptide.
  • the agent is a nucleic acid molecule.
  • the inhibitory nucleic acid molecule compnses one or more RNA agent described herein (e.g, an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein, e.g, a vector described herein; a conjugate comprising the RNA agent described herein, e.g, a conjugate described herein; a carrier compnsmg the RNA agent described herein (or a vector or conjugate comprising the same), e.g , a carrier described herein; and/or a pharmaceutical composition comprising the RNA agent described herein (or a vector, conjugate, or carrier comprising the RNA agent described herein (or a vector, conjugate, or
  • the method further comprises (c) administering to the subj ect an inhibitory nucleic acid molecule that inhibits expression of FASN if one or more somatic FASN mutation is detected in the DNA, RNA, or protein.
  • the inhibitory nucleic acid molecule comprises one or more RNA agent described herein (e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein, e.g., a vector described herein; a conjugate comprising the RNA agent described herein, e.g., a conjugate described herein; a carrier comprising the RNA agent described herein (or a vector or conjugate comprising the same), e.g., a carrier described herein; and/or a pharmaceutical composition comprising the RNA agent described herein (or a vector, conjugate, or carrier comprising the same), e.g., a pharmaceutical composition described herein).
  • the RNA agent is a dsRNA agent described herein compnsing a sense strand and an antisense strand
  • the method further comprises (c) withholding administration of an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if one or more somatic FASN mutation is not detected in the DNA, RNA, or protein.
  • the method further comprises (c) administering an alternative therapeutic agent for treatment of the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if a somatic FASN mutation in the sample is not detected.
  • the different therapeutic agent is a standard of care agent for the disease.
  • the subject is undergoing or has undergone treatment with a different therapeutic agent for the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN and/or function of FASN.
  • the treatment with the different therapeutic agent is discontinued if a somatic FASN mutation in the sample is detected and/or the inhibitory nucleic acid molecule that inhibits expression of FASN is administered to the subject.
  • RNA agent e.g., a dsRNA agent described herein
  • methods of selecting a subj ect for administration of an inhibitory nucleic acid molecule that inhibits expression of FASN comprising (a) isolating and purifying DNA, RNA, or protein, or having DNA, RNA, or protein isolated and purified from a sample obtained from the subject; (b) detecting or having detected the presence or absence of one or more somatic FASN mutation in the DNA, RNA, or protein, wherein the subject is selected for administration of an agent (e.g, inhibitory nucleic acid molecule (e.g., an RNA agent (e.g., a dsRNA agent described herein)) that inhibits expression of FASN if the somatic mutation is present.
  • an agent e.g, inhibitory nucleic acid molecule (e.g., an RNA agent (e.g., a dsRNA agent described herein)
  • (a) comprises isolating and purifying DNA, or having DNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA.
  • (a) comprises isolating and purifying RNA, or having RNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the RNA.
  • (a) comprises isolating and purifying protein, or having protein isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the protein.
  • the agent comprises a nucleic acid molecule, small molecule, protein, peptide.
  • the agent is a nucleic acid molecule.
  • the inhibitory nucleic acid molecule compnses one or more RNA agent described herein (e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein, e.g., a vector described herein; a conjugate comprising the RNA agent described herein, e.g, a conjugate described herein; a carrier compnsmg the RNA agent described herein (or a vector or conjugate comprising the same), e.g.
  • RNA agent is a dsRNA agent described herein comprising a sense strand and an antisense strand.
  • the method further comprises (c) admimstenng to the subj ect an inhibitory nucleic acid molecule that inhibits expression of FASN if one or more somatic FASN mutation is detected in the DNA, RNA, or protein.
  • the inhibitory nucleic acid molecule comprises one or more RNA agent described herein (e.g, an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein, e.g., a vector described herein; a conjugate comprising the RNA agent described herein, e.g., a conjugate described herein; a carrier comprising the RNA agent described herein (or a vector or conjugate comprising the same) e g a carrier described herein; and/or a pharmaceutical composition comprising the RNA agent described herein (or a vector, conjugate, or carrier comprising the same), e.g, a pharmaceutical composition described herein).
  • the RNA agent is a dsRNA agent described herein compnsing a sense strand and an antisense strand.
  • the method further comprises (c) withholding administration of an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if one or more somatic FASN mutation is not detected in the DNA, RNA, or protein.
  • the method further comprises (c) administering an alternative therapeutic agent for treatment of the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if a somatic FASN mutation in the sample is not detected.
  • the different therapeutic agent is a standard of care agent for the disease.
  • the subj ect is undergoing or has undergone treatment with a different therapeutic agent for the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN and/or function of FASN.
  • the treatment with the different therapeutic agent is discontinued if a somatic FASN mutation in the sample is detected and/or the inhibitory nucleic acid molecule that inhibits expression of FASN is administered to the subject.
  • RNA agent e.g., a dsRNA agent described herein
  • methods of identifying a subject for administration of an inhibitory nucleic acid molecule that inhibits expression of FASN comprising (a) isolating and purifying DNA, RNA, or protein, or having DNA, RNA, or protein isolated and purified, from a sample obtained from the subject; (b) detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA, RNA, or protein, wherein the presence of the somatic mutation indicates that the subject is identified for administration of an agent (e.g, inhibitory nucleic acid molecule (e.g., an RNA agent (e.g., a dsRNA agent described herein)) that inhibits expression of FASN.
  • an agent e.g, inhibitory nucleic acid molecule (e.g., an RNA agent (e.g., a dsRNA agent described herein)
  • (a) comprises isolating and punfying DNA, or having DNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA.
  • (a) comprises isolating and purifying RNA, or having RNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the RNA.
  • the agent comprises a nucleic acid molecule, small molecule, protein, peptide. In some preferred embodiments, the agent is a nucleic acid molecule. In some preferred embodiments, the agent is an inhibitory nucleic acid molecule.
  • the inhibitory nucleic acid molecule compnses one or more RNA agent described herein (e.g, an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein, e.g., a vector described herein; a conjugate comprising the RNA agent described herein, e.g, a conjugate described herein; a carrier comprising the RNA agent described herein (or a vector or conjugate comprising the same), e.g.
  • RNA agent described herein e.g, an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide
  • a vector comprising or encoding the RNA agent described herein e.g., a vector described herein
  • RNA agent is a dsRNA agent described herein comprising a sense strand and an antisense strand.
  • the method further comprises (c) admimstenng to the subj ect an inhibitory nucleic acid molecule that inhibits expression of FASN if one or more somatic FASN mutation is detected in the DNA, RNA, or protein.
  • the inhibitory nucleic acid molecule comprises one or more RNA agent described herein (e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein, e.g., a vector described herein; a conjugate comprising the RNA agent described herein, e.g, a conjugate described herein; a carrier comprising the RNA agent described herein (or a vector or conjugate comprising the same), e.g., a carrier described herein; and/or a pharmaceutical composition comprising the RNA agent described herein (or a vector, conjugate, or carrier comprising the same), e.g, a pharmaceutical composition described herein).
  • the RNA agent is a dsRNA agent described herein compnsing a sense strand and an antisense strand.
  • the method further comprises (c) withholding administration of an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if one or more somatic FASN mutation is not detected in the DNA, RNA, or protein.
  • the method further comprises (c) administering an alternative therapeutic agent for treatment of the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if a somatic FASN mutation in the sample is not detected.
  • the different therapeutic agent is a standard of care agent for the disease.
  • the subj ect is undergoing or has undergone treatment with a different therapeutic agent for the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN and/or function of FASN.
  • the treatment with the different therapeutic agent is discontinued if a somatic FASN mutation in the sample is detected and/or the inhibitory nucleic acid molecule that inhibits expression of FASN is administered to the subject.
  • RNA agent e.g., a dsRNA agent described herein
  • methods of identifying a subj ect having a disease who is likely to respond to treatment with an inhibitory nucleic acid molecule that inhibits expression of FASN comprising (a) isolating and purifying DNA, RNA, or protein, or having DNA, RNA, or protein isolated and purified, from a sample obtained from the subject; (b) detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA, RNA, or protein, wherein the subject is identified as a subject likely to respond to treatment with an agent (e.g., inhibitory nucleic acid molecule (e.g., an RNA agent (e.g, a dsRNA agent described herein)) that inhibits expression of FASN if the somatic mutation is present.
  • an agent e.g., inhibitory nucleic acid molecule (e.g., an RNA agent (e.g, a dsRNA agent described here
  • the FASN associated disease is fatty liver, liver inflammation, NASH or NAFLD
  • the disease is obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, or cirrhosis.
  • the disease is MASLD, MASH, MetALD, SLD, cryptogenic SLD.
  • (a) comprises isolating and purifying DNA, or having DNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA.
  • (a) comprises isolating and purifying RNA, or having RNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the RNA.
  • (a) comprises isolating and purifying protein, or having protein isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the protein.
  • the agent comprises a nucleic acid molecule, small molecule, protein, peptide.
  • the agent is a nucleic acid molecule.
  • the inhibitory nucleic acid molecule comprises one or more RNA agent described herein (e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein e g a vector described herein; a conjugate comprising the RNA agent described herein, e.g, a conjugate described herein; a carrier comprising the RNA agent described herein (or a vector or conjugate comprising the same), e.g.
  • RNA agent is a dsRNA agent described herein comprising a sense strand and an antisense strand.
  • the method further comprises (c) administering to the subj ect an inhibitory nucleic acid molecule that inhibits expression of FASN if one or more somatic FASN mutation is detected in the DNA, RNA, or protein.
  • the inhibitory nucleic acid molecule comprises one or more RNA agent described herein (e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein, e.g., a vector described herein; a conjugate comprising the RNA agent described herein, e.g., a conjugate described herein; a carrier comprising the RNA agent described herein (or a vector or conjugate comprising the same), e.g., a carrier described herein; and/or a pharmaceutical composition comprising the RNA agent described herein (or a vector, conjugate, or carrier comprising the same), e.g, a pharmaceutical composition described herein).
  • the RNA agent is a dsRNA agent described herein comprising a sense strand and an antisense strand.
  • the method further comprises (c) withholding administration of an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if one or more somatic FASN mutation is not detected in the DNA, RNA, or protein.
  • the method further comprises (c) administering an alternative therapeutic agent for treatment of the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if a somatic FASN mutation in the sample is not detected.
  • the different therapeutic agent is a standard of care agent for the disease.
  • the subject is undergoing or has undergone treatment with a different therapeutic agent for the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN and/or function of FASN.
  • the treatment with the different therapeutic agent is discontinued if a somatic FASN mutation in the sample is detected and/or the inhibitory nucleic acid molecule that inhibits expression of FASN is administered to the subject.
  • a therapy for a subject having a disease who is likely to respond to treatment with an inhibitory nucleic acid molecule that inhibits expression of FASN the method compnsing (a) isolating and purifying DNA, RNA, or protein, or having DNA, RNA, or protein isolated and purified, from a sample obtained from the subject; (b) detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA, RNA, or protein, and (c) selecting a therapy for a subject comprising an agent (e.g., inhibitory nucleic acid molecule (e.g., an RNA agent (e.g., a dsRNA agent described herein)) that inhibits expression of FASN if the somatic mutation is present.
  • an agent e.g., inhibitory nucleic acid molecule (e.g., an RNA agent (e.g., a dsRNA agent described herein)) that inhibits expression of FASN if the somatic mutation is present.
  • the FASN associated disease is fatty liver, liver inflammation, NASH or NAFLD
  • the disease is obesity-induced metabolic syndrome, insulin insensitivity, obesity, type-2 diabetes, AFLD, or cirrhosis.
  • the disease is MASLD, MASH, MetALD, SLD, cryptogenic SLD.
  • (a) comprises isolating and purifying DNA, or having DNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA.
  • (a) comprises isolating and purifying RNA, or having RNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the RNA.
  • (a) comprises isolating and purifying protein, or having protein isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the protein.
  • the agent comprises anucleic acid molecule, small molecule, protein, peptide. In some preferred embodiments, the agent is anucleic acid molecule.
  • the inhibitory nucleic acid molecule compnses one or more RNA agent described herein (e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein, e.g., a vector described herein; a conjugate compnsing the RNA agent described herein, e.g, a conjugate described herein; a carrier comprising the RNA agent described herein (or a vector or conjugate comprising the same), e.g.
  • RNA agent is a dsRNA agent described herein comprising a sense strand and an antisense strand.
  • the method further comprises (d) administering to the subject an inhibitory nucleic acid molecule that inhibits expression of FASN if one or more somatic FASN mutation is detected in the DNA, RNA, or protein.
  • the inhibitory nucleic acid molecule comprises one or more RNA agent descnbed herein (e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein, e.g., a vector described herein; a conjugate comprising the RNA agent described herein, e.g., a conjugate described herein; a carrier comprising the RNA agent described herein (or a vector or conjugate comprising the same), e.g., a carrier described herein; and/or a pharmaceutical composition comprising the RNA agent described herein (or
  • the method further comprises (d) withholding administration of an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if one or more somatic FASN mutation is not detected in the DNA, RNA, or protein.
  • the method further comprises (d) administering an alternative therapeutic agent for treatment of the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN to the subject if a somatic FASN mutation in the sample is not detected.
  • the different therapeutic agent is a standard of care agent for the disease.
  • the subject is undergoing or has undergone treatment with a different therapeutic agent for the disease that is not an inhibitory nucleic acid molecule that inhibits expression of FASN and/or function of FASN.
  • the treatment with the different therapeutic agent is discontinued if a somatic FASN mutation in the sample is detected and/or the inhibitory nucleic acid molecule that inhibits expression of FASN is administered to the subject.
  • kits for screening a sample from a subject for the presence or absence of one or more somatic FASN mutation comprising (a) isolating and purifying DNA, RNA, or protein from a sample obtained from the subject; (b) detecting the presence or absence of one or more somatic FASN mutation in the DNA, RNA, or protein.
  • (a) comprises isolating and purifying DNA, or having DNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the DNA.
  • (a) comprises isolating and purifying RNA, or having RNA isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the RNA
  • (a) comprises isolating and purifying protein, or having protein isolated and purified, from a sample obtained from the subject; and (b) comprises detecting, or having detected, the presence or absence of one or more somatic FASN mutation in the protein.
  • the method further comprises (c) administering to the subj ect an inhibitory nucleic acid molecule that inhibits expression of FASN if one or more somatic FASN mutation is detected in the DNA, RNA, or protein.
  • the agent comprises a nucleic acid molecule, small molecule, protein, peptide. In some preferred embodiments, the agent is a nucleic acid molecule.
  • the inhibitory nucleic acid molecule comprises one or more RNA agent described herein (e.g., an RNAi agent, a dsRNA agent, an antisense strand, a sense strand, an siRNA agent, an antisense oligonucleotide) (or a vector comprising or encoding the RNA agent described herein, e.g., a vector described herein; a conjugate comprising the RNA agent described herein, e.g., a conjugate described herein; a carrier comprising the RNA agent described herein (or a vector or conjugate comprising the same), e.g., a carrier described herein; and/or a pharmaceutical composition comprising the RNA agent described herein (or a vector, conjugate, or carrier comprising the same), e.g., a pharmaceutical composition described herein).
  • the RNA agent is a dsRNA agent described herein compnsing a sense strand and an antisense strand
  • a DNA molecule in a sample from a subject having a disease comprising (a) isolating and purifying DNA (or having DNA isolated and purified) in a sample from the subject; (b) analyzing the DNA (e.g., sequencing at least a portion of the FASN gene in the DNA); and (c) determining the presence or absence of a somatic FASN mutation in the DNA molecule.
  • methods of characterizing a disease in a subject comprising (a) isolating and purifying DNA (or having DNA isolated and purified) in a sample from the subject; (b) detecting the presence or absence of a somatic FASN mutation in the DNA; and (c) characterizing the liver disease as somatic FASN mutation positive or somatic FASN mutation negative based on the detection.
  • kits comprising any one or more agent described herein (e.g, an RNAi agent, a dsRNA agent, an antisense strand, a sense strand) (see, e.g, ⁇ 5.2, 5.3); a vector descnbed herein (see, e.g., ⁇ 5.6); a conjugate described herein (see, e.g, ⁇ 5.4); a carrier described herein (see, e.g., ⁇ 5.9); a host cell described herein (see, e.g, ⁇ 5.8); and/or a pharmaceutical composition described herein (see, e.g., ⁇ 5.10); or any combination thereof.
  • the kit may comprise a liquid vehicle for solubilizing or diluting, and/or technical instructions.
  • the technical instructions of the kit may contain information about administration and dosage and subject groups.
  • the agent e.g., described herein
  • the agent e.g., described herein
  • vector e.g, described herein
  • conjugate e.g., described herein
  • carrier e.g, described herein
  • host cell e.g, described herein
  • pharmaceutical composition e.g, described herein
  • the agent e.g, described herein
  • the agent e.g, described herein
  • vector e.g, described herein
  • conjugate e.g., described herein
  • carrier e.g, described herein
  • host cell e.g., described herein
  • pharmaceutical composition e.g., described herein
  • the kit may further contain as a part a vehicle (e.g, buffer solution) for solubilizing the dried or lyophilized any agent (e.g, described herein) (e.g, RNAi agent, dsRNA agent, antisense strand, sense strand), vector (e.g, described herein), conjugate (e.g, described herein), carrier (e.g, described herein), host cell (e.g, descnbed herein), and/or pharmaceutical composition (e.g, described herein).
  • a vehicle e.g, buffer solution
  • agent e.g, described herein
  • agent e.g, described herein
  • vector e.g, described herein
  • conjugate e.g, described herein
  • carrier e.g, described herein
  • host cell e.g, descnbed herein
  • pharmaceutical composition e.g, described herein
  • the kit comprises a single dose container. In some embodiments, the kit compnses a multi-dose container. In some embodiments, the kit comprises an administration device (e.g, an injector for intradermal injection or a syringe for intramuscular injection).
  • an administration device e.g, an injector for intradermal injection or a syringe for intramuscular injection.
  • kits for use in a method described herein (e.g, diagnostic method, prognostic method, subject screening, subject identification, subject selection, sample screening).
  • the kit comprises one or more reagents for detecting one or more somatic FASN mutation in a sample from a subject (e.g, in DNA, RNA, or protein from a sample from a subject).
  • kits described herein may be used in any of the methods described herein
  • results were replicated in an independent sample of 20 NASH liver tissue samples that underwent whole exome sequencing using Nanoseq at a sequencing depth of 200X Dx per sample; 10 of these samples also underwent laser capture microscopy with whole exome sequencing at a sequencing depth of lOOx.
  • Results of interest in the primary sample (defined as a global q- value ⁇ 0.1) were restricted hypothesis tested in the replication samples.
  • dsRNA agents targeting hFASN were designed and the nucleotide sequence of the unmodified FASN sense and antisense strands of each of the dsRNA agents are set forth in Table 2.
  • the dsRNA agents set forth in Table 2 or Table 3 are synthesized using standard methods known in the art and described herein. Briefly, the dsRNA agents are synthesized using a Mermade 192 synthesizer (BioAutomation) on controlled pore glass (500-1000 A) solid supports loaded with a first nucleotide of interest. Upon completion of the solid phase synthesis, solid-supported polynucleotides are treated with Methylamine (40% aqueous) at room temperature in 96 well plates for approximately 2 hours to afford cleavage from the solid support and subsequent removal of relevant protecting groups.
  • a Mermade 192 synthesizer BioAutomation
  • controlled pore glass 500-1000 A
  • Polynucleotides are precipitated by the addition of 1 mL of 9:1 acetonitrile: ethanol or 1:1 ethanolisopropanol. The plates are then centrifuged at 4°C for 45 minutes and the supernatant removed. The polynucleotide pellet is resuspended in 20 mM NaOAc and subsequently desalted using a HiTrap size exclusion column (5 mL, GE Healthcare) on an Agilent LC system equipped with an autosampler, UV detector, conductivity meter, and fraction collector. Desalted samples are collected in 96 well plates and then analyzed by LC-MS and UV spectrometry to confirm identity and quantify the amount of material, respectively.
  • HiTrap size exclusion column 5 mL, GE Healthcare
  • Duplexing of single strands is performed on a Tecan liquid handling robot.
  • Sense and antisense single strands are combined in an equimolar ratio to a final concentration of 10 pM in lx PBS in 96 well plates, the plate is sealed, incubated at 100 °C for 10 minutes, and is subsequently allowed to return slowly to room temperature over a period of 2-3 hours. The concentration and identity of each duplex is confirmed and is then subsequently utilized for screening assays.
  • Hep3B cells were seeded at 15,000 cells per well in a standard 96 well plate.
  • the cells were transfected with the indicated hFASN targeting dsRNA agent (either 0.5 nM or 20 nM) or the indicated control (AHSA1 (Activator Of HSP90 ATPase Activity 1 (referred to in FIG. 1H as “Control A”)) targeting siRNA) using Lipofectarmne RNAiMax (0.3pl/well) (Thermo Fisher Scientific) according to the manufacturer’s instructions and incubated for 24 hours.
  • AHSA1 Activator Of HSP90 ATPase Activity 1
  • FIGS. 1A-1H and Table 5 shows the percent of hFASN mRNA remaining after treatment with the indicated dsRNA agent (normalized to GAPDH and relative to control treated cells set to 100%).
  • a set of dsRNA agents targeting murine FASN were designed and generated using standard methods known in the art.
  • the nucleotide sequence of the sense and anti-sense strand of each of the dsRNA agents is set forth in Table 6.
  • the abbreviations utilized in the nucleotide sequence set forth in Table 6 are set forth above in Table 4 above.
  • Each dsRNA agent generated above was evaluated for their ability to knockdown mFASN expression in vitro. Briefly, Hepal-6 cells (ATCC) were seeded at 20,000 cells per well in a standard 96 well plate. The cells were transfected with the indicated mFASN targeting dsRNA agent (20 nM, 3.3 nM, 0.55 nM, 0.09 nM, or 0.02 nM) or the indicated control
  • Table 7 shows the calculated IC50 (nM) and the remaining mFASN mRNA percent
  • mice 9 week old female C57B16N mice (4 per treatment or control group) were administered a single dose of the indicated conjugate (5mg/kg) (or saline control) via subcutaneous injection and treated for seven days. During treatment, the mice were observed daily, and weight measurements taken. No adverse events were observed. Liver samples were taken seven days post administration (snap frozen in liquid nitrogen). Liver lysate was prepared from approximately 50mg of liver tissue by sonication in 1ml of lysis buffer. mFASN mRNA was quantified from liver lysate using standard bDNA assay (Quantigene 2.0 (Thermo Fisher Scientific)) according to manufacturer’s instructions. The level of mFASN mRNA was normalized to GAPDH.
  • Example 8 In Vivo GalNac-Conjugated dsRNA Agent Mediated Knockdown of mFASN [00442] The ability of dsRNA conjugates 231, 233, and 238 were evaluated for their ability to knockdown mFASN expression in vivo at various dosages.
  • mice 9 week old female C57B16N mice (4 per treatment or control group) were administered a single dose of the indicated conjugate (dsRNA conjugate 231 dosed at 2.5 mg/kg or 10 mg/kg, dsRNA conjugate 233 dosed at 2.5 mg/kg or 10 mg/kg, and 238 dosed at 1.25mg/kg, 2.5 mg/kg, 5 mg/kg, or 10 mg/kg, negative control conjugate dosed at 5 mg/kg) (or saline control) via subcutaneous injection and treated for 14 or 21 days. During treatment, the mice were observed daily, and weight measurements taken. No adverse events were observed. Liver samples were taken seven days post administration (snap frozen in liquid nitrogen).
  • Liver lysate was prepared from approximately 50mg of liver tissue by sonication in 1ml of lysis buffer.
  • mFASN mRNA was quantified from liver lysate using standard bDNA assay (Quantigene 2.0 (Thermo Fisher Scientific)) according to manufacturer’s instructions. The level of mFASN mRNA was normalized to GAPDH
  • FIG. 3 shows a dose dependent knockdown of mFASN mRNA with dsRNA conjugates 231, 233, and 238.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne, entre autres<i />, des agents (par exemple<i />, des agents d'ARNi, des agents d'ARNdb) comprenant un brin sens et un brin antisens ciblant FASN (par exemple<i />, hFASN) ; ainsi que des procédés de fabrication et des compositions pharmaceutiques les comprenant. L'invention concerne en outre des méthodes d'utilisation des agents (par exemple<i />, des agents d'ARNi, des agents d'ARNdb) comprenant, par exemple,<i /> des méthodes d'inhibition ou de diminution de l'expression de FASN (par exemple<i />, l'expression d'ARNm), des méthodes de traitement de maladies associées à FASN, ainsi que des méthodes de traitement de maladies hépatiques (par exemple<i />, la stéatohépatite non alcoolique (SHNA) et la maladie du foie gras non alcoolique (NAFLD)).
PCT/US2024/025323 2023-04-21 2024-04-19 Agents d'arni ciblant la synthase d'acides gras et procédés associés Ceased WO2024220746A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363497568P 2023-04-21 2023-04-21
US63/497,568 2023-04-21

Publications (2)

Publication Number Publication Date
WO2024220746A2 true WO2024220746A2 (fr) 2024-10-24
WO2024220746A3 WO2024220746A3 (fr) 2025-01-02

Family

ID=91377013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/025323 Ceased WO2024220746A2 (fr) 2023-04-21 2024-04-19 Agents d'arni ciblant la synthase d'acides gras et procédés associés

Country Status (1)

Country Link
WO (1) WO2024220746A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026038054A3 (fr) * 2024-08-15 2026-03-12 Genome Research Limited Nouveau procédé de diagnostic compagnon

Citations (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US513030A (en) 1894-01-16 Machine for waxing or coating paper
US564562A (en) 1896-07-21 Joseph p
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US4845205A (en) 1985-01-08 1989-07-04 Institut Pasteur 2,N6 -disubstituted and 2,N6 -trisubstituted adenosine-3'-phosphoramidites
US4981957A (en) 1984-07-19 1991-01-01 Centre National De La Recherche Scientifique Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5177195A (en) 1991-01-08 1993-01-05 Imperial Chemical Industries Plc Disazo dyes
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5319080A (en) 1991-10-17 1994-06-07 Ciba-Geigy Corporation Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5405939A (en) 1987-10-22 1995-04-11 Temple University Of The Commonwealth System Of Higher Education 2',5'-phosphorothioate oligoadenylates and their covalent conjugates with polylysine
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5446137A (en) 1993-12-09 1995-08-29 Syntex (U.S.A.) Inc. Oligonucleotides containing 4'-substituted nucleotides
US5455233A (en) 1989-11-30 1995-10-03 University Of North Carolina Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5466677A (en) 1993-03-06 1995-11-14 Ciba-Geigy Corporation Dinucleoside phosphinates and their pharmaceutical compositions
US5466786A (en) 1989-10-24 1995-11-14 Gilead Sciences 2'modified nucleoside and nucleotide compounds
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5514785A (en) 1990-05-11 1996-05-07 Becton Dickinson And Company Solid supports for nucleic acid hybridization assays
US5519126A (en) 1988-03-25 1996-05-21 University Of Virginia Alumni Patents Foundation Oligonucleotide N-alkylphosphoramidates
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5541316A (en) 1992-02-11 1996-07-30 Henkel Kommanditgesellschaft Auf Aktien Process for the production of polysaccharide-based polycarboxylates
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5552540A (en) 1987-06-24 1996-09-03 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
US5567811A (en) 1990-05-03 1996-10-22 Amersham International Plc Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5576427A (en) 1993-03-30 1996-11-19 Sterling Winthrop, Inc. Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5596086A (en) 1990-09-20 1997-01-21 Gilead Sciences, Inc. Modified internucleoside linkages having one nitrogen and two carbon atoms
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5610300A (en) 1992-07-01 1997-03-11 Ciba-Geigy Corporation Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5614617A (en) 1990-07-27 1997-03-25 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5639873A (en) 1992-02-05 1997-06-17 Centre National De La Recherche Scientifique (Cnrs) Oligothionucleotides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5645985A (en) 1991-11-26 1997-07-08 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5658873A (en) 1993-04-10 1997-08-19 Degussa Aktiengesellschaft Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions containing them
US5663312A (en) 1993-03-31 1997-09-02 Sanofi Oligonucleotide dimers with amide linkages replacing phosphodiester linkages
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5677439A (en) 1990-08-03 1997-10-14 Sanofi Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleotide analogues
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5830653A (en) 1991-11-26 1998-11-03 Gilead Sciences, Inc. Methods of using oligomers containing modified pyrimidines
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
WO1999014226A2 (fr) 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
US5948903A (en) 1991-01-11 1999-09-07 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US6028188A (en) 1993-11-16 2000-02-22 Genta Incorporated Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
US6124445A (en) 1994-11-23 2000-09-26 Isis Pharmaceuticals, Inc. Phosphotriester oligonucleotides, amidities and method of preparation
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US6169170B1 (en) 1994-03-18 2001-01-02 Lynx Therapeutics, Inc. Oligonucleotide N3′→N5′Phosphoramidate Duplexes
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US6239265B1 (en) 1990-01-11 2001-05-29 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US6268490B1 (en) 1997-03-07 2001-07-31 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogues
US6277603B1 (en) 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US6287591B1 (en) 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
US6326199B1 (en) 1991-12-24 2001-12-04 Isis Pharmaceuticals, Inc. Gapped 2′ modified oligonucleotides
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US6444423B1 (en) 1996-06-07 2002-09-03 Molecular Dynamics, Inc. Nucleosides comprising polydentate ligands
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6528640B1 (en) 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US6531590B1 (en) 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US6534639B1 (en) 1999-07-07 2003-03-18 Isis Pharmaceuticals, Inc. Guanidinium functionalized oligonucleotides and method/synthesis
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US6608035B1 (en) 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6639062B2 (en) 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6670461B1 (en) 1997-09-12 2003-12-30 Exiqon A/S Oligonucleotide analogues
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
WO2004106356A1 (fr) 2003-05-27 2004-12-09 Syddansk Universitet Derives de nucleotides fonctionnalises
US6858715B2 (en) 1999-02-04 2005-02-22 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6878805B2 (en) 2002-08-16 2005-04-12 Isis Pharmaceuticals, Inc. Peptide-conjugated oligomeric compounds
WO2005071093A2 (fr) 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Porteurs de vaccin adenoviral de chimpanze
US20050175682A1 (en) 2003-09-15 2005-08-11 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
US20060008378A1 (en) 2004-04-30 2006-01-12 Kunihiro Imai Sterilization method
US6998484B2 (en) 2000-10-04 2006-02-14 Santaris Pharma A/S Synthesis of purine locked nucleic acid analogues
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
WO2006048215A1 (fr) 2004-11-02 2006-05-11 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Amplicon adenoviral et cellules productrices de vecteurs adenoviraux a defaut de replication, et leurs methodes de preparation et d'utilisation
US7045610B2 (en) 1998-04-03 2006-05-16 Epoch Biosciences, Inc. Modified oligonucleotides for mismatch discrimination
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
US7273933B1 (en) 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
WO2007134181A2 (fr) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques modifiés en 5'
US7321029B2 (en) 2000-01-21 2008-01-22 Geron Corporation 2′-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates: their synthesis and use
US20080020058A1 (en) 2005-02-14 2008-01-24 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20080039618A1 (en) 2002-11-05 2008-02-14 Charles Allerson Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20080042973A1 (en) 2006-07-10 2008-02-21 Memsic, Inc. System for sensing yaw rate using a magnetic field sensor and portable electronic devices using the same
US7399845B2 (en) 2006-01-27 2008-07-15 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2008101157A1 (fr) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. Nucléosides modifiés 5'-substitués-2'-f et composés oligomères préparés à partir de ceux-ci
US7427672B2 (en) 2003-08-28 2008-09-23 Takeshi Imanishi Artificial nucleic acids of n-o bond crosslinkage type
US7495088B1 (en) 1989-12-04 2009-02-24 Enzo Life Sciences, Inc. Modified nucleotide compounds
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
WO2009127060A1 (fr) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Nouvelles formulations lipidiques pour l'administration d'acides nucléiques
WO2009132131A1 (fr) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Formulation lipidique améliorée à base d'amino lipide
WO2009150222A2 (fr) 2008-06-12 2009-12-17 Affitech A/S Système amélioré d'expression de protéine
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
US20100062967A1 (en) 2004-12-27 2010-03-11 Silence Therapeutics Ag Coated lipid complexes and their use
US7696345B2 (en) 2002-11-05 2010-04-13 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2010053572A2 (fr) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Lipidoïdes aminoalcool et leurs utilisations
WO2011005861A1 (fr) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. Coiffes d’extrémité d’oligonucléotides
US20110076335A1 (en) 2009-07-01 2011-03-31 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
US20110256175A1 (en) 2008-10-09 2011-10-20 The University Of British Columbia Amino lipids and methods for the delivery of nucleic acids
US20110313020A1 (en) 2008-12-03 2011-12-22 Marina Biotech, Inc. UsiRNA Complexes
US20120011478A1 (en) 2005-02-24 2012-01-12 Texas Instruments Incorporated Merging sub-resolution assist features of a photolithographic mask
US8106022B2 (en) 2007-12-04 2012-01-31 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US20120027803A1 (en) 2010-06-03 2012-02-02 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20120027796A1 (en) 2008-11-10 2012-02-02 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
US20120058144A1 (en) 2008-11-10 2012-03-08 Alnylam Pharmaceuticals, Inc. Lipids and compositions for the delivery of therapeutics
US20120149894A1 (en) 2009-08-20 2012-06-14 Mark Cameron Novel cationic lipids with various head groups for oligonucleotide delivery
US20120202871A1 (en) 2009-07-01 2012-08-09 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
US8278426B2 (en) 2007-06-08 2012-10-02 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US20120287670A1 (en) 2010-04-09 2012-11-15 Sharp Kabushiki Kaisha Light source module and electronic apparatus provided with same
US8314227B2 (en) 2007-05-22 2012-11-20 Marina Biotech, Inc. Hydroxymethyl substituted RNA oligonucleotides and RNA complexes
WO2012162210A1 (fr) 2011-05-26 2012-11-29 Merck Sharp & Dohme Corp. Lipides cationiques maintenus dans un anneau pour une fourniture d'oligonucléotides
US20130011922A1 (en) 2007-03-02 2013-01-10 F/K/A Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
US20130022649A1 (en) 2009-12-01 2013-01-24 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
WO2013016058A1 (fr) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Nouveaux lipides cationiques contenant du bis-azote pour administration d'oligonucléotide
US20130053572A1 (en) 2010-01-22 2013-02-28 Steven L. Colletti Novel Cationic Lipids for Oligonucleotide Delivery
WO2013036868A1 (fr) 2011-09-07 2013-03-14 Marina Biotech Inc. Synthèse et utilisations de composés acides nucléiques comportant des monomères restreints de point de vue conformationnel
US20130090372A1 (en) 2010-06-04 2013-04-11 Brian W. Budzik Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
US20130116307A1 (en) 2010-05-12 2013-05-09 Protiva Biotherapeutics Inc. Novel cyclic cationic lipids and methods of use
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
WO2013075035A1 (fr) 2011-11-18 2013-05-23 Alnylam Pharmaceuticals Agents arni, compositions et procédés d'utilisation de ceux-ci pour traiter des maladies associées à la transthyrétine (ttr)
US20130178541A1 (en) 2010-09-20 2013-07-11 Matthew G. Stanton Novel low molecular weight cationic lipids for oligonucleotide delivery
US20130189351A1 (en) 2010-08-31 2013-07-25 Novartis Ag Lipids suitable for liposomal delivery of protein coding rna
US20130190383A1 (en) 2010-04-26 2013-07-25 Marina Biotech, Inc. Nucleic acid compounds with conformationally restricted monomers and uses thereof
US20130195920A1 (en) 2011-12-07 2013-08-01 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US8501805B2 (en) 2008-09-24 2013-08-06 Isis Pharmaceuticals, Inc. Substituted alpha-L-bicyclic nucleosides
WO2013116126A1 (fr) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Nouveaux lipides cationiques biodégradables de faible masse moléculaire pour la délivrance d'oligonucléotides
US20130203836A1 (en) 2010-04-01 2013-08-08 Isis Pharmaceuticals, Inc. 2' and 5' modified monomers and oligonucleotides
US8530640B2 (en) 2008-02-07 2013-09-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
US20130274523A1 (en) 2010-09-30 2013-10-17 John A. Bawiec, III Low molecular weight cationic lipids for oligonucleotide delivery
US20130274504A1 (en) 2010-10-21 2013-10-17 Steven L. Colletti Novel Low Molecular Weight Cationic Lipids For Oligonucleotide Delivery
US20130303587A1 (en) 2010-06-30 2013-11-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US20130338210A1 (en) 2009-12-07 2013-12-19 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
US20140039032A1 (en) 2011-12-12 2014-02-06 Kyowa Hakko Kirin Co., Ltd. Lipid nano particles comprising cationic lipid for drug delivery system
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
US20140200257A1 (en) 2011-01-11 2014-07-17 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2014136086A1 (fr) 2013-03-08 2014-09-12 Novartis Ag Lipides et compositions lipidiques pour l'administration de principes actifs
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
WO2014179627A2 (fr) 2013-05-01 2014-11-06 Isis Pharmaceuticals, Inc. Compositions et méthodes pour moduler l'expression de hbv et de ttr
US20150005363A1 (en) 2011-12-07 2015-01-01 Alnylam Pharmaceuticals, Inc. Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents
US20150057373A1 (en) 2012-03-27 2015-02-26 Sirna Therapeutics, Inc DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
US20150064242A1 (en) 2012-02-24 2015-03-05 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2015074085A1 (fr) 2013-11-18 2015-05-21 Arcturus Therapeutics, Inc. Lipide cationique ionisable pour administration d'arn
US20150140070A1 (en) 2013-10-22 2015-05-21 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger rna
WO2015095340A1 (fr) 2013-12-19 2015-06-25 Novartis Ag Lipides et compositions lipidiques pour le largage d'agents actifs
WO2015106128A2 (fr) 2014-01-09 2015-07-16 Alnylam Pharmaceuticals, Inc. Agents d'arni modifiés
US20150203446A1 (en) 2011-09-27 2015-07-23 Takeda Pharmaceutical Company Limited Di-aliphatic substituted pegylated lipids
US20150239926A1 (en) 2013-11-18 2015-08-27 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for rna delivery
WO2015199952A1 (fr) 2014-06-25 2015-12-30 Acuitas Therapeutics Inc. Nouveaux lipides et formulations nanoparticulaires lipidiques pour l'administration d'acides nucléiques
US20160151284A1 (en) 2013-07-23 2016-06-02 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
US20160317458A1 (en) 2013-12-19 2016-11-03 Luis Brito Lipids and Lipid Compositions for the Delivery of Active Agents
US20160376224A1 (en) 2015-06-29 2016-12-29 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20170119904A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017099823A1 (fr) 2015-12-10 2017-06-15 Modernatx, Inc. Compositions et procédés permettant d'administrer des agents thérapeutiques
WO2017117528A1 (fr) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipides et formulations de nanoparticules de lipides pour la libération d'acides nucléiques
US9708628B2 (en) 2011-11-18 2017-07-18 Nof Corporation Cationic lipid having improved intracellular kinetics
US20170210967A1 (en) 2010-12-06 2017-07-27 Schlumberger Technology Corporation Compositions and methods for well completions
WO2017173054A1 (fr) 2016-03-30 2017-10-05 Intellia Therapeutics, Inc. Formulations de nanoparticules lipidiques pour des composés crispr/cas
US9867888B2 (en) 2015-09-17 2018-01-16 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2018081480A1 (fr) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Formulations de nanoparticules lipidiques
US10086013B2 (en) 2011-10-27 2018-10-02 Massachusetts Institute Of Technology Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof
WO2019051289A1 (fr) 2017-09-08 2019-03-14 Generation Bio Co. Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux
WO2019055633A1 (fr) 2017-09-14 2019-03-21 Arrowhead Pharmaceuticals, Inc. Agents d'arni et compositions destinées à inhiber l'expression d'analogue de l'angiopoïétine 3 (angptl3) et procédés d'utilisation
WO2019067992A1 (fr) 2017-09-29 2019-04-04 Intellia Therapeutics, Inc. Formulations
US20190240349A1 (en) 2015-06-19 2019-08-08 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof
WO2019157531A1 (fr) 2018-02-12 2019-08-15 Ionis Pharmaceuticals, Inc. Composés modifiés et leurs utilisations
WO2019217941A1 (fr) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Procédés de suppression de mutations pathogènes à l'aide de systèmes d'éditeur de base programmables
WO2020081938A1 (fr) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipides pour l'administration de nanoparticules lipidiques d'agents actifs
WO2020106946A1 (fr) 2018-11-21 2020-05-28 Translate Bio, Inc. Traitement de la fibrose kystique par administration d'arnm nébulisé codant pour la cftr
WO2020219876A1 (fr) 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Lipides aminés ionisables et nanoparticules lipidiques
WO2021113777A2 (fr) 2019-12-04 2021-06-10 Orna Therapeutics, Inc. Méthodes et compositions d'arn circulaire
WO2021257782A1 (fr) 2020-06-18 2021-12-23 Alnylam Pharmaceuticals, Inc. Compositions d'arni de xanthine déshydrogénase (xdh) et leurs procédés d'utilisation
US11446344B1 (en) 2018-12-12 2022-09-20 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
WO2022246251A2 (fr) 2021-05-21 2022-11-24 Ionis Pharmaceuticals, Inc. Composés pour moduler l'expression d'unc13a
WO2022271573A1 (fr) 2021-06-21 2022-12-29 Arrowhead Pharmaceuticals, Inc. Agents d'arni pour inhiber l'expression de la xanthine déshydrogénase (xdh), compositions pharmaceutiques associées et méthodes d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008026946A2 (fr) * 2006-08-30 2008-03-06 Genesis Research And Development Corporation Limited Compositions et procédés destinés à traiter et à prévenir des troubles néoplastiques
US20150031742A1 (en) * 2011-08-08 2015-01-29 The Brigham And Women's Hospital, Inc. Treatment of uterine leiomyomata
EP3432879B1 (fr) * 2016-03-22 2021-01-06 Mayo Foundation for Medical Education and Research Utilisation d'inhibiteurs de la synthase d'acide gras pour traiter la fibrose

Patent Citations (281)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US564562A (en) 1896-07-21 Joseph p
US513030A (en) 1894-01-16 Machine for waxing or coating paper
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4981957A (en) 1984-07-19 1991-01-01 Centre National De La Recherche Scientifique Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US4845205A (en) 1985-01-08 1989-07-04 Institut Pasteur 2,N6 -disubstituted and 2,N6 -trisubstituted adenosine-3'-phosphoramidites
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5286717A (en) 1987-03-25 1994-02-15 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5552540A (en) 1987-06-24 1996-09-03 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5405939A (en) 1987-10-22 1995-04-11 Temple University Of The Commonwealth System Of Higher Education 2',5'-phosphorothioate oligoadenylates and their covalent conjugates with polylysine
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US5519126A (en) 1988-03-25 1996-05-21 University Of Virginia Alumni Patents Foundation Oligonucleotide N-alkylphosphoramidates
US5453496A (en) 1988-05-26 1995-09-26 University Patents, Inc. Polynucleotide phosphorodithioate
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5466786A (en) 1989-10-24 1995-11-14 Gilead Sciences 2'modified nucleoside and nucleotide compounds
US5466786B1 (en) 1989-10-24 1998-04-07 Gilead Sciences 2' Modified nucleoside and nucleotide compounds
US5455233A (en) 1989-11-30 1995-10-03 University Of North Carolina Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US7495088B1 (en) 1989-12-04 2009-02-24 Enzo Life Sciences, Inc. Modified nucleotide compounds
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US6239265B1 (en) 1990-01-11 2001-05-29 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5808027A (en) 1990-01-11 1998-09-15 Isis Pharmaceuticals, Inc. N-2 substituted purines in oligonucleotides
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US6531584B1 (en) 1990-01-11 2003-03-11 Isis Pharmaceuticals, Inc. 2'modified oligonucleotides
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5750692A (en) 1990-01-11 1998-05-12 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US6166199A (en) 1990-01-11 2000-12-26 Isis Pharmaceuticals, Inc N-2 substituted purines
US5587469A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides containing N-2 substituted purines
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5536821A (en) 1990-03-08 1996-07-16 Worcester Foundation For Biomedical Research Aminoalkylphosphorothioamidate oligonucleotide deratives
US5563253A (en) 1990-03-08 1996-10-08 Worcester Foundation For Biomedical Research Linear aminoalkylphosphoramidate oligonucleotide derivatives
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5567811A (en) 1990-05-03 1996-10-22 Amersham International Plc Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
US5514785A (en) 1990-05-11 1996-05-07 Becton Dickinson And Company Solid supports for nucleic acid hybridization assays
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5614617A (en) 1990-07-27 1997-03-25 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5677439A (en) 1990-08-03 1997-10-14 Sanofi Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleotide analogues
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
US5596086A (en) 1990-09-20 1997-01-21 Gilead Sciences, Inc. Modified internucleoside linkages having one nitrogen and two carbon atoms
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5177195A (en) 1991-01-08 1993-01-05 Imperial Chemical Industries Plc Disazo dyes
US5948903A (en) 1991-01-11 1999-09-07 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5319080A (en) 1991-10-17 1994-06-07 Ciba-Geigy Corporation Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates
US5393878A (en) 1991-10-17 1995-02-28 Ciba-Geigy Corporation Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5830653A (en) 1991-11-26 1998-11-03 Gilead Sciences, Inc. Methods of using oligomers containing modified pyrimidines
US6380368B1 (en) 1991-11-26 2002-04-30 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5645985A (en) 1991-11-26 1997-07-08 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US6326199B1 (en) 1991-12-24 2001-12-04 Isis Pharmaceuticals, Inc. Gapped 2′ modified oligonucleotides
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US6277603B1 (en) 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5639873A (en) 1992-02-05 1997-06-17 Centre National De La Recherche Scientifique (Cnrs) Oligothionucleotides
US5541316A (en) 1992-02-11 1996-07-30 Henkel Kommanditgesellschaft Auf Aktien Process for the production of polysaccharide-based polycarboxylates
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5700920A (en) 1992-07-01 1997-12-23 Novartis Corporation Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US5610300A (en) 1992-07-01 1997-03-11 Ciba-Geigy Corporation Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US6683167B2 (en) 1992-07-23 2004-01-27 University Of Massachusetts Worcester Hybrid oligonucleotide phosphorothioates
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5466677A (en) 1993-03-06 1995-11-14 Ciba-Geigy Corporation Dinucleoside phosphinates and their pharmaceutical compositions
US5576427A (en) 1993-03-30 1996-11-19 Sterling Winthrop, Inc. Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5663312A (en) 1993-03-31 1997-09-02 Sanofi Oligonucleotide dimers with amide linkages replacing phosphodiester linkages
US5658873A (en) 1993-04-10 1997-08-19 Degussa Aktiengesellschaft Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions containing them
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5763588A (en) 1993-09-17 1998-06-09 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US6005096A (en) 1993-09-17 1999-12-21 Gilead Sciences, Inc. Pyrimidine derivatives
US6028188A (en) 1993-11-16 2000-02-22 Genta Incorporated Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137A (en) 1993-12-09 1995-08-29 Syntex (U.S.A.) Inc. Oligonucleotides containing 4'-substituted nucleotides
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5811534A (en) 1994-02-01 1998-09-22 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US6169170B1 (en) 1994-03-18 2001-01-02 Lynx Therapeutics, Inc. Oligonucleotide N3′→N5′Phosphoramidate Duplexes
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6608035B1 (en) 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US6124445A (en) 1994-11-23 2000-09-26 Isis Pharmaceuticals, Inc. Phosphotriester oligonucleotides, amidities and method of preparation
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US6444423B1 (en) 1996-06-07 2002-09-03 Molecular Dynamics, Inc. Nucleosides comprising polydentate ligands
US6639062B2 (en) 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6268490B1 (en) 1997-03-07 2001-07-31 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogues
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
US6287591B1 (en) 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
US6670461B1 (en) 1997-09-12 2003-12-30 Exiqon A/S Oligonucleotide analogues
WO1999014226A2 (fr) 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
US7034133B2 (en) 1997-09-12 2006-04-25 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US8080644B2 (en) 1997-09-12 2011-12-20 Exiqon A/S Oligonucleotide analogues
US8034909B2 (en) 1997-09-12 2011-10-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US8153365B2 (en) 1997-09-12 2012-04-10 Exiqon A/S Oligonucleotide analogues
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6528640B1 (en) 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US7273933B1 (en) 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US7045610B2 (en) 1998-04-03 2006-05-16 Epoch Biosciences, Inc. Modified oligonucleotides for mismatch discrimination
US6531590B1 (en) 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
USRE39464E1 (en) 1998-07-14 2007-01-09 Isis Pharmaceuticals Inc. Oligonucleolotides having site specific chiral phosphorothioate internucleoside linkages
US6858715B2 (en) 1999-02-04 2005-02-22 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US7041816B2 (en) 1999-02-04 2006-05-09 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6534639B1 (en) 1999-07-07 2003-03-18 Isis Pharmaceuticals, Inc. Guanidinium functionalized oligonucleotides and method/synthesis
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US7321029B2 (en) 2000-01-21 2008-01-22 Geron Corporation 2′-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates: their synthesis and use
US6998484B2 (en) 2000-10-04 2006-02-14 Santaris Pharma A/S Synthesis of purine locked nucleic acid analogues
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US6878805B2 (en) 2002-08-16 2005-04-12 Isis Pharmaceuticals, Inc. Peptide-conjugated oligomeric compounds
US8124745B2 (en) 2002-11-05 2012-02-28 Isis Pharmaceuticals, Inc Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7696345B2 (en) 2002-11-05 2010-04-13 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20080039618A1 (en) 2002-11-05 2008-02-14 Charles Allerson Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004106356A1 (fr) 2003-05-27 2004-12-09 Syddansk Universitet Derives de nucleotides fonctionnalises
US7427672B2 (en) 2003-08-28 2008-09-23 Takeshi Imanishi Artificial nucleic acids of n-o bond crosslinkage type
US20050175682A1 (en) 2003-09-15 2005-08-11 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
WO2005071093A2 (fr) 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Porteurs de vaccin adenoviral de chimpanze
US20060008378A1 (en) 2004-04-30 2006-01-12 Kunihiro Imai Sterilization method
WO2006048215A1 (fr) 2004-11-02 2006-05-11 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Amplicon adenoviral et cellules productrices de vecteurs adenoviraux a defaut de replication, et leurs methodes de preparation et d'utilisation
US20100062967A1 (en) 2004-12-27 2010-03-11 Silence Therapeutics Ag Coated lipid complexes and their use
US20080020058A1 (en) 2005-02-14 2008-01-24 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20120011478A1 (en) 2005-02-24 2012-01-12 Texas Instruments Incorporated Merging sub-resolution assist features of a photolithographic mask
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
US7741457B2 (en) 2006-01-27 2010-06-22 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US20090012281A1 (en) 2006-01-27 2009-01-08 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7399845B2 (en) 2006-01-27 2008-07-15 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US8022193B2 (en) 2006-01-27 2011-09-20 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US8030467B2 (en) 2006-05-11 2011-10-04 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
WO2007134181A2 (fr) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques modifiés en 5'
US7750131B2 (en) 2006-05-11 2010-07-06 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
US8268980B2 (en) 2006-05-11 2012-09-18 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
US7547684B2 (en) 2006-05-11 2009-06-16 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
US8088746B2 (en) 2006-05-11 2012-01-03 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
US20080042973A1 (en) 2006-07-10 2008-02-21 Memsic, Inc. System for sensing yaw rate using a magnetic field sensor and portable electronic devices using the same
WO2008101157A1 (fr) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. Nucléosides modifiés 5'-substitués-2'-f et composés oligomères préparés à partir de ceux-ci
US20130011922A1 (en) 2007-03-02 2013-01-10 F/K/A Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
US8314227B2 (en) 2007-05-22 2012-11-20 Marina Biotech, Inc. Hydroxymethyl substituted RNA oligonucleotides and RNA complexes
US20130096289A1 (en) 2007-05-22 2013-04-18 Marina Biotech, Inc. Hydroxymethyl substituted rna oligonucleotides and rna complexes
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US8278426B2 (en) 2007-06-08 2012-10-02 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
US8106022B2 (en) 2007-12-04 2012-01-31 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
US8530640B2 (en) 2008-02-07 2013-09-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
US20100130588A1 (en) 2008-04-15 2010-05-27 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2009127060A1 (fr) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Nouvelles formulations lipidiques pour l'administration d'acides nucléiques
WO2009132131A1 (fr) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Formulation lipidique améliorée à base d'amino lipide
WO2009150222A2 (fr) 2008-06-12 2009-12-17 Affitech A/S Système amélioré d'expression de protéine
US8501805B2 (en) 2008-09-24 2013-08-06 Isis Pharmaceuticals, Inc. Substituted alpha-L-bicyclic nucleosides
US20110256175A1 (en) 2008-10-09 2011-10-20 The University Of British Columbia Amino lipids and methods for the delivery of nucleic acids
WO2010053572A2 (fr) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Lipidoïdes aminoalcool et leurs utilisations
US20120058144A1 (en) 2008-11-10 2012-03-08 Alnylam Pharmaceuticals, Inc. Lipids and compositions for the delivery of therapeutics
US20120027796A1 (en) 2008-11-10 2012-02-02 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
US20110313020A1 (en) 2008-12-03 2011-12-22 Marina Biotech, Inc. UsiRNA Complexes
US20110076335A1 (en) 2009-07-01 2011-03-31 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US20120202871A1 (en) 2009-07-01 2012-08-09 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011005861A1 (fr) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. Coiffes d’extrémité d’oligonucléotides
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US20150191727A1 (en) 2009-08-06 2015-07-09 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US20120149894A1 (en) 2009-08-20 2012-06-14 Mark Cameron Novel cationic lipids with various head groups for oligonucleotide delivery
US20130022649A1 (en) 2009-12-01 2013-01-24 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
US20130338210A1 (en) 2009-12-07 2013-12-19 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
US20130053572A1 (en) 2010-01-22 2013-02-28 Steven L. Colletti Novel Cationic Lipids for Oligonucleotide Delivery
US20130203836A1 (en) 2010-04-01 2013-08-08 Isis Pharmaceuticals, Inc. 2' and 5' modified monomers and oligonucleotides
US20120287670A1 (en) 2010-04-09 2012-11-15 Sharp Kabushiki Kaisha Light source module and electronic apparatus provided with same
US20130190383A1 (en) 2010-04-26 2013-07-25 Marina Biotech, Inc. Nucleic acid compounds with conformationally restricted monomers and uses thereof
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US20130116307A1 (en) 2010-05-12 2013-05-09 Protiva Biotherapeutics Inc. Novel cyclic cationic lipids and methods of use
US20120027803A1 (en) 2010-06-03 2012-02-02 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20130090372A1 (en) 2010-06-04 2013-04-11 Brian W. Budzik Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
US20130303587A1 (en) 2010-06-30 2013-11-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US20130189351A1 (en) 2010-08-31 2013-07-25 Novartis Ag Lipids suitable for liposomal delivery of protein coding rna
US20130178541A1 (en) 2010-09-20 2013-07-11 Matthew G. Stanton Novel low molecular weight cationic lipids for oligonucleotide delivery
US20130274523A1 (en) 2010-09-30 2013-10-17 John A. Bawiec, III Low molecular weight cationic lipids for oligonucleotide delivery
US20130274504A1 (en) 2010-10-21 2013-10-17 Steven L. Colletti Novel Low Molecular Weight Cationic Lipids For Oligonucleotide Delivery
US20170210967A1 (en) 2010-12-06 2017-07-27 Schlumberger Technology Corporation Compositions and methods for well completions
US20140200257A1 (en) 2011-01-11 2014-07-17 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2012162210A1 (fr) 2011-05-26 2012-11-29 Merck Sharp & Dohme Corp. Lipides cationiques maintenus dans un anneau pour une fourniture d'oligonucléotides
WO2013016058A1 (fr) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Nouveaux lipides cationiques contenant du bis-azote pour administration d'oligonucléotide
WO2013036868A1 (fr) 2011-09-07 2013-03-14 Marina Biotech Inc. Synthèse et utilisations de composés acides nucléiques comportant des monomères restreints de point de vue conformationnel
US20150203446A1 (en) 2011-09-27 2015-07-23 Takeda Pharmaceutical Company Limited Di-aliphatic substituted pegylated lipids
US10086013B2 (en) 2011-10-27 2018-10-02 Massachusetts Institute Of Technology Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof
US9708628B2 (en) 2011-11-18 2017-07-18 Nof Corporation Cationic lipid having improved intracellular kinetics
WO2013075035A1 (fr) 2011-11-18 2013-05-23 Alnylam Pharmaceuticals Agents arni, compositions et procédés d'utilisation de ceux-ci pour traiter des maladies associées à la transthyrétine (ttr)
US20150005363A1 (en) 2011-12-07 2015-01-01 Alnylam Pharmaceuticals, Inc. Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
US20130195920A1 (en) 2011-12-07 2013-08-01 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20140039032A1 (en) 2011-12-12 2014-02-06 Kyowa Hakko Kirin Co., Ltd. Lipid nano particles comprising cationic lipid for drug delivery system
WO2013116126A1 (fr) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Nouveaux lipides cationiques biodégradables de faible masse moléculaire pour la délivrance d'oligonucléotides
US20150064242A1 (en) 2012-02-24 2015-03-05 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
US20150057373A1 (en) 2012-03-27 2015-02-26 Sirna Therapeutics, Inc DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
WO2014136086A1 (fr) 2013-03-08 2014-09-12 Novartis Ag Lipides et compositions lipidiques pour l'administration de principes actifs
WO2014179620A1 (fr) 2013-05-01 2014-11-06 Isis Pharmaceuticals, Inc. Composés antisens conjugués et leur utilisation
WO2014179627A2 (fr) 2013-05-01 2014-11-06 Isis Pharmaceuticals, Inc. Compositions et méthodes pour moduler l'expression de hbv et de ttr
US20160151284A1 (en) 2013-07-23 2016-06-02 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
US20150140070A1 (en) 2013-10-22 2015-05-21 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger rna
US20150141678A1 (en) 2013-11-18 2015-05-21 Arcturus Therapeutics, Inc. Ionizable cationic lipid for rna delivery
US20150239926A1 (en) 2013-11-18 2015-08-27 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for rna delivery
WO2015074085A1 (fr) 2013-11-18 2015-05-21 Arcturus Therapeutics, Inc. Lipide cationique ionisable pour administration d'arn
US20160317458A1 (en) 2013-12-19 2016-11-03 Luis Brito Lipids and Lipid Compositions for the Delivery of Active Agents
US20160311759A1 (en) 2013-12-19 2016-10-27 Luis Brito Lipids and Lipid Compositions for the Delivery of Active Agents
WO2015095340A1 (fr) 2013-12-19 2015-06-25 Novartis Ag Lipides et compositions lipidiques pour le largage d'agents actifs
WO2015106128A2 (fr) 2014-01-09 2015-07-16 Alnylam Pharmaceuticals, Inc. Agents d'arni modifiés
WO2015199952A1 (fr) 2014-06-25 2015-12-30 Acuitas Therapeutics Inc. Nouveaux lipides et formulations nanoparticulaires lipidiques pour l'administration d'acides nucléiques
US20150376115A1 (en) 2014-06-25 2015-12-31 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20190240349A1 (en) 2015-06-19 2019-08-08 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof
US10221127B2 (en) 2015-06-29 2019-03-05 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017004143A1 (fr) 2015-06-29 2017-01-05 Acuitas Therapeutics Inc. Formulations de lipides et de nanoparticules de lipides pour l'administration d'acides nucléiques
US20160376224A1 (en) 2015-06-29 2016-12-29 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US9867888B2 (en) 2015-09-17 2018-01-16 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US20170119904A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017099823A1 (fr) 2015-12-10 2017-06-15 Modernatx, Inc. Compositions et procédés permettant d'administrer des agents thérapeutiques
US20180028664A1 (en) 2015-12-10 2018-02-01 Modernatx, Inc. Compositions and methods for delivery of agents
WO2017117528A1 (fr) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipides et formulations de nanoparticules de lipides pour la libération d'acides nucléiques
US20190136231A1 (en) 2016-03-30 2019-05-09 Intellia Therapeutics, Inc. Lipid nanoparticle formulations for crispr/cas components
WO2017173054A1 (fr) 2016-03-30 2017-10-05 Intellia Therapeutics, Inc. Formulations de nanoparticules lipidiques pour des composés crispr/cas
WO2018081480A1 (fr) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Formulations de nanoparticules lipidiques
WO2019051289A9 (fr) 2017-09-08 2019-05-23 Generation Bio Co. Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux
WO2019051289A1 (fr) 2017-09-08 2019-03-14 Generation Bio Co. Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux
WO2019055633A1 (fr) 2017-09-14 2019-03-21 Arrowhead Pharmaceuticals, Inc. Agents d'arni et compositions destinées à inhiber l'expression d'analogue de l'angiopoïétine 3 (angptl3) et procédés d'utilisation
WO2019067992A1 (fr) 2017-09-29 2019-04-04 Intellia Therapeutics, Inc. Formulations
WO2019157531A1 (fr) 2018-02-12 2019-08-15 Ionis Pharmaceuticals, Inc. Composés modifiés et leurs utilisations
WO2019217941A1 (fr) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Procédés de suppression de mutations pathogènes à l'aide de systèmes d'éditeur de base programmables
WO2020081938A1 (fr) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipides pour l'administration de nanoparticules lipidiques d'agents actifs
WO2020106946A1 (fr) 2018-11-21 2020-05-28 Translate Bio, Inc. Traitement de la fibrose kystique par administration d'arnm nébulisé codant pour la cftr
US11446344B1 (en) 2018-12-12 2022-09-20 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
WO2020219876A1 (fr) 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Lipides aminés ionisables et nanoparticules lipidiques
WO2021113777A2 (fr) 2019-12-04 2021-06-10 Orna Therapeutics, Inc. Méthodes et compositions d'arn circulaire
WO2021257782A1 (fr) 2020-06-18 2021-12-23 Alnylam Pharmaceuticals, Inc. Compositions d'arni de xanthine déshydrogénase (xdh) et leurs procédés d'utilisation
WO2022246251A2 (fr) 2021-05-21 2022-11-24 Ionis Pharmaceuticals, Inc. Composés pour moduler l'expression d'unc13a
WO2022271573A1 (fr) 2021-06-21 2022-12-29 Arrowhead Pharmaceuticals, Inc. Agents d'arni pour inhiber l'expression de la xanthine déshydrogénase (xdh), compositions pharmaceutiques associées et méthodes d'utilisation

Non-Patent Citations (42)

* Cited by examiner, † Cited by third party
Title
"Antisense Drug Technology", 2008, CRC PRESS, pages: 163 - 443
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO.
ADLAKHA HUTCHEON ET AL., NAT BIOTECHNOL, vol. 17, 1999, pages 775 - 779
ALBAEK ET AL., J. ORG. CHEM., vol. 71, 2006, pages 7731 - 7740
ALTSCHUL SF ET AL., J MOL BIOL, vol. 215, 1990, pages 403
ALTSCHUL SF ET AL., NUC ACIDS RES, vol. 25, 1997, pages 3389 - 3402
CROOKE ET AL., J. PHARMACOL. EXP. THER, vol. 277, 1996, pages 923 - 937
DONG YSIEGWART DJANDERSON DG: "Strategies, design, and chemistry in siRNA delivery systems", ADV DRUG DELIV REV, vol. 144, April 2019 (2019-04-01), pages 133 - 147, XP085816831, DOI: 10.1016/j.addr.2019.05.004
EYGERIS, NANO LETT., vol. 20, no. 6, 2020, pages 4543 - 4549
FLUITER ET AL., MOL. BIOSYST, vol. 10, 2009, pages 1039
FREIER ET AL., NUCLEIC ACIDS RESEARCH, vol. 25, no. 22, 1997, pages 4429 - 4443
GABIZON ET AL., J CONTROLLED RELEASE, vol. 53, 1998, pages 275 - 279
HOU, X. ET AL., NAT REV MATER, vol. 6, 2021, pages 1078 - 1094, Retrieved from the Internet <URL:https://doi.org/10.1038/s41578-021-00358-0>
KABANOV ET AL., FEBS LETT., vol. 259, 1990, pages 327 - 330
KARLIN SALTSCHUL SF, PNAS, vol. 87, 1990, pages 2264 - 2268
KARLIN SALTSCHUL SF, PNAS, vol. 90, 1993, pages 5873 - 5877
KONING ET AL., BIOCHIM BIOPHYS ACTA, vol. 1420, 1999, pages 153 - 167
KOSHKIN ET AL., TETRAHEDRON, vol. 54, 1998, pages 3607 - 3630
KUMAR ET AL., BIOORG. MED. CHEM. LETT, vol. 8, 1998, pages 2219 - 2222
LETSINGER ET AL., PROC. NATL. ACID. SCI. USA, vol. 86, 1989, pages 6553 - 6556
MANOHARAN ET AL., ANN. N.Y. ACAD. SCI., vol. 660, 1992, pages 306 - 309
MANOHARAN ET AL., BIORG. MED. CHEM. LET., vol. 3, 1993, pages 2765 - 2770
MANOHARAN ET AL., BIORG. MED. CHEM. LET., vol. 4, 1994, pages 1053 - 1060
MANOHARAN ET AL., NUCLEOSIDES & NUCLEOTIDES, vol. 14, 1995, pages 969 - 973
MANOHARAN ET AL., TETRAHEDRON LETT., vol. 36, 1995, pages 3651 - 3654
MARTIN ET AL., CURRENT PHARMACEUTICAL DESIGN,, pages 1 - 394
MARTIN ET AL., HELV. CHIM. ACTA, vol. 78, 1995, pages 486 - 504
MISHRA ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1264, 1995, pages 229 - 237
MYERSMILLER, CABIOS, vol. 4, 1988, pages 11 - 17
NIELSEN ET AL., SCIENCE, vol. 254, 1991, pages 1497 - 1500
NUC. ACIDS SYMP., vol. 52, 2008, pages 133 - 134
OBERHAUSER ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 533 - 538
PRAKASH ET AL., ORG. LETT, vol. 5, 2003, pages 403 - 6
RINELLA M. ET AL.: "A multisociety Delphi consensus statement on new fatty liver disease nomenclature", HEPATOLOGY, vol. 78, no. 6, December 2023 (2023-12-01), pages 1966 - 1986
SAISON-BEHMOARAS ET AL., EMBO J, vol. 10, 1991, pages 1111 - 1118
SHARP ET AL., GENES DEV, vol. 15, 2001, pages 485
SHEA ET AL., NUCL. ACIDS RES., vol. 18, 1990, pages 3777 - 3783
SINGH ET AL., CHEM. COMMUN., vol. 4, 1998, pages 455 - 456
SINGH ET AL., J. ORG. CHEM., vol. 63, 1998, pages 10035 - 10039
SRIVASTAVA ET AL., J. AM. CHEM. SOC., vol. 129, 2007, pages 8362 - 8379
SVINARCHUK ET AL., BIOCHIMIE, vol. 75, 1993, pages 49 - 54
WORKING ET AL., J PHARMACOL EXP THER, vol. 289, 1999, pages 1128 - 1133

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026038054A3 (fr) * 2024-08-15 2026-03-12 Genome Research Limited Nouveau procédé de diagnostic compagnon

Also Published As

Publication number Publication date
WO2024220746A3 (fr) 2025-01-02

Similar Documents

Publication Publication Date Title
TWI694080B (zh) 抑制ａｌａｓ１基因表現的組合物及方法
KR20150013159A (ko) Ａｌａｓ1 유전자의 발현을 억제하기 위한 조성물 및 방법
KR20160118346A (ko) 케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법
TW201515650A (zh) 遞送經脂質調配之核酸分子之劑量及方法
JP7492526B2 (ja) Ｍａｌａｔ１発現のモジュレーター
TW201718857A (zh) 用於抑制alas1基因表現之組合物及方法
CA3234369A1 (fr) Compositions et procedes pour ameliorer l&#39;activite de silencage genique de composes oligonucleotidiques
WO2025178854A2 (fr) Agents d&#39;arni ciblant cideb et procédés et méthodes associés
KR20250043447A (ko) Fam13a 발현을 저해하기 위한 rnai 작제물 및 방법
WO2025217275A2 (fr) Compositions ciblées sur des cellules immunitaires et procédés associés
US20250161347A1 (en) Methods and compositions for treating non-alcoholic fatty liver disease
AU2021401424A1 (en) Compounds and methods for modulating factor xii
WO2025245188A2 (fr) Méthodes de traitement de la stéatose hépatique et d&#39;une stéatose hépatique non alcoolique
WO2025230979A1 (fr) Compositions ciblant tnfaip3 et procédés associés
WO2025194019A1 (fr) Méthodes de traitement de la fibrose hépatique et de la stéatose hépatique non alcoolique
CN119907856A (zh) 第13型17β-羟基类固醇脱氢酶(HSD17B13)iRNA组合物及其使用方法
KR20260044217A (ko) Cas 엔도뉴클레아제 및 관련 방법
KR20260044218A (ko) Cas 엔도뉴클레아제 및 관련 방법
WO2026076295A2 (fr) Agents arn ciblant zbtb7a et procédés associés
CN119331868A (zh) 一种核酸、含有该核酸的药物组合物和缀合物及其应用
NZ714577A (en) Tmprss6 irna compositions and methods of use thereof
NZ714530B2 (en) SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
NZ714530A (en) Serpina1 irna compositions and methods of use thereof
NZ714577B2 (en) Tmprss6 irna compositions and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24731093

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 24731093

Country of ref document: EP

Kind code of ref document: A2